

Access DB# 68240**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: Hong Liu Examiner #: _____ Date: 6/6/02
 Art Unit: 1624 Phone Number 30 6-5814 Serial Number: 291972, 582
 Mail Box and Bldg/Room Location: 4601 Results Format Preferred (circle) PAPER ~~DISK~~ ~~E-MAIL~~
4612

If more than one search is submitted, please prioritize searches in order of need:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Quinazoline derivs as medicaments

Inventors (please provide full names): _____


Chakravarty, S Duggan, S Perumattam, J

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Barb please !

A method of inhibiting p^{38δ} activity with the compound
 (L)_n-Ar'



RECEIVED
 JUN - 6 2002
 TECHNICAL INFORMATION CENTER (STIC)

Point of Contact:
 Barb O'Brien
 Technical Information Specialist
 STIC CM1 6A05 308-4291

STAFF USE ONLY

Searcher: BOB
 Searcher Phone #: _____
 Searcher Location: _____
 Date Searcher Picked Up: _____
 Date Completed: 6-21-02
 Searcher Prep & Review Time: 70
 Clerical Prep Time: _____
 Online Time: 62

Type of Search

NA Sequence (#) _____
 AA Sequence (#) _____
 Structure (#) 1
 Bibliographic _____
 Litigation _____
 Fulltext _____
 Patent Family _____
 Other _____

Vendors and cost where applicable

STN 616
 Dialog _____
 Questel/Orbit _____
 Dr.Link _____
 Lexis/Nexis _____
 Sequence Systems _____
 WWW/Internet _____
 Other (specify) _____

THIS PAGE BLANK (USPTO)

=> fil reg

FILE 'REGISTRY' ENTERED AT 08:57:23 ON 21 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 19 JUN 2002 HIGHEST RN 432491-02-6
DICTIONARY FILE UPDATES: 19 JUN 2002 HIGHEST RN 432491-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN **96187-53-0** REGISTRY
CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-
methyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Brequinar
FS 3D CONCORD
MF C23 H15 F2 N O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
CANCERLIT, CAPLUS, DRUGNL, DRUGUPDATES, EMBASE, MEDLINE, MRCK*, PHAR,
PROMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

85 REFERENCES IN FILE CA (1967 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
86 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d ide 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN **96201-88-6** REGISTRY
CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-
methyl-, sodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Brequinar sodium

CN DuP 785
CN NSC 368390
MF C23 H15 F2 N O2 . Na
LC STN Files: BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, DDFU, DRUGU,
DRUGUPDATES, EMBASE, IPA, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER,
USAN, USPATFULL
(*File contains numerically searchable property data)
CRN (96187-53-0)




● Na

90 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
90 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d ide l3

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS
RN 214697-26-4 REGISTRY
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN ABT 702
FS 3D CONCORD
MF C22 H19 Br N6 O
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, DRUGNL, DRUGUPDATES, SYNTHLINE, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1967 TO DATE)
10 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> fil hom
FILE 'HOME' ENTERED AT 08:57:36 ON 21 JUN 2002

Searched by Barb O'Bryen, STIC 308-4291

=> fil reg

FILE 'REGISTRY' ENTERED AT 15:39:31 ON 20 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 JUN 2002 HIGHEST RN 431976-32-8
DICTIONARY FILE UPDATES: 18 JUN 2002 HIGHEST RN 431976-32-8

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 165245-96-5

L13 1 165245-96-5
(165245-96-5/RN)

=> d ide

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2002 ACS

RN 165245-96-5 REGISTRY

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

OTHER NAMES:

CN CSBP

CN CSBP kinase

CN CSBP/p38 kinase

CN Cytokine synthesis anti-inflammatory drug-binding protein

CN Mitogen-activated protein kinase Mxi2

CN P38 kinase

CN p38 MAP kinase

CN p38 Mitogen-activated kinase

CN p38 Mitogen-activated protein kinase

CN P38-2 mitogen-activated protein kinase

CN p38.alpha. MAP kinase

CN p38.alpha. Mitogen-activated protein kinase

CN p38/RK

CN Protein kinase p38/HOG

CN Protein kinase p38/HOG1

CN Protein kinase p38mapk

CN Protein kinase p38SAPK2

CN Protein kinase RK

CN Protein kinase SAPK2a

CN Protein p38.alpha. kinase

CN Reactivating kinase

CN SAPK2a/p38 kinase

CN Stress-activated protein kinase p38.alpha.

CN Stress-activated protein kinase-2a

CN Stress-activated-protein kinase-2

MF Unspecified

CI MAN

SR CA

LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CEN,
CIN, PROMT, TOXCENTER, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

2688 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2721 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> fil reg; d stat que 112

FILE 'REGISTRY' ENTERED AT 16:03:37 ON 20 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 JUN 2002 HIGHEST RN 431976-32-8

DICTIONARY FILE UPDATES: 18 JUN 2002 HIGHEST RN 431976-32-8

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L7 782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)

L8 SCR 1841

L10 STR



VAR G1=N/C

NODE ATTRIBUTES:

CONNECT IS E3 RC AT 7

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 11 - *cyclic group at node 11 is unsaturated*

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L12 19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)

100.0% PROCESSED 302295 ITERATIONS

19590 ANSWERS

SEARCH TIME: 00.00.21

=> fil capl; d que nos 120

FILE 'CAPLUS' ENTERED AT 16:03:54 ON 20 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jun 2002 VOL 136 ISS 25
FILE LAST UPDATED: 18 Jun 2002 (20020618/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
L7      782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
L8              EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L10             SCR 1841
L10             STR
L12      19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L13      1 SEA FILE=REGISTRY ABB=ON 165245-96-5
L14      1837 SEA FILE=CAPLUS ABB=ON L12
L15      2715 SEA FILE=CAPLUS ABB=ON L13
L16      2926 SEA FILE=CAPLUS ABB=ON P38?(L)KINASE#/OBI
L17      23 SEA FILE=CAPLUS ABB=ON REACTIVATING KINASE#
L18      62 SEA FILE=CAPLUS ABB=ON STRESS ACTIVATED PROTEIN KINASE 2#
L19      62 SEA FILE=CAPLUS ABB=ON KINASE(A) (RK OR SAPK2#)
L20      1 SEA FILE=CAPLUS ABB=ON L14 AND (L15 OR L16 OR L17 OR L18 OR
L19)          L19)
```

=> fil uspatf; d que nos l31

FILE 'USPATFULL' ENTERED AT 16:04:12 ON 20 JUN 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Jun 2002 (20020618/PD)
FILE LAST UPDATED: 18 Jun 2002 (20020618/ED)
HIGHEST GRANTED PATENT NUMBER: US6408437
HIGHEST APPLICATION PUBLICATION NUMBER: US2002073472
CA INDEXING IS CURRENT THROUGH 18 Jun 2002 (20020618/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Jun 2002 (20020618/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2002

```
>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<
```

```
>>> USPATFULL and USPAT2 can be accessed and searched together <<<
```

Searched by Barb O'Bryen, STIC 308-4291

```
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L7      782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
      EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8      SCR 1841
L10     STR
L12     19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L13     1 SEA FILE=REGISTRY ABB=ON 165245-96-5
L15     2715 SEA FILE=CAPLUS ABB=ON L13
L16     2926 SEA FILE=CAPLUS ABB=ON P38?(L)KINASE#/OBI
L17     23 SEA FILE=CAPLUS ABB=ON REACTIVATING KINASE#
L18     62 SEA FILE=CAPLUS ABB=ON STRESS ACTIVATED PROTEIN KINASE 2#
L19     62 SEA FILE=CAPLUS ABB=ON KINASE(A) (RK OR SAPK2#)
L28     2416 SEA FILE=REGISTRY ABB=ON L12 AND USPATFULL/LC
L29     351 SEA FILE=USPATFULL ABB=ON L28
L30     536 SEA FILE=USPATFULL ABB=ON (L15 OR L16 OR L17 OR L18 OR L19)
L31     2 SEA FILE=USPATFULL ABB=ON L29 AND L30
```

```
=> dup rem 120,131
FILE 'CAPLUS' ENTERED AT 16:04:20 ON 20 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
```


```
FILE 'USPATFULL' ENTERED AT 16:04:20 ON 20 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L20
PROCESSING COMPLETED FOR L31
L63     3 DUP REM L20 L31 (0 DUPLICATES REMOVED)
      ANSWER '1' FROM FILE CAPLUS
      ANSWERS '2-3' FROM FILE USPATFULL
```

```
=> d ibib abs hitstr 163 1-3
```

```
L63 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:161275 CAPLUS
DOCUMENT NUMBER: 132:194387
TITLE: Preparation of quinazolines as p38-.alpha.
      kinase and TGF-.beta. inhibitors
INVENTOR(S): Chakravarty, Sarvajit; Dugar, Sundeep; Perumattam,
      John J.; Schreiner, George F.; Liu, David Y.; Lewicki,
      John A.
PATENT ASSIGNEE(S): Scios Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
      CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012497	A2	20000309	WO 1999-US19846	19990827

WO 2000012497 A3 20000629
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, EE, GE, HU, IL,
IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ,
PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ZA, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6184226 B1 20010206 US 1998-141916 19980828
AU 9962413 A1 20000321 AU 1999-62413 19990827
EP 1107959 A2 20010620 EP 1999-949568 19990827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
BR 9913648 A 20020102 BR 1999-13648 19990827
US 6277989 B1 20010821 US 2000-525034 20000314
PRIORITY APPLN. INFO.: US 1998-141916 A 19980828
US 1999-383825 A3 19990827
WO 1999-US19846 W 19990827
OTHER SOURCE(S): MARPAT 132:194387
GI




AB Title compds. [I; R = ZR1; R1 = (un)substituted cyclic (hetero)aliph.
group, -(hetero)aryl; R3 = noninterfering substituent (sic); R4R5 = atoms
to complete a 6-membered arom. ring contg. 0, 1, or 2 nonadjacent N atoms
and noninterfering substituent(s) (sic); z = bond or linker (sic); Z3 =
CR2 or N; R2 = noninterfering substituent (sic)] were prepd. Thus, prepn
of, e.g., 4-(4-pyridinylamino)-2-phenylquinazoline was described. Data
for biol. activity of I were given.

IT 165245-96-5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(mediated disorders; treatment; prepn. of quinazolines as p38
-alpha. kinase and TGF-beta. inhibitors)
RN 165245-96-5 CAPLUS
CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 259870-32-1P 259870-33-2P 259870-34-3P
259870-35-4P 259870-36-5P 259870-37-6P
259870-38-7P 259870-39-8P 259870-40-1P
259870-42-3P 259870-43-4P 259870-44-5P
259870-45-6P 259870-46-7P 259870-47-8P
259870-48-9P 259870-49-0P 259870-50-3P
259870-51-4P 259870-52-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazolines as p38-alpha. kinase and
TGF-beta. inhibitors)
RN 259870-32-1 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 259870-33-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-34-3 CAPLUS

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-35-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-36-5 CAPLUS

CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 259870-37-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-38-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-39-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-40-1 CAPLUS

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-42-3 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-43-4 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dibromophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-44-5 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-difluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-45-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-46-7 CAPLUS
CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (9CI)
(CA INDEX NAME)



RN 259870-47-8 CAPLUS
CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6-nitro-N-4-pyridinyl- (9CI) (CA
INDEX NAME)




RN 259870-48-9 CAPLUS
CN 4,7-Quinazolinodiamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (9CI) (CA
INDEX NAME)




RN 259870-49-0 CAPLUS

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(3-methoxyphenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-50-3 CAPLUS

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(4-methoxyphenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-51-4 CAPLUS

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-(2-methylpropyl)-N4-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 259870-52-5 CAPLUS

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[[4-(methylthio)phenyl]methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)



L63 ANSWER 2 OF 3 USPATFULL

ACCESSION NUMBER: 2001:136790 USPATFULL

TITLE: Quinazoline derivatives as medicaments

INVENTOR(S): Chakravarty, Sarvajit, Sunnyvale, CA, United States

Dugar, Sundeeep, Bridgewater, NJ, United States

Perumattam, John J., Los Altos, CA, United States

Schreiner, George F., Los Altos Hills, CA, United States

Liu, David Y., Palo Alto, CA, United States

Lewicki, John A., Los Gatos, CA, United States

PATENT ASSIGNEE(S): Scios, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277989	B1	20010821
APPLICATION INFO.:	US 2000-525034		20000314 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-383825, filed on 27 Aug 1999 Continuation-in-part of Ser. No. US 1998-141916, filed on 28 Aug 1998, now patented, Pat. No. US 6184226		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		parent
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)

LINE COUNT: 1181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to methods to inhibit TGF-.beta. and/or p38-.alpha. kinase using compounds of the formula
##STR1##

or the pharmaceutically acceptable salts thereof

wherein R.sup.3 is a noninterfering substituent;

each Z is CR.sup.2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N;

each R.sup.2 is independently a noninterfering substituent;

L is a linker;

n is 0 or 1; and

Ar' is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 165245-96-5

(mediated disorders; treatment; prepn. of quinazolines as p38-.alpha. kinase and TGF-.beta. inhibitors)

RN 165245-96-5 USPTAFULL

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

IT 259870-32-1P 259870-33-2P 259870-34-3P

259870-35-4P 259870-36-5P 259870-37-6P

259870-38-7P 259870-39-8P 259870-40-1P

259870-42-3P 259870-43-4P 259870-44-5P

259870-45-6P 259870-46-7P 259870-47-8P


259870-48-9P 259870-49-0P 259870-50-3P

259870-51-4P 259870-52-5P

(prepn. of quinazolines as p38-.alpha. kinase and TGF-.beta. inhibitors)


RN 259870-32-1 USPTAFULL

CN 4-Quinazolinamine, 2-phenyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 259870-33-2 USPTAFULL

CN 4-Quinazolinamine, 2-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-34-3 USPATFULL

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-35-4 USPATFULL

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-36-5 USPATFULL

CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 259870-37-6 USPATFULL

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-38-7 USPATFULL

CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-39-8 USPATFULL

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-40-1 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-42-3 USPATFULL

CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-43-4 USPATFULL

CN 4-Quinazolinamine, 2-(2,6-dibromophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-44-5 USPATFULL

CN 4-Quinazolinamine, 2-(2,6-difluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-45-6 USPATFULL

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-46-7 USPATFULL

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-47-8 USPATFULL

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-48-9 USPATFULL

CN 4,7-Quinazolinediamine, 2-(2-fluorophenyl)-N4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-49-0 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(3-methoxyphenyl)methyl]-N4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-50-3 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(4-methoxyphenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-51-4 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-(2-methylpropyl)-N4-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 259870-52-5 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[[4-(methylthio)phenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)



L63 ANSWER 3 OF 3 USPATFULL

ACCESSION NUMBER:

2001:18473 USPATFULL

TITLE:

Quinazoline derivatives as inhibitors of P-38 .alpha.

INVENTOR(S):

Chakravarty, Sarvajit, Sunnyvale, CA, United States

Perumattam, John J., Los Altos, CA, United States

Schreiner, George F., Los Altos Hills, CA, United States

Liu, David Y., Palo Alto, CA, United States

Lewicki, John A., Los Gatos, CA, United States

PATENT ASSIGNEE(S):

Scios Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184226	B1	20010206
APPLICATION INFO.:	US 1998-141916		19980828 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Truong, Tamthom N.		
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	785		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention describes compounds of the formula ##STR1##

and the pharmaceutically acceptable salts thereof

and the pharmaceutically acceptable salts thereof

wherein each R.sub.2 is independently a noninterfering substituent;

m is an integer of 0-4;

Z is CH or N;

R.sub.1 is H, alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR.sub.2, SR, --OOCR, --NROCR, RCO, --COOR, --CONR.sub.2, --SO.sub.2 NR.sub.2, CN, CF.sub.3, and NO.sub.2, wherein each R is independently H or lower alkyl (1-4C);

n is 0, 1 or 2;

Ar is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally

substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR.sub.2, SR, --OOCR, --NROCR, RCO, --COOR, --CONR.sub.2, SO.sub.2 NR.sub.2, CN, CF.sub.3, and NO.sub.2, wherein each R is independently H or lower alkyl (1-4C); and

R.sup.3 is a branched or cyclic alkyl group (5-7C) or is phenyl optionally substituted with 1-2 substituents which substituents are selected from the group consisting of alkyl (1-6C), halo, OR, NR.sub.2, SR, --OOCR, --NROCR, RCO, --COOR, --CONR.sub.2, --SO.sub.2 NR.sub.2, CN, CF.sub.3, and NO.sub.2, wherein each R is independently H or lower alkyl (1-4C) which are useful as antiinflammatories and in treating cardiac disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 165245-96-5

(mediated disorders; treatment; prepn. of quinazolines as p38-.alpha. kinase and TGF-.beta. inhibitors)

RN 165245-96-5 USPATFULL

CN Kinase (phosphorylating), protein, RK (9CI) (CA INDEX NAME)

STRUCTURE DIAGRAM IS NOT AVAILABLE

IT 259870-32-1P 259870-33-2P 259870-34-3P

259870-35-4P 259870-36-5P 259870-37-6P

259870-38-7P 259870-39-8P 259870-40-1P

259870-42-3P 259870-43-4P 259870-44-5P

259870-45-6P 259870-46-7P 259870-47-8P


259870-48-9P 259870-49-0P 259870-50-3P

259870-51-4P 259870-52-5P

(prepn. of quinazolines as p38-.alpha. kinase and TGF-.beta. inhibitors)


RN 259870-32-1 USPATFULL

CN 4-Quinazolinamine, 2-phenyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 259870-33-2 USPATFULL

CN 4-Quinazolinamine, 2-phenyl-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-34-3 USPATFULL

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-35-4 USPATFULL

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-36-5 USPATFULL

CN 4-Quinazolinamine, N-(3-methoxyphenyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 259870-37-6 USPATFULL

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-38-7 USPATFULL

CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-39-8 USPATFULL

CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-40-1 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-42-3 USPATFULL

CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-43-4 USPATFULL

CN 4-Quinazolinamine, 2-(2,6-dibromophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-44-5 USPATFULL

CN 4-Quinazolinamine, 2-(2,6-difluorophenyl)-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-45-6 USPATFULL

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-46-7 USPATFULL

CN 4-Quinazolinamine, 2-(4-fluorophenyl)-6,7-dimethoxy-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-47-8 USPATFULL

CN 4-Quinazolinamine, 2-(2-fluorophenyl)-6-nitro-N-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-48-9 USPATFULL

CN 4,7-Quinazolinediamine, 2-(2-fluorophenyl)-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-49-0 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(3-methoxyphenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-50-3 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[(4-methoxyphenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)




RN 259870-51-4 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-(2-methylpropyl)-N4-4-pyridinyl- (9CI) (CA INDEX NAME)



RN 259870-52-5 USPATFULL

CN 4,6-Quinazolinediamine, 2-(2-fluorophenyl)-N6-[[4-(methylthio)phenyl)methyl]-N4-4-pyridinyl- (9CI) (CA INDEX NAME)



=> fil capl; d que nos l41; s l41 not l20
FILE 'CAPLUS' ENTERED AT 16:04:59 ON 20 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

*emphs.
inhibiting
any kinase*

FILE COVERS 1907 - 20 Jun 2002 VOL 136 ISS 25
FILE LAST UPDATED: 18 Jun 2002 (20020618/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

L7 782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8 SCR 1841
L10 STR
L12 19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L14 1837 SEA FILE=CAPLUS ABB=ON L12
L22 23834 SEA FILE=CAPLUS ABB=ON KINASE#(L) (INHIBIT? OR ANTAGONI?)/OBI
L40 291 SEA FILE=CAPLUS ABB=ON (PHOSPHOTRANSFERASE# OR TRANSPHOSPHORYL
ASE#) (5A) (INHIBIT? OR ANTAG?)
L41 32 SEA FILE=CAPLUS ABB=ON (L22 OR L40) AND L14

L64

31 L41 NOT (L20)

*previously
printed*

=> fil uspatf; d que nos l39; s l39 not l31
FILE 'USPATFULL' ENTERED AT 16:05:16 ON 20 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Jun 2002 (20020618/PD)
FILE LAST UPDATED: 18 Jun 2002 (20020618/ED)
HIGHEST GRANTED PATENT NUMBER: US6408437
HIGHEST APPLICATION PUBLICATION NUMBER: US2002073472
CA INDEXING IS CURRENT THROUGH 18 Jun 2002 (20020618/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Jun 2002 (20020618/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2002
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2002

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<


```
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L7      782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
          EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8      SCR 1841
L10     STR
L12     19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L28     2416 SEA FILE=REGISTRY ABB=ON L12 AND USPATFULL/LC
L29     351 SEA FILE=USPATFULL ABB=ON L28
L35     3427 SEA FILE=USPATFULL ABB=ON KINASE#(5A)(ANTAG? OR INHIBIT?)
L38     21 SEA FILE=USPATFULL ABB=ON (PHOSPHOTRANSFERASE# OR TRANSPHOSPHO
          RYLASE#)(5A)(INHIBIT? OR ANTAG?)
L39     20 SEA FILE=USPATFULL ABB=ON L29 AND (L35 OR L38)
```

```
L65      18 L39 NOT (L31) previously printed
=> fil medl; d que nos 148
FILE 'MEDLINE' ENTERED AT 16:05:27 ON 20 JUN 2002
```

FILE LAST UPDATED: 19 JUN 2002 (20020619/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

```
L7      782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
          EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8      SCR 1841
L10     STR
L12     19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L42     6 SEA FILE=REGISTRY ABB=ON L12 AND MEDLINE/LC
L46     198 SEA FILE=MEDLINE ABB=ON L42
L47     226862 SEA FILE=MEDLINE ABB=ON PHOSPHOTRANSFERASES+NT/CT
L48     2 SEA FILE=MEDLINE ABB=ON L46 AND L47
```

```
=> d que nos 150; fil embase; d que nos 154; fil biosis; d que nos 158; fil drugu; d que
nos 162
```

```
L7      782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
```

EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8 SCR 1841
L10 STR
L12 19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L42 6 SEA FILE=REGISTRY ABB=ON L12 AND MEDLINE/LC
L46 198 SEA FILE=MEDLINE ABB=ON L42
L49 3964 SEA FILE=MEDLINE ABB=ON P38
L50 0 SEA FILE=MEDLINE ABB=ON L46 AND L49

FILE 'EMBASE' ENTERED AT 16:05:50 ON 20 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 13 Jun 2002 (20020613/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

L7 782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8 SCR 1841
L10 STR
L12 19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L43 9 SEA FILE=REGISTRY ABB=ON L12 AND EMBASE/LC
L51 493 SEA FILE=EMBASE ABB=ON L43
L52 118811 SEA FILE=EMBASE ABB=ON PHOSPHOTRANSFERASE+NT/CT
L53 3284 SEA FILE=EMBASE ABB=ON P38
L54 2 SEA FILE=EMBASE ABB=ON L51 AND (L52 OR L53)

FILE 'BIOSIS' ENTERED AT 16:05:51 ON 20 JUN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 19 June 2002 (20020619/ED)

L7 782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)
L8 SCR 1841
L10 STR
L12 19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)
L13 1 SEA FILE=REGISTRY ABB=ON 165245-96-5
L44 16 SEA FILE=REGISTRY ABB=ON L12 AND BIOSIS/LC
L55 251 SEA FILE=BIOSIS ABB=ON L44
L56 1718 SEA FILE=BIOSIS ABB=ON L13
L57 42879 SEA FILE=BIOSIS ABB=ON P38 OR (KINASE# OR PHOSPHOTRANSFERASE#
OR TRANSPHOSPHORYLASE#) (5A) (ANTAG? OR INHIBIT?)
L58 12 SEA FILE=BIOSIS ABB=ON L55 AND (L56 OR L57)

FILE 'DRUGU' ENTERED AT 16:05:51 ON 20 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE LAST UPDATED: 18 JUN 2002 <20020618/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> SDI'S MAY BE RUN WEEKLY OR MONTHLY AS OF JUNE 2001. <<<

>>> (WEEKLY IS THE DEFAULT). FOR PRICING INFORMATION <<<

>>> SEE HELP COST <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

L7 782940 SEA FILE=REGISTRY ABB=ON (C5N-C6/EA OR C5N-C5N/EA OR C4N2-C5N/
EA OR C4N2-C6/EA OR C4N2-C5N/EA OR C4N2-C4N2/EA)

L8 SCR 1841

L10 STR

L12 19590 SEA FILE=REGISTRY SUB=L7 SSS FUL (L10 AND L8)

L45 4 SEA FILE=REGISTRY ABB=ON L12 AND DRUGU/LC

L59 68 SEA FILE=DRUGU ABB=ON L45

L60 543 SEA FILE=DRUGU ABB=ON P38

L61 26490 SEA FILE=DRUGU ABB=ON (KINASE# OR PHOSPHOTRANSFERASE# OR
PHOSPHO TRANSFERASE# OR TRANSPHOSPHORYLASE# OR TRANS PHOSPHORYL
ASE#) (5A) (ANTAG? OR INHIBIT?)

L62 3 SEA FILE=DRUGU ABB=ON L59 AND (L60 OR L61)

=> dup rem 164,165,148,162,158,154

FILE 'CAPLUS' ENTERED AT 16:06:21 ON 20 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:06:21 ON 20 JUN 2002

CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 16:06:21 ON 20 JUN 2002

FILE 'DRUGU' ENTERED AT 16:06:21 ON 20 JUN 2002

COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 16:06:21 ON 20 JUN 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:06:21 ON 20 JUN 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

PROCESSING COMPLETED FOR L64

PROCESSING COMPLETED FOR L65

PROCESSING COMPLETED FOR L48

PROCESSING COMPLETED FOR L62

PROCESSING COMPLETED FOR L58

PROCESSING COMPLETED FOR L54

L66 63 DUP REM L64 L65 L48 L62 L58 L54 (5 DUPLICATES REMOVED)

ANSWERS '1-31' FROM FILE CAPLUS

ANSWERS '32-47' FROM FILE USPATFULL

ANSWERS '48-49' FROM FILE MEDLINE

ANSWERS '50-52' FROM FILE DRUGU

ANSWERS '53-61' FROM FILE BIOSIS

ANSWERS '62-63' FROM FILE EMBASE

=> d ibib abs hitstr 1-47; d iall 48-63


L66 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2002 ACS

DUPLICATE 1

ACCESSION NUMBER: 2001:282235 CAPLUS
DOCUMENT NUMBER: 135:87085
TITLE: The effect of ABT-702, a novel adenosine
kinase inhibitor, on the responses
of spinal neurons following carrageenan inflammation
and peripheral nerve injury
AUTHOR(S): Suzuki, Rie; Stanfa, Louise C.; Kowaluk, Elizabeth A.;
Williams, Michael; Jarvis, Michael F.; Dickenson,
Anthony H.
CORPORATE SOURCE: Department of Pharmacology, University College London,
London, WC1E 6BT, UK
SOURCE: British Journal of Pharmacology (2001), 132(7),
1615-1623
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB This study investigated the effect of a novel and potent non-nucleoside
adenosine kinase inhibitor, ABT-702, on the responses of dorsal horn
neurons to selected peripheral stimuli. ABT-702 is orally effective in
reducing behavioral signs of nociception in models of acute, inflammatory,
and neuropathic pain. Electrophysiol. recordings were made from
wide-dynamic-range neurons in halothane-anesthetized rats. ABT-702 was
given s.c. following either carrageenan inflammation or peripheral nerve
injury (L5/L6 spinal nerve ligation). Comparisons were made between
carrageenan-treated and uninjected control animals, and similarly between
spinal-nerve-ligated (SNL) and sham-operated animals. ABT-702 produced
inhibition of the postdischarge, wind-up and C-fiber evoked responses in
both carrageenan-treated and nerve-injured animals. Furthermore, the
mech. and thermal evoked responses were similarly reduced in SNL rats.
Overall, ABT-702 produced a greater inhibition of these responses in SNL
rats than in sham controls. Similarly, ABT-702 tended to produce greater
effects after carrageenan-induced inflammation; however, this did not
reach significance. Protection of endogenous adenosine by ABT-702
therefore produces a marked inhibition of the noxious evoked neuronal
activity in inflamed and neuropathic rats. The results demonstrate a
plasticity in the endogenous adenosine-mediated inhibitory system
following SNL and provide a possible basis for the use of this compd. for
the treatment of neuropathic and other persistent pain states.

IT 214697-26-4, ABT 702
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(adenosine **kinase inhibitor** ABT-702 effect on the
responses of spinal neurons following carrageenan inflammation and
peripheral nerve injury)
RN 214697-26-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-
pyridinyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


Searched by Barb O'Bryen, STIC 308-4291

L66 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 2
ACCESSION NUMBER: 2000:142524 CAPLUS
DOCUMENT NUMBER: 132:180592
TITLE: Preparation of 5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine **kinase inhibitors**
INVENTOR(S): Bhagwat, Shripad S.; Perner, Richard J.; Gu, Yu-Gui
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 28 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6030969	A	20000229	US 1998-58324	19980409
PRIORITY APPLN. INFO.:		US 1997-43252P	P	19970416
OTHER SOURCE(S):		MARPAT 132:180592		
GI				



II



III

AB Title compds. (I) [wherein R1 and R2 = independently H, (aryl)alkyl, acyl, or taken together with the N to which they are attached form a 5- to 7-membered ring optionally contg. 1-3 addnl. N, O, or S heteroatoms; R3 and R4 = independently (aryl)alkyl, alkenyl, alkynyl, (hetero)aryl, or heterocyclic; R5 = arylalkyl, (hetero)aryl, or heterocyclic], and their pharmaceutically acceptable salts, were prepd. For example, reaction of 2-(3,4-dimethoxyphenyl)-1-(thien-2-yl)ethanone (prepn. given) with 4-bromo-2-(2,2-dicyanoethenyl)thiophene (prepn. given) yielded the intermediate II (26%). Cycloaddn. of II with formamidine acetate in the presence of diglyme, followed by workup and conversion to the salt, produced the title compd. III.HCl (26%). The latter inhibited adenosine kinase in vitro with IC50 of 0.3 nM. Administration of representative invention compds. produced significant antinociception as measured by reaction time in the hot plate test of analgesia in male CF1 mice.

Compds. of the invention are useful in the treatment of cerebral ischemia, epilepsy, pain, nociception, inflammation, and sepsis.


IT 214831-14-8P 214831-16-0P 214831-17-1P
 214831-18-2P 214831-20-6P 214831-23-9P
 214831-24-0P 214831-26-2P 214831-28-4P
 214831-29-5P 214831-30-8P 214831-35-3P
 214831-36-4P 214831-37-5P 214831-38-6P
 214831-39-7P 214831-40-0P 214831-41-1P
 214831-42-2P 214831-43-3P 214831-44-4P
 214831-45-5P 214831-46-6P 214831-49-9P
 214831-51-3P 214831-52-4P 214831-53-5P
 214831-54-6P 214831-55-7P 214831-56-8P
 214831-57-9P 214831-58-0P 214831-59-1P
 214831-60-4P 214831-61-5P 214831-62-6P
 214831-65-9P 214831-68-2P 214831-69-3P
 214831-70-6P 214831-71-7P 214831-72-8P
 214831-73-9P 214831-74-0P 214831-75-1P
 214831-76-2P 214831-78-4P 214831-79-5P
 214831-80-8P 214831-81-9P 214831-82-0P
 214831-83-1P 214831-84-2P 214831-85-3P
 214831-86-4P 214831-87-5P 214831-88-6P
 214831-89-7P 214831-90-0P 214831-91-1P
 214831-92-2P 214831-93-3P 214831-94-4P
 214831-95-5P 214831-96-6P 214831-97-7P
 214831-98-8P 214831-99-9P 214832-00-5P
 214832-01-6P 214832-02-7P 214832-03-8P
 214832-04-9P 214832-05-0P 214832-06-1P
 214832-07-2P 214832-08-3P 214832-09-4P
 214832-10-7P 214832-11-8P 214832-12-9P
 214832-13-0P 214832-14-1P 214832-15-2P
 214832-16-3P 214832-17-4P 214832-18-5P
 214832-19-6P 214832-20-9P 214832-21-0P
 214832-22-1P 214832-23-2P 214832-24-3P
 214832-25-4P 214832-26-5P 214832-27-6P
 214832-28-7P 259260-11-2P 259260-12-3P
 259260-13-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of 5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 214831-14-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(dimethylamino)phenyl]-6-pentyl- (9CI) (CA INDEX NAME)




RN 214831-16-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-6-pentyl-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-17-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6,7-bis(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 214831-18-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-ethyl-7-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 214831-20-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-pentyl-7-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 214831-23-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-24-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-6-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-26-2 CAPLUS

CN Pyrido[2,3-d]pyrimidine-6-acetic acid, 4-amino-5-(3-bromophenyl)-7-(2-thienyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-28-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-[(3-methoxyphenyl)methyl]-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-29-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)





● 2 HCl


RN 214831-30-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




HCl

RN 214831-35-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-36-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-37-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-38-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-39-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


RN 214831-40-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



HCl

RN 214831-41-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-42-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-43-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-44-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-45-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-46-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-49-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214831-51-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-[(2-methoxyethyl)methylamino]phenyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-52-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 214831-53-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 214831-54-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 214831-55-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis(3-fluoro-4-methylphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-56-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3-fluoro-4-methylphenyl)-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-57-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 214831-58-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-(dimethylamino)-2-pyridinyl]-5,6-

diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-59-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-60-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-[(2-methoxyethyl)methylamino]-2-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 214831-61-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 214831-62-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-65-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(4-(dimethylaminomethyl)phenyl)-7-[(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-68-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[(4-morpholinyl)-3-pyridinyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 214831-69-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-70-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-71-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-72-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-cyclopropyl-7-[6-(dimethylamino)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-73-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-74-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-75-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-76-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-78-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-79-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-phenyl-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-80-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-81-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(1-methylethyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-82-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-83-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 214831-84-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]-6-pentyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-85-3 CAPLUS

CN Pyrido[2,3-d]pyrimidine-6-acetic acid, 4-amino-5-(3-bromophenyl)-7-(2-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 214831-86-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-[(3-methoxyphenyl)methyl]-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 214831-87-5 CAPLUS



CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-88-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 214831-89-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-90-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-91-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-92-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214831-93-3 CAPLUS



CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-94-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 214831-95-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-96-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 214831-97-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214831-98-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 214831-99-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 214832-00-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214832-01-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-02-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-[(2-methoxyethyl)methylamino]phenyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-03-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-04-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214832-05-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 214832-06-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3-fluoro-4-methylphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214832-07-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-(dimethylamino)-2-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-08-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214832-09-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-[(2-methoxyethyl)methylamino]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-10-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-11-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-12-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-13-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-14-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-15-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-16-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-17-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-18-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-cyclopropyl-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-19-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-20-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-21-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-22-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-23-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-phenyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 214832-24-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-25-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(1-methylethyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-26-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 214832-27-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-28-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]-6-pentyl- (9CI) (CA INDEX NAME)



RN 259260-11-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 259260-12-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 259260-13-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 3

ACCESSION NUMBER: 2000:846131 CAPLUS

DOCUMENT NUMBER: 134:141518

TITLE: ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine **kinase inhibitor** with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat Kowaluk, Elizabeth A.; Mikusa, Joe; Wismer, Carol T.; Zhu, Chang Z.; Schweitzer, Edmund; Lynch, James J.; Lee, Chih-Hung; Jiang, Meiqun; Bhagwat, Shripad S.; Gontsyan, Arthur; Mckie, Jeff; Cox, Bryan F.; Polakowski, James; Reinhart, Glenn; Williams, Michael; Jarvis, Michael F.

CORPORATE SOURCE: Neurological and Urological Diseases Research, Abbott Laboratories, Abbott Park, IL, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2000), 295(3), 1165-1174

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of ABT-702, a novel, potent (IC50 = 1.7 nM), and selective non-nucleoside adenosine kinase (AK) inhibitor were examd. in rat models

Searched by Barb O'Bryen, STIC 308-4291

of nociception and acute inflammation. ABT-702 was orally effective and fully effective in suppressing nociception in a spectrum of pain models in the rat, including carrageenan-induced thermal hyperalgesia, the formalin test of persistent pain, and models of nerve injury-induced and diabetic neuropathic pain. ABT-702 was esp. potent at relieving inflammatory thermal hyperalgesia (ED50 = 5 .mu.mol/kg orally). ABT-702 was also effective in the carrageenan-induced paw edema model of acute inflammation (ED50 = 70 .mu.mol/kg orally). The antinociceptive and anti-inflammatory effects of ABT-702 were blocked by selective adenosine receptor antagonists, consistent with endogenous adenosine accumulation and adenosine receptor activation as a mechanism of action. The antinociceptive effects of ABT-702 were not blocked by the opioid antagonist naloxone. In addn., ABT-702 had less potential than morphine to induce tolerance to its antinociceptive effects. ABT-702 had no significant effect on rotorod performance or heart rate (at 30-300 .mu.mol/kg orally), mean arterial pressure (at 30-100 .mu.mol/kg orally), or exploratory locomotor activity (at .ltoreq.10 .mu.mol/kg orally). Thus, ABT-702 is a novel, non-nucleoside AK inhibitor, with a nonopioid, non-nonsteroidal anti-inflammatory drug-like mechanism of action, which has antinociceptive and anti-inflammatory activity in vivo.


IT 214697-26-4, ABT 702

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(ABT-702, an adenosine **kinase inhibitor** with analgesic and anti-inflammatory properties)

RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 4

ACCESSION NUMBER: 2000:846130 CAPLUS

DOCUMENT NUMBER: 134:141517

TITLE: ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine **kinase inhibitor** with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse

AUTHOR(S): Jarvis, Michael F.; Yu, Haixia; Kohlhaas, Kathy; Alexander, Karen; Lee, Chih-Hung; Jiang, Mequin; Bhagwat, Shripad S.; Williams, Michael; Kowaluk, Elizabeth A.

CORPORATE SOURCE: Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2000), 295(3), 1156-1164
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English


AB ABT-702 is a novel and potent ($IC_{50} = 1.7$ nM) non-nucleoside adenosine kinase (AK) inhibitor that has a selectivity of several orders of magnitude over other sites of interaction with adenosine (ADO) (A_1 , A_2A , A_3 receptors, ADO transporter, and ADO deaminase). ABT-702 was 1300-7700-fold more selective for AK than were a no. of other neurotransmitter and peptide receptors, ion channel proteins, neurotransmitter/nucleoside reuptake sites, and enzymes, including cyclooxygenases-1 and -2. ABT-702 was equipotent ($IC_{50} = 1.5$ nM) in inhibiting native human AK (placenta), two human recombinant AK isoforms (AKlong and AKshort), and AK from monkey, dog, rat, and mouse brain. Kinetic studies revealed that AK inhibition by ABT-702 was competitive with respect to ADO and noncompetitive with respect to Mg ATP. AK inhibition by ABT-702 was reversible after 4 h of dialysis. ABT-702 was orally active and fully effective in reducing acute somatic nociception ($ED_{50} = 8$ μ mol/kg i.p.; 65 μ mol/kg orally) in the mouse hot-plate assay. ABT-702 also dose dependently reduced nociception in the phenyl-p-quinone-induced abdominal constriction assay in mice. The antinociceptive effects of ABT-702 in the hot-plate assay were blocked by the nonselective ADO receptor antagonist theophylline, and by the A_1 -selective antagonist cyclopentyltheophylline (10 mg/kg i.p.), but not by the peripherally selective ADO receptor antagonist 8-(p-sulfophenyl)theophylline (50 mg/kg i.p.), the A_{2A} -selective antagonist 3,7-dimethyl-1-propargylxanthine (1 mg/kg i.p.) or the opioid antagonist naloxone (5 mg/kg i.p.). Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that effectively reduces acute thermal nociception in the mouse by a nonopioid, non-steroidal anti-inflammatory drug-like, ADO A_1 receptor-mediated mechanism.

IT 214697-26-4, ABT 702

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(pharmacol. of ABT-702, an adenosine **kinase inhibitor** with analgesic and anti-inflammatory properties)

RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 5 OF 63 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5

ACCESSION NUMBER: 1996:71553 CAPLUS

DOCUMENT NUMBER: 124:261073

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which **inhibit** EGF and/or PDGF receptor tyrosine **kinase**



INVENTOR(S): Spada, Alfred P.; Myers, Michael R.; Maguire, Martin P.; Persons, Paul E.

Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SOURCE: U.S., 33 pp. Cont.-in-part of U.S. Ser. No. 988,515,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5480883	A	19960102	US 1993-166199	19931210
US 5710158	A	19980120	US 1994-229886	19940419
WO 9515758	A1	19950615	WO 1994-US14180	19941208
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN			
RW:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9513050	A1	19950627	AU 1995-13050	19941208
EP 871448	A1	19981021	EP 1995-904308	19941208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE			
US 5656643	A	19970812	US 1995-385258	19950208
US 5795889	A	19980818	US 1995-386271	19950209
US 5646153	A	19970708	US 1995-439027	19950511
US 5721237	A	19980224	US 1995-469147	19950606
US 5714493	A	19980203	US 1996-652444	19960604
US 6057320	A	20000502	US 1997-881991	19970625
US 36256	E	19990720	US 1997-988005	19971210
AU 739382	B2	20011011	AU 1999-65543	19991230
AU 9965543	A1	20000323		
US 37650	E	20020409	US 2000-496399	20000202
PRIORITY APPLN. INFO.:			US 1991-698420	B2 19910510
			US 1992-988515	B2 19921210
			WO 1992-US3736	B2 19920506
			US 1993-146072	A3 19931108
			US 1993-166199	A2 19931210
			US 1994-229886	A 19940419
			WO 1994-US14180	W 19941208
			US 1995-439027	A3 19950511
			US 1996-652444	A5 19960604

OTHER SOURCE(S): MARPAT 124:261073
GI



AB The invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compds. Ar1XAr2 [I; Ar1, Ar2 = (un)substituted mono- or bicyclic rings with 0-3 substituents; X = (CHR1)0-4 or (CHR1)mZ(CHR1)n; Z = O, NR2, S, SO, SO2; m, n = 0-3; R1, R2 = H, alkyl] exhibiting protein tyrosine kinase inhibition activity. I inhibit abnormal cell proliferation in

proliferative disorders by selectively inhibiting EGF and/or PDGF receptor. Approx. 300 compds. I are listed with characterizing data, and biol. data for selected compds. are given. For example, m-ClC6H4OH was treated with NaH in THF, followed by 4-chloro-6,7-dimethoxyquinazoline, to give title compd. II. The claimed quinoxaline deriv. III inhibited PDGF-R cell-free autophosphorylation with an IC50 of 0.02-0.05 .mu.M.


IT 146535-82-2P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of bis mono- and bicyclic aryl and heteroaryl compds. as protein tyrosine **kinase inhibitors**)

RN 146535-82-2 CAPLUS

CN 4-Quinolinedicarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:240756 CAPLUS

DOCUMENT NUMBER: 136:279345

TITLE: Preparation of hydroxyarylpyridines with I.kappa.B **kinase .beta. (IKK) inhibiting** activity

INVENTOR(S): Lowinger, Timothy B.; Murata, Toshiki; Umeda, Masaomi; Sakakibara, Sachiko; Yoshino, Takashi; Sato, Hiroki; Masuda, Tsutomu; Koriyama, Yuji; Shimada, Mitsuyuki; Shintani, Takuya; Kadono, Hiroshi; Ziegelbauer, Karl B.; Fuchikami, Kinji; Komura, Hiroshi

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 280 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024679	A1	20020328	WO 2001-EP10405	20010910
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 2002114777	A2	20020416	JP 2000-289173	20000922
PRIORITY APPLN. INFO.:			JP 2000-289173	A 20000922
OTHER SOURCE(S):		MARPAT 136:279345		

Searched by Barb O'Bryen, STIC 308-4291

GI



AB Pyridines I [R = 3-hydroxy-2-pyridyl, 3-hydroxy-2-thienyl, (substituted)-2-hydroxyphenyl; R¹ = H, halogen; R² = H, 1,2,3,6-tetrahydropyridyl, (un)substituted amino, etc.; R³ = HO₂C, alkylcarbonyl, alkylcarbamoyl, alkylamino, (heteroaryl)hydroxymethyl, (heteroaryl)alkyl, etc.; R⁴ = (un)substituted amino; R² and R³ or R³ and R⁴ may form fused cycloalkyl or bicycloalkyl moieties optionally contg. NH moieties] such as II.HCl were prepd. as I.kappa.B kinase .beta. (IKK) inhibitors for the inhibition of nuclear factor .kappa.B (NF-.kappa.B) activity and the treatment of inflammatory diseases, such as asthma and ischemia; in addn., the compds. are antitumor and immunosuppressant agents. E.g., 2'-benzyloxyacetophenone, tert-Bu 3-formyl-1-piperidinecarboxylate, and malononitrile were stirred with NH₄OAc in PhMe at 150.degree. to yield aminopyridine II (R⁵ = PhCH₂; R⁶ = Me₃COCO) in 27% yield; removal of the benzyl group with Pd/C followed by removal of the Boc group with HCl in dioxane yielded the monohydrochloride of II (R⁵ = R⁶ = H) which showed good in vitro and cellular activities. Over 300 examples are prepd. with biol. data.


IT 406208-33-1P 406208-38-6P 406208-40-0P
 406208-49-9P 406210-63-7P 406211-49-2P
 406211-50-5P 406211-51-6P 406211-52-7P
 406211-53-8P 406211-54-9P 406211-55-0P
 406211-56-1P 406211-69-6P 406211-70-9P
 406211-71-0P 406211-72-1P 406211-73-2P
 406211-74-3P 406211-75-4P 406211-76-5P
 406211-77-6P 406211-78-7P 406211-79-8P
 406211-80-1P 406211-81-2P 406211-82-3P
 406211-83-4P 406211-84-5P 406211-85-6P
 406211-86-7P 406211-87-8P 406211-89-0P
 406211-90-3P 406211-91-4P 406211-92-5P
 406211-93-6P 406211-94-7P 406211-96-9P
 406211-97-0P 406211-98-1P 406211-99-2P
 406212-00-8P 406212-01-9P 406212-02-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (hydroxyaryl)pyridines as **inhibitors** of I.kappa.B kinase .beta. and as antiinflammatory, immunosuppressant, antitumor, and antiischemic agents)


RN 406208-33-1 CAPLUS

CN 1,8-Naphthyridin-2(1H)-one, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-fluoro-5-(3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 406208-38-6 CAPLUS

CN 1,8-Naphthyridin-2(1H)-one, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-(3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 406208-40-0 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)- (9CI) (CA INDEX NAME)




RN 406208-49-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 406210-63-7 CAPLUS
CN Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione, 7-(2-hydroxyphenyl)-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-49-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 1,2-dihydro-7-(2-hydroxyphenyl)-2-oxo-5-(3-piperidinyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-50-5 CAPLUS
CN 1,8-Naphthyridin-2(1H)-one, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-fluoro-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-51-6 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(4-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 406211-52-7 CAPLUS
CN 1,8-Naphthyridin-2(1H)-one, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 406211-53-8 CAPLUS


CN 1,8-Naphthyridin-2(1H)-one, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-nitro-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 406211-54-9 CAPLUS

CN 1,8-Naphthyridine-3-carbonitrile, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-55-0 CAPLUS
 CN 1,8-Naphthyridin-2(1H)-one, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-(phenylsulfonyl)-5-(3-piperidiny)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-56-1 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidiny)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-69-6 CAPLUS
CN 1,8-Naphthyridin-2(1H)-one, 3-amino-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-70-9 CAPLUS
CN Benzamide, N-[7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-1,8-naphthyridin-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-71-0 CAPLUS
 CN Acetamide, N-[7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-1,8-naphthyridin-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-72-1 CAPLUS
 CN 1,8-Naphthyridine-3-carboxylic acid, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-73-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-N-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-74-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-N-(methanesulfonyl)-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-75-4 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-N-methyl-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-76-5 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-N,N-dimethyl-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-77-6 CAPLUS
CN Pyrrolidine, 1-[[7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-1,8-naphthyridin-3-yl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-78-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-N-(phenylmethyl)-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-79-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-N-(2-methoxyethyl)-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-80-1 CAPLUS
CN Morpholine, 4-[[7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-1,8-naphthyridin-3-yl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-81-2 CAPLUS
CN Piperazine, 1-[[7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-1,8-naphthyridin-3-yl]carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 406211-82-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-N-(1-methylethyl)-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-83-4 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-N-[2-(dimethylamino)ethyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 406211-84-5 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-N-(2,3-dihydro-1H-inden-2-yl)-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 406211-85-6 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-N-(diphenylmethyl)-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 406211-86-7 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-N-[(1S)-1-phenylethyl]-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 406211-87-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-N-[(1R)-1-phenylethyl]-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 406211-89-0 CAPLUS

CN L-Alanine, N-[[7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-1,8-naphthyridin-3-yl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 406211-90-3 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-N-(2-phenylethyl)-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 406211-91-4 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cyclohexyl-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-92-5 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, N-(cyclohexylmethyl)-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-93-6 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-N-(2-hydroxyethyl)-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-94-7 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, N-cyclopropyl-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl


RN 406211-96-9 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, N-cyclobutyl-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride
(9CI) (CA INDEX NAME)



● HCl

RN 406211-97-0 CAPLUS


CN 1,8-Naphthyridine-3-carboxamide, N-cyclopentyl-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 406211-98-1 CAPLUS

CN 1,8-Naphthyridine-3-carboxamide, N-cycloheptyl-7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406211-99-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-N-(1-ethylpropyl)-1,2-dihydro-2-oxo-5-(3-piperidinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406212-00-8 CAPLUS
CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-N-(1-propylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 406212-01-9 CAPLUS
 CN 1,8-Naphthyridine-3-carboxamide, 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-1,2-dihydro-2-oxo-5-(3-piperidinyl)-N-(2,2,2-trifluoroethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 406212-02-0 CAPLUS
 CN Phenol, 2-[4-amino-5-(3-piperidinyl)pyrido[2,3-d]pyrimidin-7-yl]-3-(cyclopropylmethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 406213-65-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of (hydroxyaryl)pyridines as **inhibitors** of I.kappa.B
kinase .beta. and as antiinflammatory, immunosuppressant,
antitumor, and antiischemic agents)

RN 406213-65-8 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-5-[1-[(1,1-dimethylethoxy)carbonyl]-3-piperidinyl]-1,2-dihydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)



IT 405282-57-7P 405282-60-2P 406212-74-6P

406212-75-7P 406213-27-2P 406213-28-3P

406213-29-4P 406213-30-7P 406213-31-8P

406213-32-9P 406213-33-0P 406213-34-1P


406213-35-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. of (hydroxyaryl)pyridines as **inhibitors** of I.kappa.B
kinase .beta. and as antiinflammatory, immunosuppressant,
antitumor, and antiischemic agents)


RN 405282-57-7 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 5-[1-[(1,1-dimethylethoxy)carbonyl]-3-piperidinyl]-1,2-dihydro-7-(2-hydroxyphenyl)-2-oxo-, ethyl ester (9CI)
(CA INDEX NAME)




RN 405282-60-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[6-(aminocarbonyl)-2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406212-74-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[1,2,3,4-tetrahydro-2,4-dioxo-7-[2-(phenylmethoxy)phenyl]pyrido[2,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406212-75-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[1,2,3,4-tetrahydro-7-(2-hydroxyphenyl)-2,4-dioxopyrido[2,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-27-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-6-fluoro-1,7-dihydro-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-28-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-29-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-6-nitro-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-30-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[6-amino-2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-31-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[6-(benzoylamino)-2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-32-9 CAPLUS

CN 1,8-Naphthyridine-3-carboxylic acid, 7-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-5-[1-[(1,1-dimethylethoxy)carbonyl]-3-piperidinyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 406213-33-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-7-oxo-6-[(propylamino)carbonyl]-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 406213-34-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[2-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]-1,7-dihydro-6-[[[methylsulfonyl]amino]carbonyl]-7-oxo-1,8-naphthyridin-4-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 406213-35-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[4-amino-7-[2-(cyclopropylmethoxy)-6-[(4-methoxyphenyl)methoxy]phenyl]pyrido[2,3-d]pyrimidin-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220584 CAPLUS

DOCUMENT NUMBER: 136:247584

TITLE: Preparation of pyrazolamines and analogs as protein

kinase inhibitors for treatment of

cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Knegt, Ronald; Golec, Julian M.

C.; Li, Pan; Davies, Robert; Charrier, Jean-Damien

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 356 pp.

CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022608	A1	20020321	WO 2001-US42152	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427
OTHER SOURCE(S):		MARPAT 136:247584		
GI				



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z₁ = N or CR₉; Z₂ = N or CH; Z₃ = N or CR_x; Z₄ = N or CR_y; R_x and R_y = independently TR₃, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R₂ and R_{2a} = independently R, TWR₆; or C₂R₂R_{2a} = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R₆)₂O, C(R₆)₂SO-2, C(R₆)₂NR₆, CO, CO₂, CR₆OCO, CR₆CONR₆, C(R₆)₂NR₆CO, C(R₆)₂NR₆CO₂, CR₆:NNR₆, CR₆:NO, C(R₆)₂NR₆NR₆, C(R₆)₂NR₆SO₂NR₆, C(R₆)₂NR₆CONR₆, or CONR₆; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R₃ = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-2R, N(R₄)₂, CON(R₄)₂, SO₂N(R₄)₂, OCOR, NR₄COR, NR₄CO₂(aliph.), NR₄N(R₄)₂, C:NN(R₄)₂, C:NOR, NR₄CO(R₄)₂, NR₄SO₂N(R₄)₂, NR₄SO₂R, or OCON(R₄)₂; R₄ = R₇, COR₇, CO₂(aliph.), CON(R₇)₂, or SO₂R₇; or N(R₄)₂ = heterocyclyl or heteroaryl; R₆ and R₇ = independently H or (un)substituted aliph. group; or N(R₆)₂ = heterocyclyl or heteroaryl; or N(R₇)₂ = heterocyclyl or heteroaryl; R₉ = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z₁ = CR₉; Z₂ and Z₃ = N; Z₄ = CR_y]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-β.3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited K_i values of

< 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.


IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, (2-Biphenyl-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-24-0P 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine 404828-61-1P, [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS

CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-


yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-(3-(phenylmethoxy)propyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-

trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P,
(5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P, (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-31-2P, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404827-37-8P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-54-9P,

(6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P**, **404828-44-0P**, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-


ylquinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-

c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine **404829-18-1P**,
[5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl)(2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**, [2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-71-6P**, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine **404829-72-7P**, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-73-8P**, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-74-9P**, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-75-0P**, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-77-2P**, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine **404829-78-3P**, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS

CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]-

(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-01-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

Searched by Barb O'Bryen, STIC 308-4291


RN 404827-03-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-11-8 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-12-9 CAPLUS
CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-14-1 CAPLUS
CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-


3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1.

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-64-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-63-0

CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-67-4 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-72-1 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-71-0

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-74-3 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2

CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-


3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazoliny)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazoliny)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)


RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-80-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-82-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-83-7 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220583 CAPLUS

DOCUMENT NUMBER: 136:247583

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Davies, Robert; Bebbington, David; Knegetel, Ronald; Wannamaker, Marion; Li, Pan; Forester, Cornelia; Pierce, Albert; Kay, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 373 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022607	A1	20020321	WO 2001-US28940	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427

OTHER SOURCE(S): MARPAT 136:247583

GI

Searched by Barb O'Bryen, STIC 308-4291




AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring C]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.

IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, [2-(Biphenyl-4-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-24-0P** **404826-97-7P** **404827-06-1P**, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-25-4P**, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypentyl-2H-pyrazol-3-yl)(2-phenyl)quinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl](2-phenyl)quinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of

heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,

[2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine **404827-05-0P**, [2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine **404827-07-2P**, (6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-08-3P**, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-09-4P**, (6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-10-7P**, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404827-11-8P**, (5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-12-9P**, [2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404827-13-0P**, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-14-1P**, [2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine **404827-15-2P**, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine **404827-16-3P**, (4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-18-5P**, **404827-20-9P**, (5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-21-0P**, **404827-23-2P**, (5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-24-3P**, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine **404827-26-5P**, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine **404827-27-6P**, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404827-37-8P**, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-38-9P**, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-40-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-54-9P**, (6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-

pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyle)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyle-2H-pyrazol-3-yl) (2-

phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl)(2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**,


[2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-73-8P, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-77-2P, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine 404829-78-3P, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine 404872-67-9P 404872-68-0P 404872-69-1P 404872-88-4P 404872-89-5P 404872-90-8P 404872-93-1P 404872-94-2P 404872-97-5P 404872-98-6P 404872-99-7P 404873-00-3P 404873-01-4P 404873-03-6P 404873-04-7P 404873-05-8P 404873-39-8P 404873-40-1P 404873-41-2P 404873-42-3P 404873-43-4P 404873-44-5P 404873-45-6P 404873-46-7P 404873-47-8P 404873-48-9P 404873-49-0P 404873-50-3P 404873-51-4P 404873-52-5P 404873-53-6P 404873-54-7P 404873-55-8P 404873-56-9P 404873-57-0P 404873-58-1P 404873-59-2P 404873-60-5P 404873-61-6P 404873-62-7P 404873-63-8P 404873-64-9P 404873-65-0P 404873-66-1P 404873-67-2P 404873-68-3P 404873-69-4P 404873-70-7P 404873-71-8P 404873-72-9P 404873-73-0P 404873-74-1P 404873-75-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS
CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS
CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-66-0 CAPLUS
CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-80-8 CAPLUS

c1ccc(cc1)C2N3CCCCC3N(C2)N4C=CC=C4

3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 404826-82-0 CAPLOS
CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(
trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404827-01-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS

CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-09-4 CAPLUS

CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS
CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-12-9 CAPLUS
CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-


3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-64-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-63-0
CMF C20 H11 Cl F2 N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-67-4 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3
CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-
yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)



RN 404828-67-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazoliny)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazoliny)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazoliny)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)


RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoindol-2-yl)- (9CI) (CA INDEX NAME)


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-12-5 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)




RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404872-67-9 CAPLUS


CN 4-Pteridinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-68-0 CAPLUS


CN 4-Pteridinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-69-1 CAPLUS

CN 4-Pteridinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-88-4 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-89-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-(4-methyl-1-piperazinyl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-90-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-93-1 CAPLUS


CN 4,8-Quinazolinediamine, N8-(2-aminoethyl)-N4-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-94-2 CAPLUS


CN 4,6-Quinazolinediamine, N4-(7-fluoro-1H-indazol-3-yl)-N6-[2-(methylamino)ethyl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-97-5 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-4-amine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-98-6 CAPLUS


CN Pyrimido[4,5-d]pyrimidine-2,5-diamine, N5-1H-indazol-3-yl-7-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404872-99-7 CAPLUS


CN 4-Quinazolinamine, 8-(2-aminoethoxy)-N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-00-3 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-4-amine, N-(7-fluoro-1H-indazol-3-yl)-7-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-01-4 CAPLUS


CN Pyrimido[4,5-d]pyrimidin-4-amine, 7-(ethylthio)-N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-03-6 CAPLUS


CN Pyrido[3,2-d]pyrimidin-4-amine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-04-7 CAPLUS


CN Pyrido[4,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-05-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-39-8 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-40-1 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-41-2 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-42-3 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(1-isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-43-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-(1-isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-44-5 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-(1-isoquinolinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-45-6 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-46-7 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-47-8 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-48-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1-isoquinolinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-49-0 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-(1-isoquinolinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-50-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethynylphenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-51-4 CAPLUS

CN 4-Quinazolinamine, 2-(2-ethynylphenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-52-5 CAPLUS


CN Benzamide, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)

(NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404873-53-6 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(1-methylethyl)phenyl]- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-54-7 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-55-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-cyclopropylphenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-56-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-cyclopropylphenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-57-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-58-1 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-(2-methoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404873-59-2 CAPLUS

CN Phenol, 2-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-60-5 CAPLUS
CN Phenol, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-61-6 CAPLUS
CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404873-62-7 CAPLUS
CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(5-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-63-8 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(4-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-64-9 CAPLUS


CN Benzamide, 2-[4-[(5-fluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-65-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-aminophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-66-1 CAPLUS


CN 4-Quinazolinamine, 2-[2-(aminomethyl)phenyl]-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-67-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-aminophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-68-3 CAPLUS


CN 4-Quinazolinamine, 2-[2-(aminomethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-69-4 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-dihydro-4-isobenzofuranyl)-N-1H-indazol-3-yl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-70-7 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-1-naphthalenyl)-N-1H-indazol-3-yl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-71-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-chloro-1-naphthalenyl)-N-1H-indazol-3-yl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-72-9 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-nitrophenyl)- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-73-0 CAPLUS


CN Benzonitrile, 2-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-74-1 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]-5-methoxy- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-75-2 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-(2-nitrophenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


IT 404873-76-3P 404873-77-4P 404873-78-5P
404873-79-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404873-76-3 CAPLUS


CN Benzenesulfonamide, 2-[4-[(5,7-difluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-77-4 CAPLUS


CN Benzenesulfonamide, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404873-78-5 CAPLUS


CN Benzenesulfonamide, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404873-79-6 CAPLUS

CN Benzenesulfonamide, 2-[4-[(5-fluoro-1H-indazol-3-yl)amino]-2-quinazolinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)
RN 404828-81-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220582 CAPLUS

DOCUMENT NUMBER: 136:247582

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Bebbington, David; Binch, Hayley; Knegt, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 355 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022606	A1	20020321	WO 2001-US28803	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				



Searched by Barb O'Bryen, STIC 308-4291

US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-232795P P 20000915
US 2000-257887P P 20001221
US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247582

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring D]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-.beta.3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.

IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, (2-Biphenyl-4-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-24-0P** **404826-97-7P** **404827-06-1P**, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-25-4P**,


[2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclylpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,

[2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine **404827-05-0P**, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine **404827-07-2P**, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-08-3P**, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-09-4P**, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-10-7P**, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-11-8P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-12-9P**, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-13-0P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-14-1P**, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-15-2P**, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-16-3P**, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-18-5P**, **404827-20-9P**, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-21-0P**, **404827-23-2P**, (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-24-3P**, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-26-5P**, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-27-6P**, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-37-8P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-38-9P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-40-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-54-9P**, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-

pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-


phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**,

[2-(2-Trifluoromethylphenyl)quinolin-4-yl] (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-71-6P**, (2-Phenylquinazolin-4-yl) (2H-1,2,4-triazol-3-yl)amine **404829-72-7P**, (5-Methyl-2H-1,2,4-triazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-73-8P**, (2H-1,2,4-Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-74-9P**, (5-Methyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-75-0P**, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-77-2P**, (2-Phenylquinolin-4-yl) (1H-1,2,4-triazol-3-yl)amine **404829-78-3P**, (1H-[1,2,4]Triazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS
CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS
CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-77-3 CAPLUS
CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS

CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)

(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-(2-(trifluoromethyl)phenyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-64-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-63-0
CMF C20 H11 Cl F2 N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-67-4 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3
CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)


RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-80-4 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-82-6 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS
CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)


Searched by Barb O'Bryen, STIC 308-4291



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-12-5 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404829-16-9 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-19-2 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220581 CAPLUS

DOCUMENT NUMBER: 136:247581

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Golec, Julian M. C.; Charrier, Jean-Damien; Knegetel, Ronald; Bebbington, David; Davies, Robert; Li, Pan

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022605	A1	20020321	WO 2001-US28793	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427

OTHER SOURCE(S): MARPAT 136:247581

GI



I



II


AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover pyrazolamines and indazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N; at least one of Z1 or Z3 = N]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-.beta.3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.

IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, [2-(Biphenyl-4-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-24-0P** **404826-97-7P** **404827-06-1P**, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-25-4P**, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylamino)propyl]-2H-pyrazol-3-yl(2-phenylquinazolin-4-yl)amine
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (protein kinase inhibitor; prepn. of heterocyclylpyrazolamines and analogs as protein kinase

inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,

[2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine **404827-05-0P**, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine **404827-07-2P**, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-08-3P**, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-09-4P**, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-10-7P**, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-11-8P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-12-9P**, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-13-0P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-14-1P**, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-15-2P**, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-16-3P**, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-18-5P**, **404827-20-9P**, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-21-0P** **404827-23-2P**, (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-24-3P**, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-26-5P**, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-27-6P**, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-37-8P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-38-9P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-40-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-54-9P**, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-

pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-


phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, (5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**,

[2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-71-6P**, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine **404829-72-7P**, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-73-8P**, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-74-9P**, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-75-0P**, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-77-2P**, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine **404829-78-3P**, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
 (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS

CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)

(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-03-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-64-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-63-0

CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-67-4 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3

CMF C20 H13 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-56-4 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)


*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)

RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)


RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-
quinazolinyl)amino]- (9CI) (CA INDEX NAME)

RN 404828-71-3 CAPLUS


Searched by Barb O'Bryen, STIC 308-4291

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-76-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS
CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoindol-2-yl)- (9CI) (CA INDEX NAME)


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-12-5 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-19-2 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT **404828-81-5**, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 11 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220580 CAPLUS

DOCUMENT NUMBER: 136:247606

TITLE: Preparation of 3-(4-pyrimidinylamino)pyrazole derivatives as protein **kinase inhibitors**, especially of Aurora-2 and GSK-3, for treating cancer, diabetes and Alzheimer's disease.

INVENTOR(S): Davies, Robert; Bebbington, David; Binch, Haley; Knegtel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 357 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022604	A1	20020321	WO 2001-US28792	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
US 2000-232795P P 20000915
US 2000-257887P P 20001221
US 2001-286949P P 20010427

OTHER SOURCE(S): MARPAT 136:247606
GI

Searched by Barb O'Bryen, STIC 308-4291



AB The prepn. of title compds. I and their pharmaceutically acceptable salts or prodrugs is described [wherein: R1, R2 = dependently form (un)substituted fused, unsatd. or partially unsatd., 5-8 membered carbocyclic ring; R3, R4 = independently H, aliph., aryl, heteroaryl, heterocyclyl, or wide variety of functionalized sidechains; or dependently form a fused, 5-8 membered, unsatd. or partially unsatd. ring having 0-3 ring heteroatoms (N, S, O); R5 = fused, (un)substituted 5-7 membered monocyclic ring or 8-10 membered bicyclic ring (aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms (N, S, O))]. For example, chlorination of quinazolinone II with phosphorus oxychloride, followed by condensation with 3-amino-5-methylpyrazole afforded claimed compd. III. Compds. I are inhibitors of GSK-3 and Aurora-2 protein kinases. The invention also relates to methods of treating diseases assocd. with these protein kinases, such as diabetes, cancer and Alzheimer's disease. In bioassays, compds. I inhibited the following kinases with Kis reported < 100 nM: GSK-3.β (163 compds.), AURORA-2 (65 compds.), CDK-2 (no data), ERK2 (8 compds.), AKT (no data), and Human Src kinase (21 compds.). Claims included 146 specific compds., and 188 examples were given. The syntheses of 6 compds. and 46 intermediates are described.


IT 404826-21-7P 404827-06-1P 404827-25-4P
404828-54-2P 404828-58-6P 404828-61-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-20-6P 404826-22-8P 404826-23-9P
404826-24-0P 404826-60-4P 404826-61-5P
404826-63-7P 404826-64-8P 404826-65-9P
404826-66-0P 404826-67-1P 404826-68-2P
404826-69-3P 404826-70-6P 404826-71-7P
404826-72-8P 404826-73-9P 404826-74-0P
404826-75-1P 404826-76-2P 404826-77-3P
404826-78-4P 404826-79-5P 404826-80-8P
404826-81-9P 404826-82-0P 404826-83-1P
404826-84-2P 404826-85-3P 404826-86-4P
404826-87-5P 404826-88-6P 404826-89-7P
404826-90-0P 404826-91-1P 404826-92-2P
404826-93-3P 404826-94-4P 404826-95-5P
404826-96-6P 404826-97-7P 404826-98-8P
404826-99-9P 404827-00-5P 404827-01-6P
404827-02-7P 404827-03-8P 404827-04-9P
404827-05-0P 404827-07-2P 404827-08-3P
404827-09-4P 404827-10-7P 404827-11-8P
404827-12-9P 404827-14-1P 404827-15-2P
404827-16-3P 404827-24-3P 404827-26-5P
404827-27-6P 404827-28-7P 404827-29-8P
404827-31-2P 404827-35-6P 404827-37-8P
404827-38-9P 404827-40-3P 404827-54-9P
404827-55-0P 404827-56-1P 404827-58-3P
404827-62-9P 404827-64-1P 404827-67-4P
404827-70-9P 404827-72-1P 404827-74-3P
404828-07-5P 404828-10-0P 404828-11-1P
404828-12-2P 404828-14-4P 404828-15-5P
404828-16-6P 404828-17-7P 404828-18-8P
404828-19-9P 404828-20-2P 404828-21-3P
404828-22-4P 404828-23-5P 404828-24-6P
404828-25-7P 404828-26-8P 404828-27-9P
404828-28-0P 404828-29-1P 404828-31-5P
404828-32-6P 404828-34-8P 404828-35-9P
404828-36-0P 404828-37-1P 404828-38-2P
404828-39-3P 404828-40-6P 404828-41-7P
404828-42-8P 404828-43-9P 404828-44-0P
404828-45-1P 404828-46-2P 404828-47-3P
404828-48-4P 404828-49-5P 404828-50-8P
404828-51-9P 404828-52-0P 404828-53-1P
404828-55-3P 404828-56-4P 404828-57-5P
404828-59-7P 404828-60-0P 404828-62-2P
404828-63-3P 404828-64-4P 404828-65-5P
404828-66-6P 404828-67-7P 404828-69-9P
404828-71-3P 404828-72-4P 404828-73-5P
404828-74-6P 404828-75-7P 404828-76-8P
404828-77-9P 404828-78-0P 404828-79-1P
404828-80-4P 404828-82-6P 404828-83-7P
404828-84-8P 404828-98-4P 404829-00-1P
404829-01-2P 404829-03-4P 404829-16-9P
404829-17-0P 404829-18-1P 404829-19-2P
404829-21-6P 404829-22-7P 404829-23-8P
404829-24-9P 404829-55-6P 404829-56-7P
404829-57-8P 404829-66-9P 404829-67-0P
404829-68-1P 404829-69-2P 404829-70-5P
404829-71-6P 404829-72-7P 404829-73-8P
404829-74-9P 404829-75-0P 404829-77-2P
404829-78-3P 404844-79-7P 404844-80-0P
404844-82-2P 404844-83-3P 404844-85-5P
404844-86-6P 404844-88-8P 404844-89-9P
404844-90-2P 404844-91-3P 404844-92-4P
404844-93-5P 404844-94-6P 404844-95-7P


404844-96-8P 404844-99-1P 404845-00-7P
404845-01-8P 404845-02-9P 404845-06-3P
404845-07-4P 404845-08-5P 404845-09-6P
404845-10-9P 404845-11-0P 404845-12-1P
404845-18-7P 404845-28-9P 404845-29-0P
404845-30-3P 404845-31-4P 404845-32-5P
404845-34-7P 404845-35-8P 404845-36-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein
kinase inhibitors)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404826-84-2 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS
CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS
CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS
CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-89-7 CAPLUS
CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-97-7 CAPLUS

CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404827-01-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS

CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(6-chloro-1H-indazol-3-yl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-09-4 CAPLUS

CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS
CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-12-9 CAPLUS
CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-
1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS


CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[(2-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-24-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[(2-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)]



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-(2-(trifluoromethyl)phenyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)]



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)]



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-64-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-63-0

CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-67-4 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-


3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-
pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazoliny)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazoliny)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinoliny)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinololinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinololinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinololinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)




RN 404829-78-3 CAPLUS

CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404844-79-7 CAPLUS


CN 4-Quinazolinamine, 7-chloro-2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-80-0 CAPLUS


CN 4-Quinazolinamine, 6-methoxy-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-82-2 CAPLUS


CN Acetamide, N-[2-(4-chlorophenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]-7-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-83-3 CAPLUS


CN Ethanone, 1-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-7-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-85-5 CAPLUS

CN 4,7-Quinazolinediamine, 2-(4-chlorophenyl)-N7-ethyl-N4-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-86-6 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-7-methyl-N-(5-methyl-1H-pyrazol-3-


yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-88-8 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-89-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-90-2 CAPLUS


4-Quinazolinamine, 8-ethoxy-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-91-3 CAPLUS


7-Quinazolinol, 2-(4-chlorophenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-92-4 CAPLUS


7-Quinazolinecarbonitrile, 2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-93-5 CAPLUS


CN 4-Quinazolinamine, 7-methoxy-8-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-94-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-7-methoxy-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-95-7 CAPLUS


CN 7-Quinazolinecarboxamide, N-methyl-2-(3-methylphenyl)-4-[(5-methyl-1H-pyrazol-3-yl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-96-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-7-(methylsulfonyl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404844-99-1 CAPLUS


CN 1(2H)-Isoquinolinone, 3,4-dihydro-2-methyl-3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404845-00-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404845-01-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-ethyl-5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 404845-02-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)


RN 404845-06-3 CAPLUS

CN 4-Quinazolinamine, 2-phenyl-N-[5-(trifluoromethyl)-2H-indazol-3-yl]- (9CI)
(CA INDEX NAME)


RN 404845-07-4 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-2H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)


RN 404845-08-5 CAPLUS
CN 4-Quinazolinamine, N-(5-fluoro-2H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 404845-09-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-2H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 404845-10-9 CAPLUS
CN 4-Quinazolinamine, N-2H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404845-11-0 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-2H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404845-12-1 CAPLUS

CN 4-Quinazolinamine, N-2H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI)
(CA INDEX NAME)



RN 404845-18-7 CAPLUS

CN 4-Quinazolinamine, 2-(2,4-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-28-9 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 404827-17-4
CMF C23 H16 F3 N5 O



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404845-29-0 CAPLUS
CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 404827-19-6
CMF C23 H15 F4 N5 O



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404845-30-3 CAPLUS
CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 404827-21-0
CMF C23 H15 F4 N5 O



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404845-31-4 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1
CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404845-32-5 CAPLUS


CN 4-Quinazolinamine, N-(4,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-34-7 CAPLUS


CN 4-Quinazolinamine, 8-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-35-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-8-methyl-2-[(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404845-36-9 CAPLUS

CN 4-Quinazolinamine, 8-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 3-(4-pyrimidinylamino)pyrazole compds. as protein kinase inhibitors)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220579 CAPLUS

DOCUMENT NUMBER: 136:247580

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
INVENTOR(S): Davies, Robert; Li, Pan; Golec, Julian; Bebbington, David

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 406 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022603	A1	20020321	WO 2001-US28738	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.:

US 2000-232795P P 20000915
US 2000-257887P P 20001221
US 2001-286949P P 20010427


OTHER SOURCE(S):

MARPAT 136:247580

GI



I



II

AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SOO-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (triazinyl)pyrazolamines and indazolamines I [wherein Z1, Z2, and Z3 = N; Z4 = CRy]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-.beta.3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.

IT 404826-20-6P, [2-(3,4-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-21-7P, [2-(4-Bromophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-22-8P, [2-(Biphenyl-4-yl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-23-9P, [2-(4-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine 404826-24-0P 404826-97-7P 404827-06-1P, (5-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-25-4P, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine 404828-54-2P, (5-Methoxycarbonyl-2H-pyrazol-3-yl) (2-phenyl)quinazolin-4-yl)amine 404828-58-6P, (5-Benzyloxypropyl-2H-pyrazol-3-yl) (2-phenyl)quinazolin-4-yl)amine 404828-61-1P,


[5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



***. FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,

[2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine **404827-05-0P**, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine **404827-07-2P**, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-08-3P**, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-09-4P**, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-10-7P**, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-11-8P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-12-9P**, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-13-0P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-14-1P**, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-15-2P**, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-16-3P**, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-18-5P**, **404827-20-9P**, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-21-0P**, **404827-23-2P**, (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-24-3P**, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-26-5P**, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-27-6P**, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-37-8P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-38-9P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-40-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-54-9P**, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-

pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-ylquinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl) (2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-


phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyle)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyle-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyle)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyle-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyle-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyle)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyle-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-yl)quinazolin-4-yl) (1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**,

[2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-71-6P**, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine **404829-72-7P**, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-73-8P**, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-74-9P**, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-75-0P**, (5-Methylsulfonyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-77-2P**, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine **404829-78-3P**, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of heterocyclpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS

CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-67-1 CAPLUS

Cc1cc(C)cc(NC2=CN(CCN2C3=CC=C(C)C3)C4=CC=C(C)C4)c1

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS

CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS

1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)

(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-03-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS

CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)






*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-24-3 CAPLUS
CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS
CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-27-6 CAPLUS
CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI). (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-(2-(trifluoromethyl)phenyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

Searched by Barb O'Bryen, STIC 308-4291


CMF C2 H F3 O2



RN 404827-64-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-63-0
CMF C20 H11 Cl F2 N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-67-4 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-66-3
CMF C20 H13 Cl N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-70-9 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6
CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS

CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)


3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME).



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-65-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-66-6 CAPLUS


Searched by Barb O'Bryen, STIC 308-4291

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-69-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-70-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-
quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS
CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 404828-78-0 CAPLUS
CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoindol-2-yl)- (9CI) (CA INDEX NAME)


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-12-5 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2'-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of heterocyclylpyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazoliny)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220578 CAPLUS

DOCUMENT NUMBER: 136:263164

TITLE: Preparation of triazolamines as protein kinase

inhibitors for treatment of cancer, diabetes, and Alzheimer's disease

INVENTOR(S):

Bebbington, David; Knegtel, Ronald; Binch, Haley; Golec, Julian M. C.; Li, Pan; Charrier, Jean-Damien

PATENT ASSIGNEE(S):

Vertex Pharmaceuticals Incorporated, USA

SOURCE:

PCT Int. Appl., 377 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 8




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022602	A2	20020321	WO 2001-US42162	20010914
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427

OTHER SOURCE(S):

MARPAT 136:263164

GI



- AB Triazolamines I and pyrazolamines II [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2S0-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (heterocyclyl)triazolamines I [wherein Z1 = N or CR9; Z2 = N or CH; R9 is defined above]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-.beta.3, Aurora-2, ERK, and Src. For instance, the N-(4-quinazolinyl)-1H-1,2,4-triazol-3-amine III was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 1.0-20 .mu.M for Aurora-2.
- IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, (2-Biphenyl-4-yl)quinazolin-4-yl(5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-24-0P** **404826-97-7P** **404827-06-1P**, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-25-4P**,


[2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminoethyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(protein **kinase inhibitor**; prepn. of triazolamines, pyrazolamines, and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,

[2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine **404827-05-0P**, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine **404827-07-2P**, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-08-3P**, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-09-4P**, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-10-7P**, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-11-8P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-12-9P**, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-13-0P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-14-1P**, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-15-2P**, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-16-3P**, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-18-5P**, **404827-20-9P**, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-21-0P**, **404827-23-2P**, (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-24-3P**, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-26-5P**, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-27-6P**, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-37-8P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-38-9P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-40-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-54-9P**, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl) (2-phenyl)quinazolin-4-yl]amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl]amine **404828-11-1P**, (7-Chloro-2-pyridin-4-yl)quinazolin-4-yl] (5-methyl-2H-

pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl)(2-pyridin-3-ylquinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P** **404828-44-0P**, (2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-

phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl) (5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl) (5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl) (5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl) (2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl] (2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-ylquinazolin-4-yl) (1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl) [2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl) (2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl) (1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**,


[2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-71-6P**, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine **404829-72-7P**, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-73-8P**, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-74-9P**, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-75-0P**, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-77-2P**, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine **404829-78-3P**, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404889-28-7P** **404889-29-8P** **404889-30-1P** **404889-31-2P** **404889-32-3P** **404889-33-4P** **404889-34-5P** **404889-35-6P** **404889-36-7P** **404889-37-8P** **404889-38-9P** **404889-39-0P** **404889-40-3P** **404889-41-4P** **404889-42-5P** **404889-43-6P** **404889-44-7P** **404889-45-8P** **404889-46-9P** **404889-47-0P** **404889-48-1P** **404889-49-2P** **404889-50-5P** **404889-51-6P** **404889-52-7P** **404889-53-8P** **404889-54-9P** **404889-55-0P** **404889-56-1P** **404889-58-3P** **404889-59-4P** **404889-60-7P** **404889-61-8P** **404889-62-9P** **404889-63-0P** **404889-64-1P** **404889-66-3P** **404889-79-8P** **404889-80-1P** **404889-86-7P** **404889-96-9P** **404890-01-3P** **404890-13-7P** **404890-88-6P** **404890-89-7P** **404890-90-0P** **404890-91-1P** **404890-92-2P** **404890-94-4P** **404891-02-7P** **404891-04-9P** **404891-05-0P** **404891-06-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; prepn. of triazolamines, pyrazolamines, and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-63-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS

CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-65-9 CAPLUS

CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-74-0 CAPLUS


CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS


CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-77-3 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(
trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS

CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS


CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


Searched by Barb O'Bryen, STIC 308-4291

RN 404827-01-6 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS

CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-09-4 CAPLUS

CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS
CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-12-9 CAPLUS
CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS

4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 404827-22-1


CMF C23 H14 F5 N5 O




CRN 76-05-1
CMF C2 H F3 O2



RN 404827-24-3 CAPLUS
CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)




RN 404827-26-5 CAPLUS
CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-27-6 CAPLUS


CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS

CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS

CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-(2-(trifluoromethyl)phenyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-


3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-64-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-63-0

CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 404827-67-4 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3

CMF C20 H13 Cl N6

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-64-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-63-0

CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-67-4 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-24-6 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-
yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-56-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-57-5 CAPLUS

CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)



RN 404828-59-7 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-69-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)


RN 404828-70-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-76-8 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS

CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-12-5 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-19-2 CAPLUS
CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinololinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinololinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)




RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404889-28-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-29-8 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-30-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dimethoxyphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-31-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-32-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-33-4 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)




Ethanone, 1-[2-[4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)



14-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-37-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-38-9 CAPLUS

CN Phenol, 2-[4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-39-0 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-40-3 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-41-4 CAPLUS


CN 4-Quinazolinamine, N-(5-phenyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-42-5 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-43-6 CAPLUS


CN 4-Quinazolinamine, N-[5-(cyclopropylmethyl)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-44-7 CAPLUS


CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-45-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-1,2,4-triazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-46-9 CAPLUS


CN 1H-1,2,4-Triazole-3-acetonitrile, 5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-47-0 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-48-1 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-cyclohexyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-49-2 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(1,1-dimethylethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-50-5 CAPLUS


CN Benzonitrile, 2-[4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-51-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-bromophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-52-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-fluoro-2-(trifluoromethyl)phenyl]-N-(5-methyl-1H-
1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-53-8 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-
yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-54-9 CAPLUS


4-Quinazolinamine, 8-methoxy-N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-55-0 CAPLUS


4-Quinazolinamine, 7-methyl-N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-56-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-58-3 CAPLUS


CN 4-Quinazolinamine, 2-(4-chloro-3-pyridinyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-59-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-60-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-61-8 CAPLUS


CN 4-Quinazolinamine, 8-methyl-N-(5-phenyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-62-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-furanyl)-1H-1,2,4-triazol-3-yl]-8-methyl-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-63-0 CAPLUS


CN 4-Quinazolinamine, 8-ethyl-N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-64-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-66-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-79-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-8-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-80-1 CAPLUS


CN 4-Quinazolinamine, 8-(4-methyl-1-piperazinyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-86-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404889-96-9 CAPLUS


CN Pyrido[3,2-d]pyrimidin-4-amine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-01-3 CAPLUS


CN Pyrido[4,3-d]pyrimidin-4-amine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-13-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-89-7 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-1,2,4-triazol-3-yl)-2-(1-naphthalenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-90-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-1,2,4-triazol-3-yl]-2-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-91-1 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-92-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-1,2,4-triazol-3-yl)-2-(1-isoquinolinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404890-94-4 CAPLUS


CN 4-Quinazolinamine, 2-(1-isoquinolinyl)-N-[5-(1-methylethyl)-1H-1,2,4-triazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-02-7 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-04-9 CAPLUS


Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404891-05-0 CAPLUS

CN 4-Quinazolinamine, 2-(2-ethynylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-06-1 CAPLUS
CN Benzamide, 2-[4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404891-07-2P 404891-08-3P 404891-09-4P
404891-10-7P 404891-12-9P 404891-13-0P
404891-14-1P 404891-15-2P 404891-18-5P
404891-19-6P 404891-21-0P 404891-23-2P
404891-25-4P 404891-26-5P 404891-28-7P
404891-29-8P 404891-31-2P 404891-32-3P
404891-34-5P 404891-35-6P 404891-36-7P
404891-38-9P 404891-39-0P 404891-41-4P
404891-42-5P 404891-43-6P 404891-64-1P
404891-78-7P 404891-79-8P 404891-80-1P
404891-89-0P 404892-28-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(protein **kinase inhibitor**; prepn. of triazolamines,
pyrazolamines, and analogs as protein **kinase**
inhibitors for treatment of cancer, diabetes, and Alzheimer's
disease)


RN 404891-07-2 CAPLUS
CN 4-Quinazolinamine, 2-[2-(1-methylethyl)phenyl]-N-(5-methyl-1H-1,2,4-
triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-08-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-cyclopropylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-09-4 CAPLUS


CN 4-Quinazolinamine, 2-[2-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-10-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-aminophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-12-9 CAPLUS


CN 4-Quinazolinamine, 2-[2-(aminomethyl)phenyl]-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-13-0 CAPLUS


CN 4-Quinazolinamine, 2-(1,3-dihydro-4-isobenzofuranyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-14-1 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-2-[4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-15-2 CAPLUS


CN Benzonitrile, 2-[4-[[5-(2-methylpropyl)-1H-1,2,4-triazol-3-yl]amino]-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-18-5 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-19-6 CAPLUS


CN Ethanone, 1-[4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-2-phenyl-7-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-21-0 CAPLUS

CN 4,7-Quinazolinediazine, 2-(4-chlorophenyl)-N7-ethyl-N4-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-23-2 CAPLUS

CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-7-methyl-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)


triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-7-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-26-5 CAPLUS


CN 4-Quinazolinamine, 8-ethoxy-N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-28-7 CAPLUS


CN 7-Quinazolinol, 2-(4-chlorophenyl)-4-[(5-methyl-1H-1,2,4-triazol-3-yl)amino]-, methylcarbamate (ester) (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-29-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-31-2 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-32-3 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-1,2,4-triazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404891-34-5 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404891-35-6 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-(3-thienyl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-36-7 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-38-9 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-39-0 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-41-4 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-42-5 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-43-6 CAPLUS


CN 1H-1,2,4-Triazole-3-carboxamide, N-methyl-N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404891-64-1 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404891-78-7 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404891-79-8 CAPLUS

CN 4-Quinolinamine, 2-(2-chlorophenyl)-N-(5-cyclopropyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



RN 404891-80-1 CAPLUS


CN 4-Quinolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404891-89-0 CAPLUS


CN 1,7-Naphthyridin-4-amine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-

(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404892-28-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-(2-naphthalenyl)-
(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

IT 404828-81-5, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of triazolamines, pyrazolamines, and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404828-81-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



L66 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:220577 CAPLUS

DOCUMENT NUMBER: 136:247579

TITLE: Preparation of pyrazolamines and analogs as protein
kinase inhibitors for treatment of
cancer, diabetes, and Alzheimer's disease

INVENTOR(S): Knegtel, Ronald; Bebbington, David; Binch, Hayley;
Golec, Julian; Patel, Sanjay; Charrier, Jean-Damien;
Kay, David; Davies, Robert; Li, Pan; Wannamaker,
Marion; Forster, Cornelia; Pierce, Albert

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 376 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022601	A1	20020321	WO 2001-US28740	20010914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915
			US 2000-257887P	P 20001221
			US 2001-286949P	P 20010427

OTHER SOURCE(S): MARPAT 136:247579

GI



I



II

AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteroaryl, heterocyclyl, or carbocyclyl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)satd. fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring contg. 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO-2, C(R6)2NR6, CO, CO2, CR6OCO, CR6OCONR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliph., (hetero)aryl, or heterocyclyl ring; R3 = R, halo, O, OR, COR, CO2R, COCOR, COCH2COR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, NR4CO2(aliph.), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2; R4 = R7, COR7, CO2(aliph.), CON(R7)2, or SO2R7; or N(R4)2 = heterocyclyl or heteroaryl; R6 and R7 = independently H or (un)substituted aliph. group; or N(R6)2 = heterocyclyl or heteroaryl; or N(R7)2 = heterocyclyl or heteroaryl; R9 = R, halo, OR, COR, CO2R, COCOR, etc.] were prepd. as protein kinase inhibitors, esp. as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover pyrimidinyl- and pyridinyl- pyrazolamines and indazolamines I [wherein Z1 = N, CRa, or CH; Z2 = N or CH; and at least one of Z1 or Z2 = N; Z3 = CRx; Z4 = CRy; Ra = halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2N(R4)2, OCOR, NR4COR, etc.; R and R4 are defined above]. Examples include data for approx. 300 invention compds. prepd. by a variety of synthetic methods and bioassay results for the inhibition of GSK-.beta.3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepd. and exhibited Ki values of < 0.1 .mu.M for glycogen synthetase kinase 3.beta. (GSK-3.beta.) and 0.1-1.0 .mu.M for Aurora-2.


IT **404826-20-6P**, [2-(3,4-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-21-7P**, [2-(4-Bromophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-22-8P**, [2-Biphenyl-4-ylquinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-23-9P**, [2-(4-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine **404826-24-0P** **404826-97-7P** **404827-06-1P**, (5-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-25-4P**, [2-(2-Chloro-4-nitrophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine **404828-54-2P**, (5-Methoxycarbonyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-58-6P**, (5-Benzoyloxypropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-61-1P**, [5-(3-tert-Butoxycarbonylaminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(protein **kinase inhibitor**; prepn. of
heterocyclylpyrazolamines and analogs as protein **kinase
inhibitors** for treatment of cancer, diabetes, and Alzheimer's
disease)

RN 404826-20-6 CAPLUS


CN 4-Quinazolinamine, 2-(3,4-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-21-7 CAPLUS


CN 4-Quinazolinamine, 2-(4-bromophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-22-8 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-4-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-23-9 CAPLUS


CN 4-Quinazolinamine, 2-(4-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-24-0 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX
NAME)



RN 404826-97-7 CAPLUS


CN 4-Quinazolinamine, N-(5-nitro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-06-1 CAPLUS


CN 4-Quinazolinamine, N-(5-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-25-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-chloro-4-nitrophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-54-2 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 404828-58-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-[5-[3-(phenylmethoxy)propyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-61-1 CAPLUS

CN Carbamic acid, [3-[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P, [2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P, [2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P, (2-Biphenyl-2-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P, [5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P, (4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P, (5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P, (4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P, (5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P, (5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P, (4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P, (7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P, (4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P, (1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P, (7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P, (5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P, [2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-04-9P,

[2-(2-Chlorophenyl)quinazolin-4-yl] (5-trifluoromethyl-1H-indazol-3-yl)amine **404827-05-0P**, [2-(2-Cyanophenyl)quinazolin-4-yl] (1H-indazol-3-yl)amine **404827-07-2P**, (6-Chloro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-08-3P**, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-09-4P**, (6-Bromo-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-10-7P**, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-11-8P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-12-9P**, [2-(2-Bromophenyl)quinazolin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine **404827-13-0P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-14-1P**, [2-(2,4-Dichlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-15-2P**, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-16-3P**, (4-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-18-5P**, **404827-20-9P**, (5-Fluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-21-0P** **404827-23-2P**, (5,7-Difluoro-1H-indazol-3-yl) [8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate **404827-24-3P**, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-26-5P**, [2-(4-Amino-2-chlorophenyl)quinazolin-4-yl] (5,7-Difluoro-1H-indazol-3-yl)amine **404827-27-6P**, (4,5,6,7-Tetrahydro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-28-7P**, (1H-Pyrazolo[4,3-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-29-8P**, (1H-Pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-30-1P**, (6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-31-2P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-35-6P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404827-37-8P**, (1H-Indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-38-9P**, (5,7-Difluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine **404827-40-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-54-9P**, (6-Fluoro-1H-indazol-3-yl) [2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404827-55-0P**, 3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester **404827-56-1P**, (5-Methyl-2H-pyrazol-3-yl) [2-(2-naphthyl-1-yl)quinazolin-4-yl]amine **404827-58-3P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-62-9P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-64-1P**, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-67-4P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-70-9P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-72-1P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404827-74-3P**, [2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl] (5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) **404828-07-5P**, (1H-Indazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-10-0P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-4-ylquinazolin-4-yl)-amine **404828-11-1P**, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl) (5-methyl-2H-

pyrazol-3-yl)amine **404828-12-2P**, (6-Chloro-2-pyridin-4-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-14-4P**, (5-Methyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-15-5P**, [2-(4-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-16-6P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-17-7P**, [2-(3,5-Dichlorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-18-8P**, [2-(4-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-19-9P**, [2-(3-Iodophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-20-2P**, [2-(4-Ethylsulfanyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-21-3P**, (5-Cyclopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-22-4P**, [2-(4-tert-Butylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-23-5P**, [2-(4-Chlorophenyl)quinazolin-4-yl] (5-cyclopropyl-2H-pyrazol-3-yl)amine **404828-24-6P**, (2-Benzo[1,3]dioxol-5-yl)quinazolin-4-yl) (5-methyl-2H-pyrazol-3-yl)amine **404828-25-7P**, [2-(4-Dimethylaminophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-26-8P**, [2-(3-Methoxyphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-27-9P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3,4-dichlorophenyl)quinazolin-4-yl]amine **404828-28-0P**, [2-(3-Ethynylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-29-1P**, [2-(3-Methylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-31-5P**, [2-(3,5-Difluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-32-6P**, [2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-34-8P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404828-35-9P**, [2-(3-Cyanophenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-36-0P**, [2-(3-Isopropylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-37-1P**, (5-Methyl-2H-pyrazol-3-yl) (2-pyridin-3-yl)quinazolin-4-yl)amine **404828-38-2P**, [2-(3-Acetylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-39-3P**, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-40-6P**, [2-(3-Hydroxymethylphenyl)quinazolin-4-yl] (5-methyl-2H-pyrazol-3-yl)amine **404828-41-7P**, (5-Methyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-42-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl) [2-(3-phenoxyphenyl)quinazolin-4-yl]amine **404828-43-9P**, **404828-44-0P**, [2-Phenylquinazolin-4-yl] (2H-pyrazol-3-yl)amine **404828-45-1P**, (2H-Pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-46-2P**, (5-Ethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-47-3P**, (2-Phenylquinazolin-4-yl) (5-propyl-2H-pyrazol-3-yl)amine **404828-48-4P**, (5-Isopropyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-49-5P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-50-8P**, (5-tert-Butyl-2H-pyrazol-3-yl) (2-pyridin-4-yl)quinazolin-4-yl)amine **404828-51-9P**, (5-Cyclopentyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-52-0P**, (5-Phenyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-53-1P**, (5-Carboxy-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-55-3P**, (5-Hydroxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-56-4P**, (5-Methoxymethyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-57-5P**, [5-(3-Hydroxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-59-7P**, [5-(3-Methoxypropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-60-0P**, [5-(3-Aminopropyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-62-2P**, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-63-3P**, (5-Allylcarbamoyl-2H-pyrazol-3-yl) (2-phenylquinazolin-4-yl)amine **404828-64-4P**, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl] (2-phenylquinazolin-4-yl)amine **404828-65-5P**, (5-Benzylcarbamoyl-2H-pyrazol-3-yl) (2-

phenylquinazolin-4-yl)amine **404828-66-6P**, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-67-7P**, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-68-8P**, [5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-69-9P**, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine **404828-70-2P**, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-71-3P**, (5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-72-4P**, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-73-5P**, [5-((3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-74-6P**, (2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-75-7P**, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine **404828-76-8P**, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-77-9P**, [5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-78-0P**, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-79-1P**, [5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine **404828-80-4P**, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-82-6P**, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-83-7P**, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-84-8P**, (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine **404828-98-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine **404829-00-1P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine **404829-01-2P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine **404829-03-4P**, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine **404829-11-4P**, (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-12-5P**, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-13-6P**, (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-14-7P**, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-15-8P**, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-16-9P**, [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-17-0P**, (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine **404829-18-1P**, [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-19-2P**, [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-21-6P**, [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-22-7P**, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-23-8P**, [5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine **404829-24-9P**, (2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine **404829-25-0P**, (1H-Indazol-3-yl)[2-(2-methylimidazol-1-yl)quinazolin-4-yl]amine **404829-55-6P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-56-7P**, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-yl)amine **404829-57-8P**, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine **404829-66-9P**, (1H-Indazol-3-yl)(2-phenylquinolin-4-yl)amine **404829-67-0P**, (2-Phenylquinolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-68-1P**, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-69-2P**, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404829-70-5P**,


[2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-yl)amine **404829-71-6P**, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-yl)amine **404829-72-7P**, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-phenylquinazolin-4-yl)amine **404829-73-8P**, (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-74-9P**, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-75-0P**, (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine **404829-77-2P**, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine **404829-78-3P**, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-yl]amine **404858-63-5P** **404858-64-6P** **404858-65-7P** **404858-66-8P** **404858-83-9P** **404859-15-0P** **404859-17-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein **kinase inhibitor**; prepn. of heterocyclpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)

RN 404826-60-4 CAPLUS


CN 4-Quinazolinamine, 2-(2-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-61-5 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-62-6 CAPLUS


CN 4-Quinazolinamine, 2-(2,5-dimethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-63-7 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-64-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-65-9 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-66-0 CAPLUS


CN Ethanone, 1-[2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-67-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,3-dimethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-68-2 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-69-3 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-70-6 CAPLUS


CN 4-Quinazolinamine, 2-[1,1'-biphenyl]-2-yl-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-71-7 CAPLUS


CN Phenol, 2-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-72-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-ethoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-73-9 CAPLUS


CN 4-Quinazolinamine, N-[5-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-74-0 CAPLUS

CN 4-Quinazolinamine, N-[4-(2-thienyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-75-1 CAPLUS
CN 4-Quinazolinamine, N-(4-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-76-2 CAPLUS
CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-77-3 CAPLUS
CN 4-Quinazolinamine, N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-78-4 CAPLUS


CN 4-Quinazolinamine, N-(4,5-diphenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-79-5 CAPLUS


CN 1H-Pyrazole-4-carboxamide, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-80-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404826-81-9 CAPLUS

CN 3H-Pyrazol-3-one, 1,2-dihydro-5-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



RN 404826-82-0 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-83-1 CAPLUS

CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-[2-


(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-84-2 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-85-3 CAPLUS


CN 4-Quinazolinamine, N-(4-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-86-4 CAPLUS


CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-87-5 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-88-6 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-89-7 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-90-0 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX
NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-91-1 CAPLUS


CN 4-Quinazolinamine, N-[5-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-92-2 CAPLUS


CN 4-Quinazolinamine, N-[4-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-93-3 CAPLUS


CN 4-Quinazolinamine, 2-(2,6-dichlorophenyl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-94-4 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methylphenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-95-5 CAPLUS


CN 4-Quinazolinamine, N-[7-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-96-6 CAPLUS


CN 4-Quinazolinamine, N-[6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-98-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404826-99-9 CAPLUS


CN 4-Quinazolinamine, N-[4-(1H-pyrrol-1-yl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-00-5 CAPLUS

CN 1H-Indazole-3,5-diamine, N-[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-01-6 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)- (9CI)

(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-02-7 CAPLUS

CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)- (9CI)
(CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-03-8 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-04-9 CAPLUS


CN 4-Quinazolinamine, 2-(2-chlorophenyl)-N-[5-(trifluoromethyl)-1H-indazol-3-yl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-05-0 CAPLUS


CN Benzonitrile, 2-[4-(1H-indazol-3-ylamino)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-07-2 CAPLUS


CN 4-Quinazolinamine, N-(6-chloro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-08-3 CAPLUS


CN 4-Quinazolinamine, N-[7-fluoro-6-(trifluoromethyl)-1H-indazol-3-yl]-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-09-4 CAPLUS


CN 4-Quinazolinamine, N-(6-bromo-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-10-7 CAPLUS


CN 4-Quinazolinamine, 2-[2,4-bis(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-11-8 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-12-9 CAPLUS


CN 4-Quinazolinamine, N-(2-bromophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-13-0 CAPLUS


CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[5-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-14-1 CAPLUS


CN 4-Quinazolinamine, 2-(2,4-dichlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-15-2 CAPLUS


CN 4-Quinazolinamine, 2-[2-chloro-5-(trifluoromethyl)phenyl]-N-(5,7-difluoro-1H-indazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-16-3 CAPLUS

CN 4-Quinazolinamine, N-(4-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-18-5 CAPLUS

CN 4-Quinazolinamine, N-1H-indazol-3-yl-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-17-4

CMF C23 H16 F3 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-20-9 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-19-6

CMF C23 H15 F4 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-21-0 CAPLUS

CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-23-2 CAPLUS

CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-8-methoxy-2-[2-(trifluoromethyl)phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-22-1

CMF C23 H14 F5 N5 O




*** FRAGMENT DIAGRAM IS INCOMPLETE ***


CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-24-3 CAPLUS
CN 4-Quinazolinamine, 2-(2-chloro-3-pyridinyl)-N-(5,7-difluoro-1H-indazol-3-yl)-(9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-26-5 CAPLUS
CN 4-Quinazolinamine, 2-(4-amino-2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-27-6 CAPLUS
CN 4-Quinazolinamine, N-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]-(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-28-7 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-29-8 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazolo[3,4-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-30-1 CAPLUS


CN 4-Quinazolinamine, N-(6-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-31-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-35-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-37-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-39-0

CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404827-54-9 CAPLUS


CN 4-Quinazolinamine, N-(6-fluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-55-0 CAPLUS


CN 1H-Indazole-5-carboxylic acid, 3-[[2-[2-(trifluoromethyl)phenyl]-4-quinazolinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404827-56-1 CAPLUS

CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(1-naphthalenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404827-58-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-57-2

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-61-8

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-64-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-63-0
CMF C20 H11 Cl F2 N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-67-4 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-1H-indazol-3-yl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-66-3
CMF C20 H13 Cl N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 404827-70-9 CAPLUS

CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(7-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-69-6

CMF C20 H12 Cl F N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 404827-72-1 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5-fluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 404827-71-0
CMF C20 H12 Cl F N6



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 404827-74-3 CAPLUS
CN Pyrido[3,4-d]pyrimidin-4-amine, 2-(2-chlorophenyl)-N-(5,7-difluoro-1H-indazol-3-yl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 404827-73-2
CMF C20 H11 Cl F2 N6




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 404828-07-5 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-10-0 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-11-1 CAPLUS


CN 4-Quinazolinamine, 7-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-12-2 CAPLUS


CN 4-Quinazolinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-pyridinyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-14-4 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-15-5 CAPLUS


CN 4-Quinazolinamine, 2-(4-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-16-6 CAPLUS


CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-17-7 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-dichlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-18-8 CAPLUS


CN Benzonitrile, 4-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-19-9 CAPLUS


CN 4-Quinazolinamine, 2-(3-iodophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-20-2 CAPLUS


CN 4-Quinazolinamine, 2-[4-(ethylthio)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-21-3 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-22-4 CAPLUS


CN 4-Quinazolinamine, 2-[4-(1,1-dimethylethyl)phenyl]-N-(5-methyl-1H-pyrazol-

3-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-23-5 CAPLUS

CN 4-Quinazolinamine, 2-(4-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-24-6 CAPLUS

CN 4-Quinazolinamine, 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)

*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-25-7 CAPLUS


CN 4-Quinazolinamine, 2-[4-(dimethylamino)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-26-8 CAPLUS


CN 4-Quinazolinamine, 2-(3-methoxyphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-27-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-28-0 CAPLUS


CN 4-Quinazolinamine, 2-(3-ethynylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-29-1 CAPLUS


CN 4-Quinazolinamine, 2-(3-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-31-5 CAPLUS


CN 4-Quinazolinamine, 2-(3,5-difluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-32-6 CAPLUS


CN 4-Quinazolinamine, 2-(3-chloro-4-fluorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-34-8 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-35-9 CAPLUS


CN Benzonitrile, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-36-0 CAPLUS


CN 4-Quinazolinamine, 2-[3-(1-methylethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-37-1 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-38-2 CAPLUS


CN Ethanone, 1-[3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-39-3 CAPLUS


CN 4-Quinazolinamine, 2-[3,5-bis(trifluoromethyl)phenyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-40-6 CAPLUS


CN Benzenemethanol, 3-[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-quinazolinyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-41-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-42-8 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3-phenoxyphenyl)-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-43-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-44-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-45-1 CAPLUS


CN 4-Quinazolinamine, N-1H-pyrazol-3-yl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-46-2 CAPLUS


CN 4-Quinazolinamine, N-(5-ethyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-47-3 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-propyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-48-4 CAPLUS


CN 4-Quinazolinamine, N-[5-(1-methylethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-49-5 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-50-8 CAPLUS


CN 4-Quinazolinamine, N-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-2-(4-
pyridinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-51-9 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopentyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-52-0 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-53-1 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-55-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-56-4 CAPLUS
CN 4-Quinazolinamine, N-[5-(methoxymethyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-57-5 CAPLUS
CN 1H-Pyrazole-3-propanol, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA
INDEX NAME)




RN 404828-59-7 CAPLUS
CN 4-Quinazolinamine, N-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-60-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(3-aminopropyl)-1H-pyrazol-3-yl]-2-phenyl- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404828-62-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-63-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 404828-64-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-methoxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(phenylmethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-66-6 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-cyclohexyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-67-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N,N-diethyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-68-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(2-phenylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-69-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]-N-propyl-
(9CI) (CA INDEX NAME)




RN 404828-70-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-ethyl-N-(1-methylethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-71-3 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-cyclopropyl-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-72-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(2-methylpropyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-73-5 CAPLUS


CN Pyrrolidine, 3-(methoxymethyl)-1-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 404828-74-6 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(3-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-75-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-(4-methylphenyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-76-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-methyl-5-[(2-phenyl-4-quinazolinyl)amino]-
(9CI) (CA INDEX NAME)




RN 404828-77-9 CAPLUS
CN Morpholine, 4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-
yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-78-0 CAPLUS

CN Piperazine, 1-methyl-4-[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 404828-79-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-(2-hydroxyethyl)-5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)




RN 404828-80-4 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



RN 404828-82-6 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-83-7 CAPLUS


CN 4-Quinazolinamine, N-(4-bromo-5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-84-8 CAPLUS


CN 1H-Pyrazole-4-carbonitrile, 3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404828-98-4 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1,3-dihydro-2H-isoindol-2-yl)- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-00-1 CAPLUS

CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-2(1H)-isoindol-2-yl)- (9CI) (CA INDEX NAME)


isoquinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-01-2 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2,3-dihydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-03-4 CAPLUS


CN 4-Quinazolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(3,4-dihydro-1(2H)-quinolinyl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-11-4 CAPLUS


CN 4-Quinazolinamine, N-(7-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-12-5 CAPLUS

CN 4-Quinazolinamine, N-(5-fluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-13-6 CAPLUS
CN 4-Quinazolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-phenyl- (9CI) (CA
INDEX NAME)




*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-14-7 CAPLUS
CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-[3-(trifluoromethyl)phenyl]- (9CI)
(CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-15-8 CAPLUS
CN 4-Quinazolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA
INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-16-9 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(3-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-17-0 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-phenyl-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-18-1 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-methoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-19-2 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(2,4-dichlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-21-6 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-22-7 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 1,5-dihydro-5-(4-phenoxyphenyl)-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-23-8 CAPLUS


CN 6H-Pyrazolo[4,3-c]pyridazin-6-one, 5-(4-chlorophenyl)-1,5-dihydro-3-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-24-9 CAPLUS


CN 4-Quinazolinamine, 2-(1H-imidazol-1-yl)-N-1H-indazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-25-0 CAPLUS


CN 4-Quinazolinamine, N-1H-indazol-3-yl-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-55-6 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-56-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-57-8 CAPLUS


CN Pyrido[3,4-d]pyrimidin-4-amine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-phenyl-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-66-9 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-phenyl- (9CI) (CA INDEX NAME)




RN 404829-67-0 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-pyrazolo[4,3-b]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 404829-68-1 CAPLUS

CN 4-Quinolinamine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-69-2 CAPLUS

CN 4-Quinolinamine, N-(5,7-difluoro-1H-indazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404829-70-5 CAPLUS

CN 4-Quinolinamine, N-1H-pyrazolo[4,3-b]pyridin-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404829-71-6 CAPLUS


CN 4-Quinazolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-72-7 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-phenyl- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-73-8 CAPLUS


CN 4-Quinazolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-74-9 CAPLUS


CN 4-Quinazolinamine, N-(5-methyl-1H-1,2,4-triazol-3-yl)-2-[2-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***

RN 404829-75-0 CAPLUS


CN 4-Quinazolinamine, N-[5-(methylthio)-1H-1,2,4-triazol-3-yl]-2-[2-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



*** FRAGMENT DIAGRAM IS INCOMPLETE ***


RN 404829-77-2 CAPLUS

CN 4-Quinolinamine, 2-phenyl-N-1H-1,2,4-triazol-3-yl- (9CI) (CA INDEX NAME)




RN 404829-78-3 CAPLUS

CN 4-Quinolinamine, N-1H-1,2,4-triazol-3-yl-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404858-63-5 CAPLUS

CN 4-Quinolinamine, N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404858-64-6 CAPLUS

CN 4-Quinolinamine, 2-(2-chlorophenyl)-N-(5-cyclopropyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)



RN 404858-65-7 CAPLUS


CN 4-Quinolinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 404858-66-8 CAPLUS

CN 4-Quinolinamine, 2-(2-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (9CI)


(CA INDEX NAME)




RN 404858-83-9 CAPLUS
CN 1,8-Naphthyridin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 404859-15-0 CAPLUS
CN 1,7-Naphthyridin-4-amine, N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 404859-17-2 CAPLUS
CN 1,7-Naphthyridin-4-amine, N-1H-indazol-3-yl-2-[2-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)



IT **404828-81-5**, 5-(2-Phenylquinazolin-4-ylamino)-1H-pyrazole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of heterocyclylpyrazolamines and analogs as protein **kinase inhibitors** for treatment of cancer, diabetes, and Alzheimer's disease)
RN 404828-81-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[[[5-[(2-phenyl-4-quinazolinyl)amino]-1H-pyrazol-3-yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:816643 CAPLUS

DOCUMENT NUMBER: 135:344500

TITLE: Preparation of condensed heteroaryl derivatives as phosphatidylinositol 3-**kinase inhibitors** and anticancer agents

INVENTOR(S): Hayakawa, Masahiko; Kaizawa, Hiroyuki; Moritomo, Hiroyuki; Kawaguchi, Ken-ichi; Koizumi, Tomonobu; Yamano, Mayumi; Matsuda, Koyo; Okada, Minoru; Ohta, Mitsuaki

PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Ludwig

Institute for Cancer Research; Imperial Cancer
Research Technology Ltd.

SOURCE:

PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

Japanese

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083456	A1	20011108	WO 2001-JP3650	20010426
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p> <p>RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG</p>				


PRIORITY APPLN. INFO.:

JP 2000-128472 A 20000427

OTHER SOURCE(S):

MARPAT 135:344500

GI



AB The title compds, e.g. I [n = 0 - 3; R1 = alkyl, etc.; R2, R3 = H, alkyl, etc; further detail on R2 and R3 is given; R4 = (un)substituted aryl, etc.; X = N, CH; Y = O, S, NH], are prepd. Several compds. of this invention in vitro showed IC50 values of .ltoreq. 1 .mu.M against phosphatidylinositol 3-kinase (p110 .alpha. subtype). The antitumor activity of compds. of this invention is also demonstrated.


IT 371949-41-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and effect of condensed heteroaryl derivs. with activity against phosphatidylinositol 3-kinase)

RN 371949-41-6 CAPLUS

CN Phenol, 3-[4-(4-morpholinyl)-2-pteridinyl]- (9CI) (CA INDEX NAME)




IT 307544-21-4P 371937-75-6P 371937-80-3P
371937-89-2P 371937-94-9P 371937-98-3P
371938-03-3P 371938-08-8P 371938-18-0P
371938-23-7P 371938-26-0P 371938-30-6P
371938-40-8P 371938-45-3P 371938-50-0P
371938-61-3P 371938-71-5P 371938-76-0P
371938-83-9P 371938-87-3P 371938-92-0P
371938-97-5P 371939-08-1P 371939-13-8P
371939-18-3P 371939-28-5P 371939-33-2P
371939-38-7P 371939-43-4P 371939-48-9P
371939-52-5P 371939-57-0P 371939-62-7P
371939-67-2P 371939-71-8P 371939-76-3P
371939-81-0P 371939-85-4P 371939-95-6P
371940-00-0P 371940-05-5P 371940-10-2P
371940-15-7P 371940-19-1P 371940-24-8P
371940-28-2P 371940-32-8P 371940-36-2P
371940-40-8P 371940-44-2P 371940-48-6P
371940-52-2P 371940-56-6P 371940-60-2P
371940-64-6P 371940-68-0P 371940-72-6P
371940-75-9P 371940-79-3P 371940-83-9P
371940-87-3P 371940-91-9P 371940-95-3P
371940-99-7P 371941-03-6P 371941-07-0P
371941-11-6P 371941-15-0P 371941-19-4P
371941-24-1P 371941-28-5P 371941-32-1P
371941-36-5P 371941-41-2P 371941-45-6P
371941-49-0P 371941-53-6P 371941-57-0P
371941-61-6P 371941-65-0P 371941-69-4P
371941-73-0P 371941-77-4P 371941-81-0P
371941-85-4P 371941-91-2P 371941-94-5P
371941-99-0P 371942-03-9P 371942-07-3P
371942-11-9P 371942-16-4P 371942-20-0P
371942-24-4P 371942-27-7P 371942-31-3P
371942-35-7P 371942-39-1P 371942-43-7P
371942-47-1P 371942-51-7P 371942-55-1P
371942-62-0P 371942-65-3P 371942-89-1P
371942-93-7P 371942-97-1P 371943-01-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of condensed heteroaryl derivs. as phosphatidylinositol 3-kinase inhibitors and anticancer agents)


RN 307544-21-4 CAPLUS

CN Quinazoline, 4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371937-75-6 CAPLUS

CN Quinazoline, 6-fluoro-4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371937-80-3 CAPLUS

CN Quinazoline, 6,7-dimethoxy-4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371937-89-2 CAPLUS

CN Quinazoline, 4-(4-morpholinyl)-6-nitro-2-phenyl- (9CI) (CA INDEX NAME)




RN 371937-94-9 CAPLUS

CN Acetamide, N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371937-98-3 CAPLUS


CN Quinazoline, 6-methoxy-4-(4-morpholinyl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 371938-03-3 CAPLUS
CN Acetamide, N-[4-(4-morpholinyl)-2-(3-nitrophenyl)-6-quinazolinyl]- (9CI)
(CA INDEX NAME)




RN 371938-08-8 CAPLUS
CN Quinazoline, 6-methoxy-2-phenyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 371938-18-0 CAPLUS
CN Methanesulfonamide, N-[4-(4-morpholinyl)-2-(3-nitrophenyl)-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371938-23-7 CAPLUS
CN Quinoline, 6-methoxy-4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371938-26-0 CAPLUS

CN 7-Quinazolinol, 6-methoxy-4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371938-30-6 CAPLUS

CN 6-Quinazolinol, 4-(4-morpholinyl)-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 371938-40-8 CAPLUS

CN 6-Quinazolinol, 2-phenyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 371938-45-3 CAPLUS

CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371938-50-0 CAPLUS

CN Formamide, N-[4-(4-morpholinyl)-2-phenyl-6-quinazoliny]- (9CI) (CA INDEX NAME)




RN 371938-61-3 CAPLUS

CN 4-Piperidinone, 1-(6-hydroxy-2-phenyl-4-quinazoliny)- (9CI) (CA INDEX NAME)




RN 371938-71-5 CAPLUS


CN 6-Quinazolinol, 4-(4-hydroxy-1-piperidinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371938-76-0 CAPLUS
CN 6-Quinazolinol, 4-(2,6-dimethyl-4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371938-83-9 CAPLUS
CN Acetamide, N-methyl-N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371938-87-3 CAPLUS
CN Benzenesulfonamide, 4-methyl-N-[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 371938-92-0 CAPLUS
CN 6-Quinazolinamine, N,N-dimethyl-4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371938-97-5 CAPLUS
CN 6-Quinazolinol, 2-phenyl-4-(4-thiomorpholinyl)-, hydrochloride (2:1) (9CI)
(CA INDEX NAME)




1/2 HCl

RN 371939-08-1 CAPLUS
CN 7-Quinazolinol, 4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371939-13-8 CAPLUS
CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 371939-18-3 CAPLUS

CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 371939-28-5 CAPLUS

CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 371939-33-2 CAPLUS


CN 6-Quinazolinol, 2-(2-furanyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 371939-38-7 CAPLUS


CN Benzoic acid, 4-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]-, methyl

ester (9CI) (CA INDEX NAME)




RN 371939-43-4 CAPLUS

CN Benzoic acid, 3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 371939-48-9 CAPLUS

CN 6-Quinazolinol, 2-(3-hydroxyphenyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 371939-52-5 CAPLUS


CN 1,3-Benzenediol, 5-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371939-57-0 CAPLUS
CN 6-Quinazolinol, 2-(2-fluorophenyl)-4-(4-morpholinyl)- (9CI) (CA INDEX
NAME)



RN 371939-62-7 CAPLUS
CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(5-nitro-3-thienyl)- (9CI) (CA INDEX
NAME)




RN 371939-67-2 CAPLUS
CN 6-Quinazolinol, 2-(3,4-dimethoxyphenyl)-4-(4-morpholinyl)- (9CI) (CA
INDEX NAME)




RN 371939-71-8 CAPLUS

CN 6-Quinazolinol, 4-(4-morpholinyl)-2-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 371939-76-3 CAPLUS

CN 6-Quinazolinol, 2-(4-hydroxy-3-methoxyphenyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 371939-81-0 CAPLUS

CN 6-Quinazolinol, 2-(2-benzofuranyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 371939-85-4 CAPLUS

CN Benzamide, 3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]-N-phenyl- (9CI)
(CA INDEX NAME)


RN 371939-95-6 CAPLUS

CN 6-Quinazolinol, 4-(4-morpholinyl)-2-pyrazinyl- (9CI) (CA INDEX NAME)




RN 371940-00-0 CAPLUS


CN 6-Quinazolinol, 2-(4-aminophenyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 371940-05-5 CAPLUS
CN Benzoic acid, 4-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)







RN 371940-10-2 CAPLUS
CN Benzoic acid, 3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371940-15-7 CAPLUS
CN 6-Quinazolinol, 2-[3-(hydroxymethyl)phenyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 371940-19-1 CAPLUS
CN 6-Quinazolinol, 2-(3-aminophenyl)-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 371940-36-2 CAPLUS
CN Benzamide, 4-[6-amino-4-(4-morpholinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371940-40-8 CAPLUS
CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-[4-(4-morpholinyl)-3-nitrophenyl]- (9CI) (CA INDEX NAME)



RN 371940-44-2 CAPLUS
CN Acetamide, N-[4-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-48-6 CAPLUS
CN 6-Quinazolinol, 4-(4-morpholinyl)-2-[3-[(phenylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-52-2 CAPLUS

CN Benzenesulfonamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-56-6 CAPLUS

CN Ethenesulfonamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 371940-60-2 CAPLUS


CN 2-Thiophenesulfonamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-64-6 CAPLUS
CN Acetamide, N-[4-(4-morpholinyl)-2-[3-[(phenylsulfonyl)amino]phenyl]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371940-68-0 CAPLUS
CN Benzenesulfonamide, N-[3-[6-[(methylsulfonyl)amino]-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-72-6 CAPLUS
CN Acetamide, N-[4-(4-morpholinyl)-2-[3-[(2-thienylsulfonyl)amino]phenyl]-6-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 371940-75-9 CAPLUS
CN Acetamide, N-[4-(4-morpholinyl)-2-[3-[(1-naphthalenylsulfonyl)amino]phenyl]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 371940-79-3 CAPLUS


CN Urea, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-N'-phenyl-
(9CI) (CA INDEX NAME)

RN 371940-83-9 CAPLUS


CN Carbamic acid, [3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-,
phenyl ester (9CI) (CA INDEX NAME)

RN 371940-87-3 CAPLUS


CN 4-Pyridinecarboxamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-91-9 CAPLUS
CN Cyclohexanecarboxamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-95-3 CAPLUS
CN Benzeneacetamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371940-99-7 CAPLUS
CN 2-Furancarboxamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371941-03-6 CAPLUS
CN Benzamide, 2-chloro-N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371941-07-0 CAPLUS
CN Benzamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 371941-11-6 CAPLUS
CN Benzamide, 4-cyano-N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371941-15-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 371941-19-4 CAPLUS

CN Benzamide, N-[3-[6-hydroxy-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 371941-24-1 CAPLUS

CN Acetic acid, [[4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 371941-28-5 CAPLUS


CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-phenyl-N-2-thiazolyl- (9CI) (CA INDEX NAME)




RN 371941-32-1 CAPLUS
CN 6-Quinazolinamine, 4-(4-morpholinyl)-2-phenyl-N-(4-phenyl-2-thiazolyl)-
(9CI) (CA INDEX NAME)



RN 371941-36-5 CAPLUS
CN 6-Quinolinol, 4-(4-morpholinyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371941-41-2 CAPLUS
CN Pyrido[4,3-d]pyrimidine, 2-(3-methoxyphenyl)-4-(4-morpholinyl)-,
dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 371941-45-6 CAPLUS
CN Phenol, 3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371941-49-0 CAPLUS
CN Pyrido[4,3-d]pyrimidine, 4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 371941-53-6 CAPLUS
CN Pyrido[4,3-d]pyrimidine, 4-(4-morpholinyl)-2-[3-[3-(4-morpholinyl)propoxy]phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



3 HCl


RN 371941-57-0 CAPLUS

CN Pyrido[4,3-d]pyrimidine, 4-(4-morpholinyl)-2-(3-nitrophenyl)-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371941-61-6 CAPLUS
CN Benzenamine, 3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]- (9CI) (CA
INDEX NAME)




RN 371941-65-0 CAPLUS
CN Benzenamine, 3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]-,
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 371941-69-4 CAPLUS
CN Acetamide, N-[3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291




● HCl

RN 371941-73-0 CAPLUS
CN Benzenesulfonamide, N-[3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 371941-77-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino-N-[3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 371941-81-0 CAPLUS


CN Phenol, 3-[4-(4-morpholinyl)pyrido[3,2-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 371941-85-4 CAPLUS


CN Pyrido[3,2-d]pyrimidine, 4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 371941-91-2 CAPLUS

CN Phenol, 3-[4-(4-morpholinyl)pyrido[3,4-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371941-94-5 CAPLUS
CN Pyrido[3,4-d]pyrimidine, 4-(4-morpholinyl)-2-[3-(2-(4-morpholinyl)ethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 371941-99-0 CAPLUS
CN Pyrido[2,3-d]pyrimidine, 2-(3-methoxyphenyl)-4-(4-morpholinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 371942-03-9 CAPLUS


CN Phenol, 3-[4-(4-morpholinyl)pyrido[2,3-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 371942-07-3 CAPLUS


CN Pyrido[2,3-d]pyrimidine, 4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 371942-11-9 CAPLUS


CN Phenol, 3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 371942-16-4 CAPLUS


CN Phenol, 3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291




● HCl

RN 371942-20-0 CAPLUS
CN Quinazoline, 6-fluoro-4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 371942-24-4 CAPLUS
CN Quinazoline, 6-fluoro-4-(4-morpholinyl)-2-(3-nitrophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 371942-27-7 CAPLUS
CN Benzenamine, 3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]-,
dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 371942-31-3 CAPLUS
CN Acetamide, N-[3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371942-35-7 CAPLUS
CN Benzenesulfonamide, N-[3-[6-fluoro-4-(4-morpholinyl)-2-
quinazolinyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371942-39-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-amino-N-[3-[6-fluoro-4-(4-morpholinyl)-2-quinazolinyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 371942-43-7 CAPLUS
CN Phenol, 3-[6-methoxy-4-(4-morpholinyl)-2-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 371942-47-1 CAPLUS

CN Quinazoline, 6-methoxy-4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 371942-51-7 CAPLUS
CN 6-Quinazolinol, 4-(4-morpholinyl)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 371942-55-1 CAPLUS
CN Phenol, 3-[4-(4-morpholinyl)-2-quinazolinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 371942-62-0 CAPLUS
CN Phenol, 3-[4-(4-morpholinyl)-2-pteridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 371942-65-3 CAPLUS
CN Phenol, 3-[4-(4-morpholinyl)-6-[2-(4-morpholinyl)ethoxy]-2-quinazolinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl


RN 371942-89-1 CAPLUS

CN Phenol, 3-[4-(4-morpholinyl)pyrido[4,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 371942-93-7 CAPLUS

CN Phenol, 3-[4-(4-morpholinyl)pyrido[3,2-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)




RN 371942-97-1 CAPLUS

CN Phenol, 3-[4-(4-morpholinyl)pyrido[3,4-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 371943-01-0 CAPLUS

CN Phenol, 3-[6-methoxy-4-(4-morpholinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




IT 371946-28-0P 371946-80-4P 371947-90-9P
371948-00-4P 371948-77-5P 371949-21-2P
371949-26-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of condensed heteroaryl derivs. as phosphatidylinositol 3-
kinase inhibitors and anticancer agents)


RN 371946-28-0 CAPLUS

CN Benzamide, 4-(1,4-dihydro-6-hydroxy-4-oxo-2-quinazolinyl)-N-phenyl- (9CI)
(CA INDEX NAME)




RN 371946-80-4 CAPLUS

CN 4(1H)-Quinazolinone, 6-[[4-(4-methylphenyl)sulfonyloxy]-2-phenyl]- (9CI)
(CA INDEX NAME)




RN 371947-90-9 CAPLUS


CN 4(1H)-Quinazolinone, 6-methoxy-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-
(9CI) (CA INDEX NAME)




RN 371948-00-4 CAPLUS
CN Benzamide, 4-[6-(acetyloxy)-1,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl-
(9CI) (CA INDEX NAME)




RN 371948-77-5 CAPLUS
CN 4(1H)-Quinazolinone, 6-(acetyloxy)-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-
(9CI) (CA INDEX NAME)



RN 371949-21-2 CAPLUS
CN 6-Quinazolinol, 2-phenyl-4-(4-thiomorpholinyl)-, 4-methylbenzenesulfonate
(ester) (9CI) (CA INDEX NAME)



RN 371949-26-7 CAPLUS
CN Thiourea, [4-(4-morpholinyl)-2-phenyl-6-quinazolinyl]- (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:381214 CAPLUS

DOCUMENT NUMBER: 135:116531

TITLE: Discovery of 4-Amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine, an Orally Active, Non-Nucleoside Adenosine **Kinase Inhibitor**

AUTHOR(S): Lee, Chih-Hung; Jiang, Meiqun; Cowart, Marlon; Gfesser, Greg; Perner, Richard; Kim, Ki Hwan; Gu, Yu Gui; Williams, Michael; Jarvis, Michael F.; Kowaluk, Elizabeth A.; Stewart, Andrew O.; Bhagwat, Shripad S.

CORPORATE SOURCE: Neurological and Urological Diseases Research Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL, 60064-6125, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(13), 2133-2138

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concns. at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (AK IC50 = 440 nM), led to the identification of the title compd. ABT-702, a novel, potent (AK IC50 = 1.7 nM) non-nucleoside AK inhibitor with oral activity in animal models of pain and inflammation.


IT 214696-47-6P 214696-74-9P 214697-20-8P
214697-63-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and structure activity relations of non-nucleoside adenosine **kinase inhibitors** and antinociceptive and anti-inflammatory activities)


RN 214696-47-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214696-74-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-20-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214697-63-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




IT 214697-26-4P, abt 702

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and structure activity relations of non-nucleoside adenosine
kinase inhibitors and antinociceptive and
anti-inflammatory activities)

RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:612013 CAPLUS

DOCUMENT NUMBER: 135:366315

TITLE: Pyridopyrimidine analogues as novel adenosine
kinase inhibitors

AUTHOR(S): Zheng, G. Z.; Lee, C.-H.; Pratt, J. K.; Perner, R. J.;
Jiang, M. Q.; Gomtsyan, A.; Matulenko, M. A.; Mao, Y.;
Koenig, J. R.; Kim, K. H.; Muchmore, S.; Yu, H.;
Kohlhaas, K.; Alexander, K. M.; McGaraughty, S.; Chu,
K. L.; Wismer, C. T.; Mikusa, J.; Jarvis, M. F.;
Marsh, K.; Kowaluk, E. A.; Bhagwat, S. S.; Stewart, A.
O.

CORPORATE SOURCE: Dept. 4PM, Abbott Laboratories, Abbott Park, IL,
60064-6115, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2001),
11(16), 2071-2074
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB A novel series of pyridopyrimidine analogs was identified as potent
adenosine kinase inhibitors based on the SAR and computational studies.
Substitution of the C7 position of the pyridopyrimidino core with C2'
substituted pyridino moiety increased the in vivo potency and enhanced
oral bioavailability of these adenosine kinase inhibitors.

IT 214697-26-4P 214697-28-6P 214700-50-2P
214700-62-6P 265103-70-6P 265103-73-9P
265105-63-3P 265106-10-3P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); PROC (Process); USES (Uses)
(pyridopyrimidine analogs as adenosine **kinase
inhibitors**)


RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-28-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-50-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-62-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265103-70-6 CAPLUS


CN 4-Piperidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265103-73-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265105-63-3 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)



RN 265106-10-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[methyl(3-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 214698-56-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(pyridopyrimidine analogs as adenosine kinase inhibitors)

RN 214698-56-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-chloro-3-pyridinyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:87302 CAPLUS

DOCUMENT NUMBER: 134:261046

TITLE: Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis

AUTHOR(S): Boyle, David L.; Kowaluk, Elizabeth A.; Jarvis, Michael F.; Lee, Chih-Hung; Bhagwat, Shripad S.; Williams, Michael; Firestein, Gary S.

CORPORATE SOURCE: Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2001), 296(2), 495-500
CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Adenosine (ADO) is a homeostatic inhibitory autocoid that is released at sites of inflammation and tissue injury, and exerts anti-inflammatory effects via multiple interactions at ADO receptor subtypes. Inhibition of ADO kinase (AK) increases extracellular ADO concns. and AK inhibitors have demonstrated ADO-mediated anti-inflammatory effects in acute models of inflammation. To evaluate the potential utility of this approach in chronic inflammation, a novel, potent, and selective non-nucleoside AK inhibitor, ABT-702, was tested in the rat adjuvant arthritis model.

Animals were immunized with complete Freund's adjuvant on day 0 and were treated with vehicle or ABT-702 (20 mg/kg/b.i.d.p.o.) beginning on day 8. ABT-702 significantly inhibited arthritis as detd. by paw vol. In addn., histol. and radiog. evidence of bone and cartilage destruction was significantly decreased in the treated group. Coadministration of the ADO receptor antagonist theophylline attenuated the anti-inflammatory effects of ABT-702, suggesting that this action was mediated through endogenous ADO release. To evaluate the mechanism of chondroprotection, Northern blot and electrophoretic mobility shift assays were performed on joints samples. These studies demonstrated that ABT-702 suppressed collagenase and stromelysin gene expression in treated animals. In addn., the activator protein-1 and nuclear factor-.kappa.B binding activity was also decreased. Therefore, ABT-702 inhibited clin., radiog., and histol. evidence of chronic inflammatory arthritis. The mechanism of joint protection is likely related to suppressed transcription factor activation and matrix metalloproteinase gene expression.


IT 214697-26-4, ABT-702

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis)

RN 214697-26-4 CAPLUS

CN Pyrdo[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:573775 CAPLUS

DOCUMENT NUMBER: 133:177164

TITLE: Preparation of pyrazolecarboxamides and pyrrolecarboxamides as inhibitors of the proliferation of activated lymphocytes and as remedies for autoimmune disease.

INVENTOR(S): Ushio, Hiroyuki; Ishibuchi, Seigo; Naito, Youichiro; Sugiyama, Naoki; Kawaguchi, Takafumi; Chiba, Kenji; Ohtsuki, Makio; Naka, Yoichi

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 315 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047558	A1	20000817	WO 2000-JP767	20000210
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				

CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1176140 A1 20020130 EP 2000-902925 20000210



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

JP 1999-33367 A 19990210
JP 1999-198473 A 19990713
WO 2000-JP767 W 20000210

OTHER SOURCE(S): MARPAT 133:177164

GI




AB The title compds. I [R1 represents substituted aryl, heteroaryl, etc.; R2 and R3 represent each hydrogen, alkyl, halogeno, hydroxy, etc.; Q represents N, CH, etc.; W represents hydrogen, alkyl, hydroxycarbonylalkyl, etc.; X represents halogeno, cyano, nitro, amino, etc.; X' represents hydrogen, halogeno, cyano or nitro; and Y represents alkyl, hydroxy, alkoxy, etc.] are prepd. For example, pyrazolecarboxamide deriv. II was prepd. The title compds. are said to show significant inhibiting activity against the proliferation of activated lymphocytes in vitro tests. A formulation is given.

IT 96201-88-6, Brequinar sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combination including pyrazolecarboxamides and
pyrrolecarboxamides and other agents)

RN 96201-88-6 CAPLUS

CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:314687 CAPLUS

DOCUMENT NUMBER: 132:334454

TITLE: Preparation of 2-amino-thiazole derivatives as antitumor agents

INVENTOR(S): Pevarello, Paolo; Amici, Raffaella; Traquandi, Gabriella; Villa, Manuela; Vulpetti, Anna; Isacchi, Antonella

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026202	A1	20000511	WO 1999-EP8306	19991027
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1124810	A1	20010822	EP 1999-955931	19991027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9914958	A	20011218	BR 1999-14958	19991027
NO 2001002057	A	20010628	NO 2001-2057	20010426
PRIORITY APPLN. INFO.:				
			GB 1998-23871	A 19981030
			US 1998-823871	A 19981030
			WO 1999-EP8306	W 19991027

OTHER SOURCE(S): MARPAT 132:334454

GI



AB The title compds. [I; R = halo, NO2, (un)substituted amino NH2, etc.; R1 =


alkyl, alkenyl, 3-6 membered carbocycle, etc.], useful for treating cell proliferative disorders assocd. with an altered cell dependent kinase activity such as cancer, Alzheimer's disease, viral infections, autoimmune diseases or neurodegenerative disorders, were prepd. E.g., thiazole I [R = iso-Pr; R1 = 4-Me2NC6H4CH2] showed Ki of 0.1 .mu.M against cdk2/cyclin A complex.

IT 267656-32-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-amino-thiazole derivs. as antitumor agents)

RN 267656-32-6 CAPLUS

CN 4-Quinolinecarboxamide, N-[5-(1-methylethyl)-2-thiazolyl]-2-phenyl- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:277982 CAPLUS

DOCUMENT NUMBER: 132:308351

TITLE: Preparation of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine **kinase inhibitors**

INVENTOR(S): Bhagwat, Shripad S.; Lee, Chih-hung; Cowart, Marlon D.; Mckie, Jeffrey A.; Grillot, Anne Laure; Stewart, Andrew O.; Zheng, Guo Zhu; Perner, Richard J.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 411 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023444	A1	20000427	WO 1999-US24901	19991021
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.: US 1998-176521			19981021	
OTHER SOURCE(S): MARPAT 132:308351				
GI				

Searched by Barb O'Bryen, STIC 308-4291




AB The title compds. [I; R¹, R² = H, alkenyl, alkoxyalkyl, alkoxycarbonyl, etc.; NR¹R² = 5-7 membered ring contg. 1-2 addnl. heteroatoms selected from O, N and S; R³ = alkenyl, alkyl, alkynyl, etc.; R⁴ = alkenyl, alkoxyalkynyl, alkyl, etc.] which inhibit adenosine kinase and therefore are useful in treating cerebral ischemia, epilepsy, nociception, inflammation and sepsis, were prepd. E.g., a 2-step synthesis of II was presented. Biol. data for compds. I were given.

IT 214695-90-6P 214696-24-9P 214696-50-1P
 214696-60-3P 214696-74-9P 214697-26-4P
 214697-61-7P 214697-64-0P 214697-81-1P
 214698-56-3P 214699-84-0P 214700-38-6P
 214700-50-2P 214700-53-5P 214700-56-8P
 214700-62-6P 214700-86-4P 214700-92-2P
 214701-00-5P 214701-05-0P 265103-42-2P
 265103-58-0P 265103-70-6P 265103-72-8P
 265103-78-4P 265103-86-4P 265103-88-6P
 265104-74-3P 265104-87-8P 265105-27-9P
 265105-49-5P 265105-52-0P 265105-68-8P
 265105-82-6P 265105-87-1P 265106-05-6P
 265106-22-7P 265106-24-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 214695-90-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-24-9 CAPLUS


CN Benzonitrile, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-
(9CI) (CA INDEX NAME)




RN 214696-50-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-iodophenyl)- (9CI)
(CA INDEX NAME)



RN 214696-60-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-aminophenyl)-5-(3-bromophenyl)- (9CI)
(CA INDEX NAME)




RN 214696-74-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-61-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-64-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromo-5-chlorophenyl)methyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-81-1 CAPLUS

CN Formamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214698-56-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-chloro-3-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 214699-84-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-amino-7-[6-(4-morpholinyl)-3-pyridinyl]pyrido[2,3-d]pyrimidin-5-yl]methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)




RN 214700-38-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-(1-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)




RN 214700-50-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,4-dioxaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-53-5 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-56-8 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-62-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-86-4 CAPLUS

CN Ethanol, 2-[2-[[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 214700-92-2 CAPLUS

CN Ethanol, 2-[2-[[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-1-oxido-2-pyridinyl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 214701-00-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-methylene-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214701-05-0 CAPLUS

CN 4-Piperidinone, 1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-42-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 265103-58-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 265103-70-6 CAPLUS

CN 4-Piperidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-72-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-78-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265103-86-4 CAPLUS


CN 4-Piperidinone, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265103-88-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-3-pyridazinyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




3 HCl

RN 265104-74-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-fluorophenyl)-7-[6-(4-


thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265104-87-8 CAPLUS


CN 3,4-Pyrrolidinediol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 265105-27-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(1,4-dioxaspiro[4.5]dec-8-yl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-49-5 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-52-0 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 265105-68-8 CAPLUS

CN Ethanone, 1-[1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-hydroxy-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 265105-82-6 CAPLUS


CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 265105-87-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3,6-dihydro[1(2H),2'-bipyridin]-5'-yl)- (9CI) (CA INDEX NAME)




RN 265106-05-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-oxa-4-thia-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265106-22-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(2,5-dihydro-1H-pyrrol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265106-24-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



IT 105387-96-0P 144632-91-7P 144632-92-8P
149065-08-7P 149065-12-3P 171254-48-1P
171254-49-2P 214695-91-7P 214695-92-8P
214695-93-9P 214695-94-0P 214695-95-1P
214695-96-2P 214695-97-3P 214695-98-4P
214695-99-5P 214696-00-1P 214696-03-4P
214696-04-5P 214696-06-7P 214696-07-8P
214696-10-3P 214696-11-4P 214696-12-5P
214696-13-6P 214696-14-7P 214696-15-8P
214696-16-9P 214696-17-0P 214696-18-1P
214696-19-2P 214696-20-5P 214696-21-6P
214696-22-7P 214696-23-8P 214696-25-0P
214696-26-1P 214696-27-2P 214696-28-3P
214696-29-4P 214696-30-7P 214696-31-8P
214696-32-9P 214696-33-0P 214696-34-1P
214696-35-2P 214696-36-3P 214696-37-4P
214696-38-5P 214696-39-6P 214696-40-9P
214696-41-0P 214696-42-1P 214696-43-2P
214696-44-3P 214696-45-4P 214696-46-5P
214696-47-6P 214696-48-7P 214696-49-8P
214696-51-2P 214696-52-3P 214696-55-6P
214696-56-7P 214696-57-8P 214696-58-9P
214696-59-0P 214696-61-4P 214696-62-5P
214696-63-6P 214696-64-7P 214696-65-8P
214696-66-9P 214696-67-0P 214696-68-1P
214696-69-2P 214696-70-5P 214696-71-6P
214696-73-8P 214696-75-0P 214696-76-1P
214696-77-2P 214696-78-3P 214696-79-4P
214696-80-7P 214696-81-8P 214696-82-9P
214696-83-0P 214696-84-1P 214696-85-2P
214696-86-3P 214696-87-4P 214696-88-5P
214696-90-9P 214696-91-0P 214696-92-1P
214696-93-2P 214696-94-3P 214696-95-4P
214696-96-5P 214696-97-6P 214696-98-7P
214696-99-8P 214697-00-4P 214697-01-5P
214697-02-6P 214697-03-7P 214697-04-8P
214697-05-9P 214697-06-0P 214697-07-1P
214697-08-2P 214697-09-3P 214697-10-6P
214697-11-7P 214697-12-8P 214697-13-9P
214697-14-0P 214697-15-1P 214697-16-2P
214697-18-4P 214697-20-8P 214697-21-9P
214697-22-0P 214697-23-1P 214697-27-5P
214697-28-6P 214697-29-7P 214697-30-0P
214697-31-1P 214697-32-2P 214697-33-3P
214697-34-4P 214697-35-5P 214697-36-6P
214697-37-7P 214697-38-8P 214697-39-9P
214697-40-2P 214697-41-3P 214697-42-4P
214697-43-5P 214697-44-6P 214697-45-7P
214697-46-8P 214697-47-9P 214697-48-0P
214697-49-1P 214697-52-6P 214697-54-8P
214697-55-9P 214697-56-0P 214697-57-1P


214697-60-6P 214697-62-8P 214697-63-9P
214697-66-2P 214697-67-3P 214697-68-4P
214697-69-5P 214697-70-8P 214697-71-9P
214697-72-0P 214697-73-1P 214697-74-2P
214697-75-3P 214697-76-4P 214697-78-6P
214697-79-7P 214697-80-0P 214697-82-2P
214697-83-3P 214697-84-4P 214697-85-5P
214697-86-6P 214697-87-7P 214697-89-9P
214697-91-3P 214697-95-7P 214697-97-9P
214697-99-1P 214698-01-8P 214698-02-9P
214698-04-1P 214698-06-3P 214698-08-5P
214698-10-9P 214698-12-1P 214698-14-3P
214698-16-5P 214698-18-7P 214698-20-1P
214698-22-3P 214698-23-4P 214698-25-6P
214698-27-8P 214698-30-3P 214698-32-5P
214698-34-7P 214698-36-9P 214698-37-0P
214698-39-2P 214698-41-6P 214698-43-8P
214698-50-7P 214698-52-9P 214698-54-1P
214698-58-5P 214698-59-6P 214698-62-1P
214698-64-3P 214698-66-5P 214698-68-7P
214698-70-1P 214698-72-3P 214698-78-9P
214698-81-4P 214698-85-8P 214698-87-0P
214698-89-2P 214698-91-6P 214698-93-8P
214698-95-0P 214698-97-2P 214698-99-4P
214699-01-1P 214699-03-3P 214699-05-5P
214699-06-6P 214699-08-8P 214699-10-2P
214699-11-3P 214699-12-4P 214699-14-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 105387-96-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5,7-diphenyl- (9CI) (CA INDEX NAME)




RN 144632-91-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-chlorophenyl)-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 144632-92-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-methoxyphenyl)-7-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 149065-08-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-aminophenyl)-5-phenyl- (9CI) (CA
INDEX NAME)




RN 149065-12-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 171254-48-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,7-bis(4-fluorophenyl)- (9CI) (CA INDEX
NAME)




RN 171254-49-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-chlorophenyl)-7-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 214695-91-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5,7-bis[4-(dimethylamino)phenyl]- (9CI)
(CA INDEX NAME)




RN 214695-92-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214695-93-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[4-(dimethylamino)phenyl]-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214695-94-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214695-95-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[4-(2,2-dimethylpropyl)phenyl]-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214695-96-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-butoxyphenyl)-7-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 214695-97-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-[4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214695-98-4 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[4-[4-amino-5-(4-butoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214695-99-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-00-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-03-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-04-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-06-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-07-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-10-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-11-4 CAPLUS

CN Benzamide, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-12-5 CAPLUS

CN Benzonitrile, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-13-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Ph-CH₂-O


RN 214696-14-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-butoxyphenyl)-
(9CI) (CA INDEX NAME)

RN 214696-15-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-
pyridinyl)phenyl]- (9CI) (CA INDEX NAME)

RN 214696-16-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-
methylphenyl)- (9CI) (CA INDEX NAME)


RN 214696-17-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-18-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 214696-19-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-20-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-21-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-phenyl- (9CI) (CA INDEX NAME)



RN 214696-22-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-ethylphenyl)- (9CI)
(CA INDEX NAME)

RN 214696-23-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-bromophenyl)- (9CI)
(CA INDEX NAME)


RN 214696-25-0 CAPLUS

CN Phenol, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI)
(CA INDEX NAME)




RN 214696-26-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-iodophenyl)- (9CI) (CA INDEX NAME)




RN 214696-27-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-28-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-29-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dichlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-30-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214696-31-8 CAPLUS
CN Phenol, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-32-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-33-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-34-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-35-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 214696-36-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-37-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-38-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-39-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-40-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-[(3-methoxyphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214696-41-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-42-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1,3-benzodioxol-5-yl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-43-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-ethoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 214696-44-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2-thienyl)- (9CI)
(CA INDEX NAME)




RN 214696-45-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 214696-46-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3-(dimethylamino)phenyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-47-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214696-48-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-49-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 214696-51-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-
(9CI) (CA INDEX NAME)

RN 214696-52-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(4-morpholinyl)phenyl]-5-(2-thienyl)-
(9CI) (CA INDEX NAME)


RN 214696-55-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-(2-thienyl)-
(9CI) (CA INDEX NAME)

RN 214696-56-7 CAPLUS


CN Benzamide, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI)

(CA INDEX NAME)




RN 214696-57-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-58-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-59-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(2-thienyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-61-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-(2-thienyl)-
(9CI) (CA INDEX NAME)


RN 214696-62-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-(2-furanyl)-
(9CI) (CA INDEX NAME)


RN 214696-63-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-(4-iodophenyl)-
(9CI) (CA INDEX NAME)


RN 214696-64-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-65-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214696-66-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-67-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-methyl-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-68-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-69-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-70-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-71-6 CAPLUS

CN Benzenamine, 4-[5-(3-bromophenyl)-4-(4-morpholinyl)pyrido[2,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 214696-73-8 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214696-75-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-76-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 214696-77-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-78-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214696-79-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 214696-80-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-iodophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214696-81-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3,5-bis(trifluoromethyl)phenyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214696-82-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3,5-bis(trifluoromethyl)phenyl]-7-[4-(4-

morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-83-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dibromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-84-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dibromophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-85-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(4-methyl-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-86-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-87-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-88-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 214696-90-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methythio)phenyl]-
(9CI) (CA INDEX NAME)

RN 214696-91-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3,4-dichlorophenyl)-
(9CI) (CA INDEX NAME)


RN 214696-92-1 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214696-93-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-94-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-95-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(3-amino-4-methoxyphenyl)-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214696-96-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[3-bromo-4-(dimethylamino)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214696-97-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 214696-98-7 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 214696-99-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)-3-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 214697-00-4 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 214697-01-5 CAPLUS

CN Acetamide, N-acetyl-N-[7-[4-(acetilmethylamino)phenyl]-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-02-6 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-03-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(ethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-04-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 214697-05-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(1-methylethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 214697-06-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[ethyl(2-methoxyethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 214697-07-1 CAPLUS

CN Propanamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-3-methoxy-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 214697-08-2 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214697-09-3 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 214697-10-6 CAPLUS

CN Propanenitrile, 3-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]methylamino]- (9CI) (CA INDEX NAME)




RN 214697-11-7 CAPLUS

CN Propanamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-12-8 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-13-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-methyl-4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-14-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(3-methoxy-1-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-15-1 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-1,3-dihydro-N-methyl-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 214697-16-2 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-18-4 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-20-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-21-9 CAPLUS

CN Benzonitrile, 3-[4-amino-7-[4-(methylsulfonyl)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214697-22-0 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-cyanophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-23-1 CAPLUS

CN Formamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-27-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-28-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-29-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(dimethylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-30-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-[(2-methoxyethyl)methylamino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-31-1 CAPLUS


CN Formamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-32-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(methylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 214697-33-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(1-pyrrolidinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-34-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-morpholinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-35-5 CAPLUS
CN 2-Oxazolidinone, 3-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-

yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-36-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 214697-37-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 214697-38-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-39-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-furanyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214697-40-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3'-methoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 214697-41-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-42-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-43-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-(4-iodophenyl)- (9CI) (CA INDEX NAME)




RN 214697-44-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-45-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-(4-(5-pyrimidinyl)phenyl)- (9CI) (CA INDEX NAME)




RN 214697-46-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-(4-iodophenyl)- (9CI) (CA INDEX NAME)




RN 214697-47-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214697-48-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(3-bromophenyl)methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-49-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-(2-bromophenylethyl)- (9CI) (CA INDEX NAME)




RN 214697-52-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[2-(4-bromophenyl)ethyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-54-8 CAPLUS

CN Benzonitrile, 3-[[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 214697-55-9 CAPLUS

CN Carbamic acid, [2-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 214697-56-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cycloheptyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-57-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[[5-chloro-2-(3-thienyl)phenyl]methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-60-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[2-(3-bromophenyl)ethyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-62-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclopropyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-63-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[4-(dimethylamino)phenyl]-
(9CI) (CA INDEX NAME)



RN 214697-66-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1,3-benzodioxol-4-yl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-67-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-68-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[4-

(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-69-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 214697-70-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,4-dichlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-71-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-72-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-73-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-74-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-75-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-76-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-78-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,3-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-79-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-80-0 CAPLUS

CN Acetamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-82-2 CAPLUS

CN Acetamide, N-[5-(3-bromophenyl)-7-[4-(diethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 214697-83-3 CAPLUS

CN Acetamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 214697-84-4 CAPLUS

CN Pentanamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 214697-85-5 CAPLUS


CN Benzamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 214697-86-6 CAPLUS


CN Carbamic acid, [2-[[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA

INDEX NAME)




RN 214697-87-7 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 214697-89-9 CAPLUS

CN Carbamic acid, [5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 214697-91-3 CAPLUS

CN Urea, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 214697-95-7 CAPLUS


CN 1,2-Ethanediamine, N'-[5-(4-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N,N-dimethyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 214697-97-9 CAPLUS


CN 1,4-Butanediamine, N'-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N,N-dimethyl-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl


RN 214697-99-1 CAPLUS

CN Formamide, N-[7-(4-bromophenyl)-5-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 214698-01-8 CAPLUS

CN Acetamide, N-acetyl-N-[7-(4-bromophenyl)-5-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214698-02-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(5-amino-2-pyridinyl)-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)



RN 214698-04-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 214698-06-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)pyrazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214698-08-5 CAPLUS

CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 214698-10-9 CAPLUS


CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 214698-12-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(4-chloro-3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214698-14-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-16-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-[[2-(2-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 214698-18-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-[[2-(3-thienyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 214698-20-1 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 214698-22-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(2-methoxyethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 214698-23-4 CAPLUS

CN 1,2-Ethanediamine, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 214698-25-6 CAPLUS

CN Acetamide, N-[2-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 214698-27-8 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214698-30-3 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 214698-32-5 CAPLUS

CN 2-Oxazolidinone, 3-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 214698-34-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-methylethyl)-3-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 214698-36-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-methyl-4-(1-pyrrolidinyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 214698-37-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-imidazol-1-yl)-3-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 214698-39-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 214698-41-6 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[[2-(3-amino-1-propynyl)phenyl]methyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214698-43-8 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-50-7 CAPLUS
 CN Urea, [4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214698-52-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-[1-(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 214698-54-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(3-methyl-5-isoxazolyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214698-58-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214698-59-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4H-1,2,4-triazol-4-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214698-62-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(1-pyrrolidinyl)phenyl]-5-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 214698-64-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-pyrazol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214698-66-5 CAPLUS

CN Urea, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN: 214698-68-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methyl-2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-70-1 CAPLUS

CN Formamide, N-[4-{4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl}-2-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214698-72-3 CAPLUS

CN Formamide, N-[4-{5-(3-bromophenyl)-4-(formylamino)pyrido[2,3-d]pyrimidin-7-yl}-2-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 214698-78-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,3-dihydro-1-methyl-1H-indol-5-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-81-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(1-methyl-1H-benzimidazol-5-yl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 214698-85-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-87-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-pyrrolidinyl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-89-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)pyrazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-91-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-[(2-methoxyethyl)methylamino]pyrazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-93-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-morpholinylmethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214698-95-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-[(bis(2-methoxyethyl)amino)-2-pyridinyl]-5-(3-bromophenyl)-, trihydrochloride (9CI) (CA INDEX NAME)



3 HCl

RN 214698-97-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1H-imidazol-1-ylmethyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 214698-99-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)-2-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl

RN 214699-01-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(dimethylamino)methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 214699-03-3 CAPLUS


CN 4-Piperidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214699-05-5 CAPLUS


CN Formamide, N-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridinyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 214699-06-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(2-propenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214699-08-8 CAPLUS


CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214699-10-2 CAPLUS

CN Formamide, N-[1-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 214699-11-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214699-12-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214699-14-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 214699-16-8P 214699-17-9P 214699-19-1P
214699-21-5P 214699-23-7P 214699-25-9P
214699-27-1P 214699-29-3P 214699-31-7P
214699-32-8P 214699-33-9P 214699-35-1P
214699-37-3P 214699-40-8P 214699-43-1P
214699-46-4P 214699-48-6P 214699-50-0P
214699-52-2P 214699-54-4P 214699-56-6P
214699-58-8P 214699-60-2P 214699-62-4P
214699-64-6P 214699-66-8P 214699-68-0P
214699-70-4P 214699-72-6P 214699-74-8P
214699-78-2P 214699-80-6P 214699-82-8P
214699-86-2P 214699-88-4P 214699-90-8P
214699-91-9P 214699-93-1P 214699-97-5P
214699-98-6P 214700-00-2P 214700-02-4P
214700-04-6P 214700-06-8P 214700-08-0P
214700-10-4P 214700-16-0P 214700-18-2P
214700-24-0P 214700-27-3P 214700-30-8P
214700-32-0P 214700-35-3P 214700-41-1P
214700-44-4P 214700-47-7P 214700-59-1P
214700-65-9P 214700-68-2P 214700-71-7P
214700-74-0P 214700-80-8P 214700-83-1P
214700-89-7P 214700-95-5P 214700-98-8P
214701-02-7P 214701-07-2P 214701-09-4P
265102-96-3P 265102-97-4P 265103-00-2P
265103-04-6P 265103-10-4P 265103-17-1P
265103-41-1P 265103-43-3P 265103-44-4P

265103-51-3P 265103-52-4P 265103-53-5P
265103-54-6P 265103-55-7P 265103-56-8P
265103-57-9P 265103-61-5P 265103-63-7P
265103-65-9P 265103-66-0P 265103-67-1P
265103-68-2P 265103-69-3P 265103-71-7P
265103-73-9P 265103-74-0P 265103-75-1P
265103-76-2P 265103-77-3P 265103-79-5P
265103-80-8P 265103-81-9P 265103-82-0P
265103-83-1P 265103-84-2P 265103-85-3P
265103-87-5P 265103-89-7P 265103-90-0P
265103-91-1P 265103-92-2P 265103-93-3P
265103-94-4P 265103-95-5P 265103-96-6P
265103-97-7P 265103-98-8P 265103-99-9P
265104-00-5P 265104-01-6P 265104-02-7P
265104-03-8P 265104-04-9P 265104-05-0P
265104-06-1P 265104-07-2P 265104-08-3P
265104-09-4P 265104-10-7P 265104-11-8P
265104-12-9P 265104-13-0P 265104-14-1P
265104-15-2P 265104-16-3P 265104-17-4P
265104-18-5P 265104-19-6P 265104-20-9P
265104-21-0P 265104-22-1P 265104-23-2P
265104-24-3P 265104-25-4P 265104-26-5P
265104-27-6P 265104-28-7P 265104-29-8P
265104-30-1P 265104-31-2P 265104-32-3P
265104-33-4P 265104-34-5P 265104-35-6P
265104-36-7P 265104-37-8P 265104-38-9P
265104-39-0P 265104-40-3P 265104-41-4P
265104-42-5P 265104-44-7P 265104-46-9P
265104-48-1P 265104-50-5P 265104-51-6P
265104-53-8P 265104-54-9P 265104-55-0P
265104-56-1P 265104-57-2P 265104-58-3P
265104-59-4P 265104-61-8P 265104-62-9P
265104-63-0P 265104-64-1P 265104-65-2P
265104-66-3P 265104-67-4P 265104-68-5P
265104-69-6P 265104-70-9P 265104-71-0P
265104-72-1P 265104-73-2P 265104-75-4P
265104-76-5P 265104-77-6P 265104-78-7P
265104-79-8P 265104-80-1P 265104-81-2P
265104-82-3P 265104-83-4P 265104-84-5P
265104-85-6P 265104-86-7P 265104-88-9P
265104-89-0P 265104-90-3P 265104-91-4P
265104-92-5P 265104-93-6P 265104-94-7P
265104-95-8P 265104-96-9P 265104-97-0P
265104-98-1P 265104-99-2P 265105-00-8P
265105-01-9P 265105-02-0P 265105-03-1P
265105-04-2P 265105-05-3P 265105-06-4P
265105-07-5P 265105-08-6P 265105-09-7P
265105-10-0P 265105-11-1P 265105-12-2P
265105-13-3P 265105-14-4P 265105-15-5P
265105-16-6P 265105-17-7P 265105-18-8P
265105-19-9P 265105-20-2P 265105-21-3P
265105-22-4P 265105-23-5P 265105-24-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 214699-16-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-methyl-1H-imidazol-2-yl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 214699-17-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(aminomethyl)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214699-19-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[2-bromo-4-(dimethylamino)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214699-21-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[2-(dimethylamino)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-23-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[3-(dimethylamino)-1-propynyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-25-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(3-amino-3-methyl-1-butynyl)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214699-27-1 CAPLUS

CN Phosphonic acid, [4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 214699-29-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(3-methoxy-1-propynyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214699-31-7 CAPLUS

CN Benzoic acid, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 214699-32-8 CAPLUS


CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 214699-33-9 CAPLUS
CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-4-[2-(dimethylamino)ethyl]- (9CI)
(CA INDEX NAME)



RN 214699-35-1 CAPLUS
CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214699-37-3 CAPLUS
CN 2H-1,4-Benzoxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 214699-40-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2,2,4-trimethyl- (9CI) (CA INDEX NAME)




RN 214699-43-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 7-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-4-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214699-46-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(1-methylethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-48-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(1-piperidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-50-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(4-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-52-2 CAPLUS

CN Formamide, N-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 214699-54-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[1-methyl-1-(methylamino)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-56-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[1-(dimethylamino)-1-methylethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-58-8 CAPLUS


CN 1H-Indole, 1-acetyl-5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 214699-60-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(6-chloro-3-pyridinyl)-5-cyclohexyl-
(9CI) (CA INDEX NAME)

RN 214699-62-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-
(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)

RN 214699-64-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(4-
morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)


RN 214699-66-8 CAPLUS

CN Formamide, N-[5-[4-amino-5-[1-(2-bromophenyl)ethyl]pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214699-68-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-70-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-72-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 214699-74-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-78-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclopentyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-80-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(2-chloro-3-pyridinyl)-5-cyclohexyl- (9CI) (CA INDEX NAME)




RN 214699-82-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(dimethylamino)-3-pyridinyl]-5-(3,5-dimethylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 214699-86-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(6-bromo-3-pyridinyl)-5-cyclohexyl-
(9CI) (CA INDEX NAME)




RN 214699-88-4 CAPLUS

CN Benzonitrile, 3-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)- (9CI)
(CA INDEX NAME)




RN 214699-90-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(dimethylamino)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-91-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-imidazol-1-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-93-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(hexahydro-1H-azepin-1-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-97-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-98-6 CAPLUS

CN Piperazine, 1-acetyl-4-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-00-2 CAPLUS

CN 1H-1,4-Diazepine, 1-acetyl-4-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]hexahydro- (9CI) (CA INDEX NAME)




RN 214700-02-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-04-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[methyl[2-(2-pyridinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-06-8 CAPLUS

CN 1,2-Ethanediamine, N-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 214700-08-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1-azetidiny)-3-pyridinyl]-5-cyclohexyl- (9CI) (CA INDEX NAME)




RN 214700-10-4 CAPLUS

CN Acetamide, N-[1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214700-16-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[2-(methoxymethyl)-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-18-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[(2-methoxyethyl)propylamino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-24-0 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[4-(dimethylamino)-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-27-3 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214700-30-8 CAPLUS
 CN 1,3-Propanediamine, N-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 214700-32-0 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[methyl[2-(4-pyridinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-35-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[methyl(3-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-41-1 CAPLUS

CN 1H-Indole-2,3-dione, 5-[4-amino-5-[1-(2-bromophenyl)ethyl]pyrido[2,3-d]pyrimidin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 214700-44-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-fluoro-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214700-47-7 CAPLUS

CN Phenol, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-nitro-
(9CI) (CA INDEX NAME)


RN 214700-59-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-65-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,1-dioxido-4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-68-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-71-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-methoxyphenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-74-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-80-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-chloro-6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-83-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-oxido-4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-89-7 CAPLUS
CN Formamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 214700-95-5 CAPLUS
CN 3-Morpholinol, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-98-8 CAPLUS
CN 2-Morpholinol, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214701-02-7 CAPLUS

CN 4-Piperidinemethanol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 214701-07-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(4-methylene-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214701-09-4 CAPLUS

CN Methanimidamide, N-[5-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 265102-96-3 CAPLUS

CN Propanedioic acid, [3-[4-[4-amino-5-[4-(1-methylethyl)phenyl]pyrido[2,3-d]pyrimidin-7-yl]phenyl]-2-propenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 265102-97-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[4-amino-5-[4-(1-methylethyl)phenyl]pyrido[2,3-d]pyrimidin-7-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265103-00-2 CAPLUS


CN 2-Propenoic acid, 3-[3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 265103-04-6 CAPLUS


CN Propanedioic acid, [3-[3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-

d]pyrimidin-5-yl]phenyl]-2-propenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 265103-10-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-methoxyphenyl)-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 265103-17-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[4-(5-bromo-2-thienyl)phenyl]-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265103-41-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3-bromo-5-(methylthio)phenyl]-7-(2-


thienyl)- (9CI) (CA INDEX NAME)



RN 265103-43-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-furanyl)-7-[4-(4-morpholinyl)phenyl]-
(9CI) (CA INDEX NAME)


RN 265103-44-4 CAPLUS

CN Urea, [4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl


RN 265103-51-3 CAPLUS

CN Methanesulfonamide, N-[4-[5-(3-bromophenyl)-4-(formylamino)pyrido[2,3-
d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 265103-52-4 CAPLUS

CN Methanesulfonamide, N-[5-[5-(3-bromophenyl)-4-(formylamino)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 265103-53-5 CAPLUS


CN 1H-Indole, 1-acetyl-5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265103-54-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265103-55-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(4-morpholinyl)-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265103-56-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[6-(4-morpholinyl)-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 265103-57-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(tetrahydro-2H-pyran-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265103-61-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(dimethylamino)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265103-63-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-imidazol-1-yl)-3-pyridazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 265103-65-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(hexahydro-1H-azepin-1-yl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265103-66-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-{methyl(1-methylethyl)amino}-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265103-67-1 CAPLUS

CN Formamide, N-[1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 265103-68-2 CAPLUS


CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 265103-69-3 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-chlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-71-7 CAPLUS
 CN 4-Piperidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, dihydrogen phosphate (ester), disodium salt (9CI) (CA INDEX NAME)



● 2 Na

RN 265103-73-9 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265103-74-0 CAPLUS


CN 2-Pyrrolidineethanol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265103-75-1 CAPLUS


CN 4-Piperidinol, 1-[5-[4-amino-5-(2-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265103-76-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,4-dioxaspiro[4.5]dec-8-yl)-3-

pyridinyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 265103-77-3 CAPLUS

CN 4-Piperidinol, 1-[6-[4-amino-5-(2-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265103-79-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-morpholinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265103-80-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1-methyl-1H-indol-3-yl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-81-9 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-ethyloxime (9CI) (CA INDEX NAME)




RN 265103-82-0 CAPLUS

CN 1,2-Propanediol, 3-[[5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]pyrido[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)




RN 265103-83-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-N-[3-(4-morpholinyl)propyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-84-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-N-[2-(1H-imidazol-4-yl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-85-3 CAPLUS

CN Butanoic acid, 4-[[5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]pyrido[2,3-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)




RN 265103-87-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(4-morpholinylimino)-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265103-89-7 CAPLUS

CN 4-Piperidinone, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, O-methyloxime (9CI) (CA INDEX NAME)



RN 265103-90-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(phenylmethoxy)-3-pyridazinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 265103-91-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-methoxy-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265103-92-2 CAPLUS

CN 4-Piperidinone, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)




RN 265103-93-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(2-methylpropoxy)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265103-94-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(4-methyl-1-piperazinyl)imino]-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265103-95-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(tetrahydro-2H-

pyran-4-yl)oxy]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265103-96-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[2-(4-morpholinyl)ethoxy]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265103-97-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-ethoxy-1-piperidinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265103-98-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(2-ethoxyethoxy)-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265103-99-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265104-00-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(3R)-tetrahydro-3-furanyl]oxy]-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265104-01-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(3S)-tetrahydro-3-furanyl]oxy]-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265104-02-7 CAPLUS

3-Pyrrolidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-ethoxy-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-03-8 CAPLUS

CN 3-Pyrrolidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-ethoxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-04-9 CAPLUS

CN 3-Pyrrolidinol, 1-[5-{4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl}-2-pyridinyl]-4-ethoxy-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-05-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3R,4R)-3,4-diethoxy-1-pyrrolidinyl]-3-pyridazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-06-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3R,4R)-3,4-diethoxy-1-pyrrolidinyl]-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-07-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3R,4S)-3,4-diethoxy-1-pyrrolidinyl]-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-08-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3R,4S)-3,4-diethoxy-1-pyrrolidinyl]-3-pyridazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-09-4 CAPLUS

CN 3-Pyrrolidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-ethoxy-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-10-7 CAPLUS

CN 3-Pyrrolidinol, 4-amino-1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-11-8 CAPLUS


CN 3-Pyrrolidinol, 4-amino-1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 265104-12-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 265104-13-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,3-dichlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 265104-14-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(2-


Searched by Barb O'Bryen, STIC 308-4291

pyridinyl)- (9CI) (CA INDEX NAME)




RN 265104-15-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]-5-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 265104-16-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromo-5-ethoxyphenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-17-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,5-dichlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 265104-18-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,5-dimethylphenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-19-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-20-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265104-21-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]-5-[3-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265104-22-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dichlorophenyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-23-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,5-dioxo-9-azaspiro[5.5]undec-9-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-24-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME).




RN 265104-25-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(1,1-dimethylethyl)-1-piperidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265104-26-5 CAPLUS

CN Formamide, N-[1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 265104-27-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-2-thienyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265104-28-7 CAPLUS


CN Benzonitrile, 3-[4-amino-7-[6-(4-morpholinyl)-3-pyridazinyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)



RN 265104-29-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S)-2-(ethoxymethyl)-1-pyrrolidinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265104-30-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S,3S)-2,3-dimethyl-1,4-dioxo-8-azaspiro[4.5]dec-8-yl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265104-31-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3aR,6aS)-tetrahydrospiro[4H-cyclopenta-1,3-dioxole-2,4'-piperidin]-1'-yl]-3-pyridazin-3-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 265104-32-3 CAPLUS


CN 1-Oxa-4,8-diazaspiro[4.5]decane, 4-acetyl-8-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265104-33-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2R,3R)-2,3-bis(methoxymethyl)-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-3-pyridazinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265104-34-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(3-methoxy-1,5-dioxa-9-azaspiro[5.5]undec-9-yl)-3-pyridazinyl]-(9CI) (CA INDEX NAME)




RN 265104-35-6 CAPLUS

CN 1,5-Dioxa-9-azaspiro[5.5]undecane-3-methanol, 9-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-(9CI) (CA INDEX NAME)




RN 265104-36-7 CAPLUS

CN 1,7,14-Trioxa-11-azadispiro[4.2.5.2]pentadecane, 11-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265104-37-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridazinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 265104-38-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(4-morpholinylimino)-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-39-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(4-methyl-1-piperazinyl)imino]-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-40-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(1H-1,2,4-triazol-1-ylimino)-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-41-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1H-indol-3-yl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-42-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1H-indol-5-yl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-44-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 265104-46-9 CAPLUS

CN 3(2H)-Pyridazinone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 265104-48-1 CAPLUS

CN Morpholine, 4-[[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 265104-50-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-4-morpholinyl- (9CI) (CA INDEX NAME)




RN 265104-51-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 265104-53-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 265104-54-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(4-quinolinyl)- (9CI) (CA INDEX NAME)




RN 265104-55-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 265104-56-1 CAPLUS

CN 4-Piperidinemethanol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-57-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-58-3 CAPLUS

CN Piperazine, 1-acetyl-4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-59-4 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-61-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-62-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-63-0 CAPLUS

CN Morpholine, 4-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265104-64-1 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265104-65-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]benzenesulfonamide, N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 265104-66-3 CAPLUS

CN Piperidine, 1-[[4-[[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265104-67-4 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[4-[[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265104-68-5 CAPLUS

CN Benzenesulfonamide, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N-(cyclopropylmethyl)- (9CI) (CA INDEX NAME)



RN 265104-69-6 CAPLUS


CN Benzenesulfonamide, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 265104-70-9 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265104-71-0 CAPLUS


CN 4-Piperidinol, 1-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 265104-72-1 CAPLUS


CN Morpholine, 4-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]sulfonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 265104-73-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-fluoro-4-(4-thiomorpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265104-75-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,1-dioxido-4-thiomorpholinyl)-3-pyridinyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 265104-76-5 CAPLUS

CN Pyrido[2,3-d]pyrimidine, 5-(3-bromophenyl)-4-methoxy-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-77-6 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]benzoyl]- (9CI) (CA INDEX NAME)




RN 265104-78-7 CAPLUS

CN Benzamide, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 265104-79-8 CAPLUS

CN Morpholine, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]benzoyl- (9CI) (CA INDEX NAME)




RN 265104-80-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(cyclopropylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265104-81-2 CAPLUS


CN 4-Piperidinol, 1-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]benzoyl]- (9CI) (CA INDEX NAME)



RN 265104-82-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265104-83-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(2-ethoxyethoxy)-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-84-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(tetrahydro-1(2H)-pyrimidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265104-85-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4,4-difluorocyclohexyl)-7-[6-(1,4-dioxaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265104-86-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2R)-2-(2-ethoxyethoxy)-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265104-88-9 CAPLUS

CN 4H-1,3-Dioxolo[4,5-c]pyrrol-2-one, 5-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]tetrahydro-, (3aR,6aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265104-89-0 CAPLUS


CN 2,3-Pyrrolidinediol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 265104-90-3 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 265104-91-4 CAPLUS

CN 2-Pyrrolidinemethanol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265104-92-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265104-93-6 CAPLUS

CN 2-Imidazolidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-94-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1,1-dimethyl-3-butenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-95-8 CAPLUS

CN 2,4(1H,3H)-Quinazolin-2-one, 3-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265104-96-9 CAPLUS

CN 3-Pyridazinecarboxamide, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 265104-97-0 CAPLUS

CN Morpholine, 4-[[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 265104-98-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-methoxy-3-pyridazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 265104-99-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[bis(2-ethoxyethyl)amino]-3-pyridazinyl]-5-(3-bromophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 265105-00-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(ethoxymethyl)-1-piperidinyl]-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 265105-01-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-1-piperidinyl]-3-pyridazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 265105-02-0 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(2-ethoxyethoxy)methyl]-1-piperidinyl]-3-pyridazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 265105-03-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(1,3-dioxolan-2-ylmethyl)methylamino]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265105-04-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,4-dioxaspiro[4.5]dec-8-yloxy)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265105-05-3 CAPLUS


CN 1,3-Propanediol, 2-[[[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265105-06-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[(3-pyridinyloxy)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265105-07-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 265105-08-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-N-ethyl-N-(2-methoxyethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265105-09-7 CAPLUS
 CN 4-Piperidinecarboxamide, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 265105-10-0 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(3R,4S)-3,4-bis(methoxymethoxy)-1-pyrrolidinyl]-3-pyridazinyl]-5-(3-bromophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 265105-11-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265105-12-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 265105-13-3 CAPLUS

CN 3-Pyrrolidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-methyl-, dihydrochloride, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



●2 HCl

RN 265105-14-4 CAPLUS
CN 3-Pyrrolidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-methyl-, dihydrochloride, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



●2 HCl

RN 265105-15-5 CAPLUS
CN 3-Pyrrolidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-methyl-, dihydrochloride, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 265105-16-6 CAPLUS

CN 3-Pyrrolidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-methyl-, dihydrochloride, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 265105-17-7 CAPLUS


CN 3-Pyrrolidinecarbonitrile, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-, dihydrochloride, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● 2 HCl


RN 265105-18-8 CAPLUS
 CN 3-Pyrrolidinecarboxamide, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-(1,1-dimethylethyl)-4-hydroxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265105-19-9 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S)-2-[[[tetrahydro-2H-pyran-4-yl]oxy]methyl]-1-pyrrolidinyl]-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 265105-20-2 CAPLUS


CN 3-Pyrrolidinone, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 265105-21-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(5-bromo-2-thienyl)-(9CI) (CA INDEX NAME)




RN 265105-22-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,5-dimethyl-3-thienyl)-(9CI) (CA INDEX NAME)


Searched by Barb O'Bryen, STIC 308-4291



RN 265105-23-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(5-chloro-2-thienyl)-
(9CI) (CA INDEX NAME)

RN 265105-24-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,4-dimethyl-5-thiazolyl)-
(9CI) (CA INDEX NAME)


IT 265105-25-7P 265105-26-8P 265105-28-0P
265105-29-1P 265105-30-4P 265105-31-5P
265105-32-6P 265105-33-7P 265105-34-8P
265105-35-9P 265105-36-0P 265105-37-1P
265105-38-2P 265105-39-3P 265105-40-6P
265105-41-7P 265105-42-8P 265105-43-9P
265105-44-0P 265105-45-1P 265105-46-2P
265105-47-3P 265105-48-4P 265105-50-8P
265105-51-9P 265105-53-1P 265105-54-2P
265105-55-3P 265105-56-4P 265105-57-5P
265105-58-6P 265105-59-7P 265105-60-0P
265105-61-1P 265105-62-2P 265105-63-3P
265105-64-4P 265105-65-5P 265105-66-6P
265105-67-7P 265105-69-9P 265105-70-2P
265105-71-3P 265105-72-4P 265105-73-5P
265105-74-6P 265105-75-7P 265105-76-8P

265105-77-9P 265105-78-0P 265105-79-1P
265105-80-4P 265105-81-5P 265105-83-7P
265105-84-8P 265105-85-9P 265105-86-0P
265105-88-2P 265105-89-3P 265105-90-6P
265105-91-7P 265105-92-8P 265105-93-9P
265105-94-0P 265105-95-1P 265105-96-2P
265105-97-3P 265105-98-4P 265105-99-5P
265106-00-1P 265106-01-2P 265106-02-3P
265106-03-4P 265106-04-5P 265106-06-7P
265106-07-8P 265106-08-9P 265106-09-0P
265106-10-3P 265106-11-4P 265106-12-5P
265106-13-6P 265106-14-7P 265106-15-8P
265106-16-9P 265106-17-0P 265106-18-1P
265106-19-2P 265106-20-5P 265106-21-6P
265106-23-8P 265106-25-0P 265106-26-1P
265106-27-2P 265106-28-3P 265106-29-4P
265106-30-7P 265106-31-8P 265106-33-0P
265106-34-1P 265106-35-2P 265106-36-3P
265106-37-4P 265106-38-5P 265106-39-6P
265106-40-9P 265106-41-0P 265106-42-1P
265106-43-2P 265106-44-3P 265106-45-4P
265106-46-5P 265106-47-6P 265106-48-7P
265106-49-8P 265106-50-1P 265106-51-2P
265106-52-3P 265106-53-4P 265106-54-5P
265106-55-6P 265106-56-7P 265106-57-8P
265106-58-9P 265106-59-0P 265106-61-4P
265106-62-5P 265106-63-6P 265106-64-7P
265106-65-8P 265106-66-9P 265106-67-0P
265106-68-1P 265106-69-2P 265106-70-5P
265106-71-6P 265106-72-7P 265106-73-8P
265106-74-9P 265106-75-0P 265106-76-1P
265106-77-2P 265106-78-3P 265106-79-4P
265106-80-7P 265106-81-8P 265106-82-9P
265106-83-0P 265106-84-1P 265106-85-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine **kinase inhibitors**)


RN 265105-25-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(5-methyl-2-thienyl)-(9CI) (CA INDEX NAME)




RN 265105-26-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2-furanyl)-(9CI)
(CA INDEX NAME)




RN 265105-28-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3-thienyl)- (9CI)
(CA INDEX NAME)




RN 265105-29-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3-methyl-2-thienyl)-
(9CI) (CA INDEX NAME)



RN 265105-30-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-morpholinyl)-4-
thiazolyl]- (9CI) (CA INDEX NAME)



RN 265105-31-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-morpholinyl)-4-

(trifluoromethyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-32-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 265105-33-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-methyl-2-(4-morpholinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-34-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,5-dichloro-3-thienyl)- (9CI) (CA INDEX NAME)




RN 265105-35-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,5-dimethyl-3-furanyl)- (9CI) (CA INDEX NAME)




RN 265105-36-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(1-methyl-1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)




RN 265105-37-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(dimethylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-38-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(1,1-dioxido-4-thiomorpholinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-39-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[1-methyl-2-(4-morpholinyl)-1H-imidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 265105-40-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-morpholinyl)-5-oxazolyl]- (9CI) (CA INDEX NAME)




RN 265105-41-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-[(2-methoxyethyl)methylamino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-42-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(ethylmethlamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-43-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(1-pyrrolidinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-44-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(methylpropylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-45-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(diethylamino)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-46-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-methyl-1-piperazinyl)-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-47-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-[4-(2-pyridinyl)-1-piperazinyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-48-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-[methyl[2-(2-pyridinyl)ethyl]amino]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-50-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-[4-(4-morpholinylimino)-1-piperidinyl]-5-thiazolyl]- (9CI) (CA INDEX NAME)




RN 265105-51-9 CAPLUS

CN Morpholine, 4-[[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265105-53-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 265105-54-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 265105-55-3 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 265105-56-4 CAPLUS

CN 2-Pyridinesulfonamide, 5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 265105-57-5 CAPLUS

CN 1,4-Dioxo-8-azaspiro[4.5]decane, 8-[[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 265105-58-6 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]pyrazinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)




RN 265105-59-7 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(phenylmethyl)oxime (9CI) (CA INDEX NAME)




RN 265105-60-0 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(1,1-dimethylethyl)oxime (9CI) (CA INDEX NAME)




RN 265105-61-1 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-cyclohexyloxime (9CI) (CA INDEX NAME)



RN 265105-62-2 CAPLUS


CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, oxime (9CI) (CA INDEX NAME)



RN 265105-63-3 CAPLUS


CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)

(NAME)




RN 265105-64-4 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(2-methoxyethyl)oxime (9CI) (CA INDEX NAME)




RN 265105-65-5 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(2-thienylmethyl)oxime (9CI) (CA INDEX NAME)




RN 265105-66-6 CAPLUS


CN 2-(5H)-Furanone, 5-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 265105-67-7 CAPLUS
CN Ethanone, 1-[1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-hydroxy-4-piperidinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)




RN 265105-69-9 CAPLUS
CN Acetic acid, [[[1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]ethylidene]amino]oxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 265105-70-2 CAPLUS
CN Acetic acid, [[[1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]ethylidene]amino]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 265105-71-3 CAPLUS
CN Acetic acid, [[[1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]ethylidene]amino]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 265105-72-4 CAPLUS

CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]-, O-(tetrahydro-2H-pyran-2-yl)oxime (9CI) (CA INDEX NAME)




RN 265105-73-5 CAPLUS

CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]-, O-2-propenyloxime (9CI) (CA INDEX NAME)




RN 265105-74-6 CAPLUS

CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]-, O-ethyloxime (9CI) (CA INDEX NAME)




RN 265105-75-7 CAPLUS

CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidyl]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 265105-76-8 CAPLUS

CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidyl]-, oxime (9CI) (CA INDEX NAME)




RN 265105-77-9 CAPLUS


CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(tetrahydro-2H-pyran-2-yl)oxime (9CI) (CA INDEX NAME)




RN 265105-78-0 CAPLUS
CN Acetic acid, [[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-piperidinylidene]amino]oxy]-, 1-methylethyl ester (9CI)
(CA INDEX NAME)




RN 265105-79-1 CAPLUS
CN Ethanone, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime
(9CI) (CA INDEX NAME)



RN 265105-80-4 CAPLUS
CN 2(3H)-Furanone, 4-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]dihydro- (9CI) (CA INDEX NAME)




RN 265105-81-5 CAPLUS
CN 2(3H)-Furanone, 3-[1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-hydroxy-4-piperidinyl]dihydro- (9CI) (CA INDEX NAME)




RN 265105-83-7 CAPLUS

CN 3-Azetidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265105-84-8 CAPLUS


CN 8-Azabicyclo[3.2.1]octan-3-ol, 8-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265105-85-9 CAPLUS


CN 2,3-Piperidinediol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, (2R,3R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 265105-86-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[methyl(3-pyridinylmethyl)amino]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265105-88-2 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 265105-89-3 CAPLUS

CN 2(3H)-Furanone, 3-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-4-piperidinyl]dihydro- (9CI) (CA INDEX NAME)




RN 265105-90-6 CAPLUS


CN Carbamic acid, (4-methoxyphenyl)-, (3R,4R)-1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-3,4-pyrrolidinediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 265105-91-7 CAPLUS

CN 3,4-Pyrrolidinediol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, (3S,4S)- (9CI) (CA INDEX NAME)

Searched by Barb O'Bryen, STIC 308-4291


Absolute stereochemistry.



RN 265105-92-8 CAPLUS

CN 3,4-Pyrrolidinediol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 265105-93-9 CAPLUS


CN 3,4-Pyrrolidinediol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, (3R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265105-94-0 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[5-[4-amino-5-(3-bromophenyl)pyrimidin-7-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 265105-95-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-oxido-1-oxa-4-thia-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265105-96-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4,4-dioxido-1-oxa-4-thia-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265105-97-3 CAPLUS

CN 1,3,8-Triazaspiro[4.5]dec-2-en-4-one, 8-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)




RN 265105-98-4 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 265105-99-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-oxido-4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-00-1 CAPLUS

CN 2H-Benzimidazol-2-one, 1-[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-piperidinyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 265106-01-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[methyl[2-(2-pyridinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-02-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[methyl[2-(4-pyridinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-03-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-04-5 CAPLUS

CN 2-Piperidinemethanol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-06-7 CAPLUS

CN 4-Piperidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 265106-07-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(2-pyridinyl)-1-piperazinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-08-9 CAPLUS

CN Ethanol, 2-[2-[4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)




RN 265106-09-0 CAPLUS

CN Ethanol, 2,2'-[[1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-piperidinylidene]bis(thio)]bis-, diacetate (ester) (9CI) (CA INDEX NAME)




RN 265106-10-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[methyl(3-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-11-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-(1-pyrrolidinyl)-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-12-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[[2-(1H-imidazol-4-yl)ethyl]amino]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-13-6 CAPLUS

CN 1-Piperazineacetonitrile, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-14-7 CAPLUS

CN 3-Pyrrolidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-15-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-methyl-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-16-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(3R,5S)-3,5-dimethyl-4-morpholinyl]-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265106-17-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4,4-difluoro-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-18-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,1-dioxido-4-thiomorpholinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-19-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(3-thiazolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-20-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,1-dioxido-3-thiazolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-21-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-23-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,3-dioxaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-25-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,3-dichlorophenyl)-7-[6-(1,4-dioxaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-26-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1,4-dioxaspiro[4.5]dec-8-yl)-3-pyridinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 265106-27-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-28-3 CAPLUS

CN 3-Pyrrolidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)




RN 265106-29-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265106-30-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-phenyl- (9CI) (CA INDEX NAME)




RN 265106-31-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-aminophenyl)-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 265106-33-0 CAPLUS

CN 1,2-Ethanediamine, N'-(5-(4-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl)-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 265106-34-1 CAPLUS

CN 1,4-Butanediamine, N'-(5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl)-N,N-dimethyl- (9CI)
(CA INDEX NAME)




RN 265106-35-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-36-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 265106-37-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 265106-38-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-(3-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 265106-39-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-methylethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-40-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-methyl-4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265106-41-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-imidazol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-42-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(3-bromophenyl)ethyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 265106-43-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,3-dihydro-1-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)




RN 265106-44-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(1-methyl-1H-benzimidazol-5-yl)- (9CI) (CA INDEX NAME)




RN 265106-45-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-46-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-47-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-pyrrolidinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-48-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 265106-49-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-[(2-methoxyethyl)methylamino]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 265106-50-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265106-51-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 265106-52-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1H-imidazol-1-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 265106-53-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-54-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(dimethylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 265106-55-6 CAPLUS

CN 4-Piperidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-56-7 CAPLUS

CN Formamide, N-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 265106-57-8 CAPLUS

CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 265106-58-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(diethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265106-59-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[methyl(1-methylethyl)amino]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265106-61-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-3-pyridazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265106-62-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(phenylmethoxy)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-63-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,3-dichlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-64-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,5-dichlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265106-65-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridazinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 265106-66-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S)-2-(2-ethoxyethoxy)-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 265106-67-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-methoxy-3-pyridazinyl)- (9CI) (CA INDEX NAME)




RN 265106-68-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-bis(2-ethoxyethyl)amino]-3-pyridazinyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 265106-69-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-(ethoxymethyl)-1-piperidinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-70-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(2-ethoxymethyl)-1-piperidinyl]-3-pyridazinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-71-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[4-[(2-ethoxyethoxymethyl)-1-piperidinyl]-3-pyridazinyl]-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265106-72-7 CAPLUS


CN 1,3-Propanediol, 2-[[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]oxy]- (9CI) (CA INDEX NAME)



RN 265106-73-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(3-pyridinyloxy)-3-

pyridazinyl)- (9CI) (CA INDEX NAME)




RN 265106-74-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 265106-75-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-N-ethyl-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 265106-76-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 265106-77-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 265106-78-3 CAPLUS

CN 3-Pyrrolidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265106-79-4 CAPLUS

CN 3-Pyrrolidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265106-80-7 CAPLUS

CN 3-Pyrrolidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-4-methyl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265106-81-8 CAPLUS

CN 3-Pyrrolidinol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-methyl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 265106-82-9 CAPLUS


CN 3-Pyrrolidinecarbonitrile, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 265106-83-0 CAPLUS


CN 3-Pyrrolidinecarboxamide, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-(1,1-dimethylethyl)-4-hydroxy- (9CI) (CA INDEX NAME)



RN 265106-84-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2S)-2-[[[(tetrahydro-2H-pyran-4-yl)oxy]methyl]-1-pyrrolidinyl]-3-pyridazinyl]-1-pyrrolidinyl]-3-pyridazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 265106-85-2 CAPLUS

CN 3-Pyrrolidinone, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridazinyl]-, O-(tetrahydro-2H-pyran-4-yl)oxime (9CI) (CA INDEX NAME)




IT 265107-69-5 265108-35-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 265107-69-5 CAPLUS

CN Benzenamine, 4-[5-(4-bromophenyl)-4-chloropyrido[2,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 265108-35-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4(1H)-one, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 265106-97-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine **kinase inhibitors**)

RN 265106-97-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-chloro-3-pyridazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:792834 CAPLUS

DOCUMENT NUMBER: 134:110046

TITLE: Design of Adenosine **Kinase Inhibitors** from the NMR-Based Screening of Fragments

AUTHOR(S): Hajduk, Philip J.; Gomtsyan, Arthur; Didomenico, Stanley; Cowart, Marlon; Bayburt, Erol K.; Solomon,

Searched by Barb O'Bryen, STIC 308-4291

Larry; Severin, Jean; Smith, Richard; Walter, Karl; Holzman, Thomas F.; Stewart, Andrew; McGaraughty, Steve; Jarvis, Michael F.; Kowaluk, Elizabeth A.; Fesik, Stephen W.

CORPORATE SOURCE: Pharmaceutical Discovery Division and Department of Neurological and Urological Diseases Research, Abbott Laboratories, Abbott Park, IL, 60064, USA

SOURCE: Journal of Medicinal Chemistry (2000), 43(25), 4781-4786

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

AB A strategy is described for designing high-affinity ligands using information derived from the NMR-based screening of fragments. The method involves the fragmentation of an existing lead mol., identification of suitable replacements for the fragments, and incorporation of the newly identified fragments into the original scaffold. Using this technique, novel substituents were rapidly identified and incorporated into lead inhibitors of adenosine kinase that exhibited potent in vitro and in vivo activities. This approach is a valuable strategy for modifying existing leads to improve their potency, bioavailability, or toxicity profile and thus represents a useful technique for lead optimization.

IT 214697-26-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(design of adenosine **kinase inhibitors** from NMR-based screening of fragments)

RN 214697-26-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT 321522-72-9P 321522-73-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design of adenosine **kinase inhibitors** from NMR-based screening of fragments)


RN 321522-72-9 CAPLUS

CN Pyrido[2,3-d]pyrimidine-4,5-diamine, N5-[2-(1H-indol-3-yl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 321522-73-0 CAPLUS

CN Pyrido[2,3-d]pyrimidine-4,5-diamine, N5-(1H-indol-3-ylmethyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 321522-70-7P 321522-71-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design of adenosine **kinase inhibitors** from
NMR-based screening of fragments)


RN 321522-70-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(methylthio)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 321522-71-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(methylsulfonyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:872667 CAPLUS

DOCUMENT NUMBER: 134:207780

TITLE: Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors

AUTHOR(S): Cowart, M.; Lee, C.-H.; Gfesser, G. A.; Bayburt, E. K.; Bhagwat, S. S.; Stewart, A. O.; Yu, H.; Kohlhaas, K. L.; McGaraughty, S.; Wismer, C. T.; Mikusa, J.; Zhu, C.; Alexander, K. M.; Jarvis, M. F.; Kowaluk, E. A.

CORPORATE SOURCE: Neurological and Urological Diseases Research, Abbott Laboratories, Abbott Park, IL, 60064, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), Volume Date 2001, 11(1), 83-86
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis and SAR of a novel series of non-nucleoside pyridopyrimidine inhibitors of the enzyme adenosine kinase (AK) are described. It was found that pyridopyrimidines with a broad range of medium and large non-polar substituents at the 5-position potently inhibited AK activity. A narrower range of analogs was capable of potently inhibiting adenosine phosphorylation in intact cells indicating an enhanced ability of these analogs to penetrate cell membranes. Potent AK inhibitors were found to effectively reduce nociception in animal models of thermal hyperalgesia and persistent pain.


IT 214696-06-7 214696-10-3 214696-11-4
214696-12-5 214696-17-0 214696-26-1
214696-31-8 214696-47-6 214696-74-9
214697-26-4 214697-62-8 214697-63-9
214699-64-6 214699-68-0 214699-70-4
214699-72-6 214699-78-2 214700-68-2
214700-74-0 214700-77-3 265106-63-6
265106-64-7 328526-91-6 328526-92-7
328526-93-8 328526-94-9 328526-95-0
328899-60-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(prepn. and structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitor)


RN 214696-06-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-10-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-11-4 CAPLUS

CN Benzamide, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-12-5 CAPLUS

CN Benzonitrile, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-17-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-26-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-iodophenyl)- (9CI) (CA INDEX NAME)




RN 214696-31-8 CAPLUS

CN Phenol, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-47-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214696-74-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-62-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclopropyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-63-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214699-64-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-68-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-70-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-72-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 214699-78-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclopentyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-68-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-74-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-77-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-63-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,3-dichlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 265106-64-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,5-dichlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 328526-91-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 328526-92-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 328526-93-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-furanyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 328526-94-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1-ethylpropyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 328526-95-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1,1-dimethyl-2-propenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 328899-60-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(3R,5S)-3,5-dimethylcyclohexyl]-7-[6-(4-morpholinyl)-3-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:48609 CAPLUS

DOCUMENT NUMBER: 130:119591

TITLE: Antioxidant enhancement of therapy for hyperproliferative conditions

INVENTOR(S): Chinery, Rebecca; Beauchamp, R. Daniel; Coffey, Robert J.; Medford, Russell M.; Wadsinski, Brian

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901118	A2	19990114	WO 1998-US13750	19980701
WO 9901118	A3	19990422		

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ,

Searched by Barb O'Bryen, STIC 308-4291

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9882827 A1 19990125 AU 1998-82827 19980701
EP 1019034 A2 20000719 EP 1998-933078 19980701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO
JP 2002511878 T2 20020416 JP 1999-507360 19980701
US 2001049349 A1 20011206 US 2001-779086 20010207
PRIORITY APPLN. INFO.: US 1997-886653 A 19970701
US 1997-967492 A 19971111
US 1998-108609 B1 19980701
WO 1998-US13750 W 19980701

OTHER SOURCE(S): MARPAT 130:119591

AB A method to enhance the cytotoxic activity of an antineoplastic drug comprises administering an effective amt. of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amt. of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.


IT 96201-88-6, Brequinar sodium

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antioxidant enhancement of therapy for hyperproliferative conditions)

RN 96201-88-6 CAPLUS

CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

L66 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:206884 CAPLUS

DOCUMENT NUMBER: 130:267450

TITLE: Preparation of ethynylpyrimidine derivatives as tyrosine **kinase inhibitors** and their pharmaceutical uses

INVENTOR(S): Kitano, Yasunori; Kawahara, Eiji; Takayanagi, Hisao; Suzuki, Takeshi; Ohya, Atsushi; Hara, Hiroto

PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 235 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11080131	A2	19990326	JP 1997-251348	19970901

OTHER SOURCE(S): MARPAT 130:267450
GI




AB The derivs. I [A, B = NO₂, (CH₂)_n (n = 0, 1), NR₃R₄ (R₃, R₄ = H, C1-5 alkyl which may be substituted with CO₂H or C1-5 alkoxy carbonyl) or AB = CX₁:CX₂CX₃:CX₄ [X₁-X₄ = H, halo, NO₂, OR (R = C3-8 cycloalkyl which may contain O, C1-5 alkyl which may be substituted with C1-5 alkoxy, amino, morpholino), amino which may be substituted with C1-5 alkyl; neighboring 2 groups of X₁-X₄ may be bonded to each other to be C1-5 oxyalkylene], N: CX₅CX₆:CX₇ (X₅-X₇ = H, halo, C1-5 alkoxy, amino which may be substituted with C1-5 alkyl), CX₈:NCX₉:CX₁₀ (X₈-X₁₀ = any group given for X₅-X₇), N: CX₁₁CX₁₂:N (X₁₁, X₁₂ = H, C1-5 alkyl), W: CX₁₃NX₁₄ (W = N, CX₁₅, X₁₃-X₁₅ = H, C1-5 alkyl), CX₁₆:CX₁₇O (X₁₅, X₁₇ = H, C1-5 alkyl); R₁ = H, halo, (halo)phenyl, C1-5 (phenyl)alkyl, C1-5 alkoxy which may be substituted with CO₂H or C1-5 alkoxy carbonyl, OH, amino which may be substituted with C1-5 alkyl or C1-5 alkanoyl; R₂ = CR₃R₄R₅ [R₃, R₄ = H, halo, pyridyl, pyridazinyl, (C3-8 cycloalkyl)-C1-5 alkyl, etc.]; R₅ = OH, C1-5 alkyl, C1-5 alkoxy carbonyl, C1-5 alkanoyloxy, CO₂H, etc], their hydrates, pharmacol. acceptable salts, optically-active isomers, racemates, and diastereomer mixts. are prepd. I are useful for prophylactic and/or therapeutic agents for diseases due to acceleration of tyrosine kinase activity, e.g. as antitumor agents, immunosuppressants, platelet aggregation inhibitors, antiatherosclerotics, inflammation inhibitors, etc. Et₂NCMe₂C.tplbond.CH was treated with EtMgBr and the resulting grignard reagent was treated with 4-chloro-2-phenylquinazoline (prepn. given) to give I (R₁ = Ph, R₂ = CMe₂Net₂, AB = CH:CHCH:CH) (II). This was dissolved in Et₂O and treated with HCl/EtOAc to give II.HCl. IC₅₀ values of this salt against EGF receptor tyrosine kinase activity and growth of human nasopharyngeal carcinoma KB cells were 14 .mu.M and 0.89 .mu.M, resp.

IT 221697-90-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of ethynylpyrimidine derivs. as tyrosine **kinase inhibitors** and their pharmaceutical uses)

RN 221697-90-1 CAPLUS


CN Benzeneethanamine, N,N-diethyl-.alpha.-methyl-.alpha.-[(2-phenyl-4-quinazolinyl)ethynyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L66 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1998:745041 CAPLUS
 DOCUMENT NUMBER: 130:10618
 TITLE: Modulating serine/threonine protein kinase function
 with quinazoline-based compounds and their use as
 antitumor and anti-fibrotic agents
 INVENTOR(S): Tang, Peng C.; McMahon, Gerald; Weinberger, Heinz;
 Kutscher, Bernhard; App, Harald
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850370	A1	19981112	WO 1998-US9060	19980501
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
ZA 9803669	A	19991101	ZA 1998-3669	19980430
AU 9872829	A1	19981127	AU 1998-72829	19980501
EP 981519	A1	20000301	EP 1998-920203	19980501
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 6204267	B1	20010320	US 1998-71682	19980501
JP 2001524128	T2	20011127	JP 1998-548336	19980501
US 2001014679	A1	20010816	US 2001-769360	20010126
PRIORITY APPLN. INFO.:			US 1997-45351P	P 19970502
			US 1997-60152P	P 19970926
			US 1998-71682	A3 19980501
			WO 1998-US9060	W 19980501
OTHER SOURCE(S):		CASREACT 130:10618; MARPAT 130:10618		
GI				




AB The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compds (I). The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addn., the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions (e.g., tumors, fibrotic disorders, or other signal transduction aberrations) in organisms with a compd. identified by the invention. Furthermore, the invention pertains to quinazoline compds. and pharmaceutical compns. comprising these compds. Syntheses and biol. activities are provided for 38 quinazoline-based compds.

IT 215925-73-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modulating serine/threonine protein kinase function with quinazoline-based compds. and their use as antitumor and anti-fibrotic agents)

RN 215925-73-8 CAPLUS

CN 4-Quinazolinamine, 5-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 27 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:708824 CAPLUS

DOCUMENT NUMBER: 129:316240

TITLE: 5,7-Disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine **kinase inhibitors**

INVENTOR(S): Bhagwat, Shripad S.; Lee, Chih-hung; Cowart, Marlon D.; McKie, Jeffrey; Grillot, Anne Laure

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 172 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 9846605	A1	19981022	WO 1998-US7207	19980414

Searched by Barb O'Bryen, STIC 308-4291

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9871083 A1 19981111 AU 1998-71083 19980414
EP 989986 A1 20000405 EP 1998-918093 19980414


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO

BR 9809055 A 20000808 BR 1998-9055 19980414
JP 2001520655 T2 20011030 JP 1998-544088 19980414
ZA 9803177 A 19990122 ZA 1998-3177 19980415
NO 9905036 A 19991015 NO 1999-5036 19991015

PRIORITY APPLN. INFO.: US 1997-838216 A 19970416
WO 1998-US7207 W 19980414

OTHER SOURCE(S): MARPAT 129:316240

GI




AB Title compds. such as I were prep'd. as adenosine kinase inhibitors. Thus, aminopyridinecarbonitrile II was refluxed in formamide to give I. II was prep'd. from 4'-bromoacetophenone, 4-(dimethylamino)benzaldehyde, malononitrile, and ammonium acetate.

IT 214700-50-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn. as adenosine **kinase inhibitor**)

RN 214700-50-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 214695-95-1P 214696-03-4P 214696-31-8P
214696-40-9P 214696-43-2P 214696-44-3P
214696-51-2P 214696-68-1P 214696-70-5P
214696-87-4P 214696-92-1P 214697-20-8P
214697-23-1P 214697-29-7P 214697-39-9P
214697-41-3P 214697-61-7P 214697-66-2P
214697-68-4P 214697-97-9P 214698-04-1P
214698-10-9P 214698-83-6P 214698-85-8P
214699-03-3P 214699-27-1P 214699-31-7P
214699-33-9P 214699-54-4P 214699-64-6P
214699-68-0P 214699-70-4P 214699-72-6P
214699-93-1P 214699-95-3P 214699-98-6P
214700-02-4P 214700-04-6P 214700-16-0P
214700-27-3P 214700-59-1P 214700-68-2P
214700-77-3P 214700-80-8P 214700-83-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. as adenosine kinase inhibitor)


RN 214695-95-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[4-(2,2-dimethylpropyl)phenyl]-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-03-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-31-8 CAPLUS

CN Phenol, 3-[4-amino-7-[(4-(dimethylamino)phenyl)]pyrido[2,3-d]pyrimidin-5-yl]-
(9CI) (CA INDEX NAME)


RN 214696-40-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-[(3-methoxyphenyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214696-43-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-ethoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 214696-44-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2-thienyl)- (9CI)
(CA INDEX NAME)

RN 214696-51-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-
(9CI) (CA INDEX NAME)


RN 214696-68-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-70-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-87-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-92-1 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-20-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-23-1 CAPLUS

CN Formamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-29-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(dimethylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-39-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-furanyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-41-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-61-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-66-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1,3-benzodioxol-4-yl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-68-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214697-97-9 CAPLUS


CN 1,4-Butanediolamine, N'-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N,N-dimethyl-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 214698-04-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 214698-10-9 CAPLUS

CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 214698-83-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridazinyl]-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 214698-85-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214699-03-3 CAPLUS


CN 4-Piperidinol, 1-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 214699-27-1 CAPLUS

CN Phosphonic acid, [4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 214699-31-7 CAPLUS

CN Benzoic acid, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-(9CI) (CA INDEX NAME)




RN 214699-33-9 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-4-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214699-54-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[1-methyl-1-(methylamino)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-64-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-68-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-70-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-72-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)



RN 214699-93-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(hexahydro-1H-azepin-1-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)



RN 214699-95-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[6-[methyl(1-

methylethyl)amino]-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-98-6 CAPLUS

CN Piperazine, 1-acetyl-4-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-02-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-04-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[methyl[2-(2-pyridinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-16-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[2-(methoxymethyl)-1-pyrrolidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-27-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-59-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-68-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-77-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-80-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-chloro-6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214700-83-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-oxido-4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 214701-09-4P

RL: BYP (Byproduct); PREP (Preparation)
(prepn. as adenosine **kinase inhibitor**)

RN 214701-09-4 CAPLUS

CN Methanimidamide, N-[5-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




IT 214697-64-0P 214700-62-6P 214700-86-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. as adenosine **kinase inhibitor**)


RN 214697-64-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromo-5-chlorophenyl)methyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214700-62-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214700-86-4 CAPLUS

CN Ethanol, 2-[2-[[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]amino]ethoxy]- (9CI) (CA INDEX NAME)




IT 149065-12-3P 214695-90-6P 214695-91-7P
214695-92-8P 214695-93-9P 214695-94-0P
214695-96-2P 214695-97-3P 214695-98-4P
214695-99-5P 214696-00-1P 214696-01-2P
214696-02-3P 214696-04-5P 214696-05-6P
214696-06-7P 214696-07-8P 214696-08-9P
214696-09-0P 214696-10-3P 214696-11-4P
214696-12-5P 214696-13-6P 214696-14-7P
214696-15-8P 214696-16-9P 214696-17-0P
214696-18-1P 214696-19-2P 214696-20-5P
214696-21-6P 214696-22-7P 214696-23-8P
214696-24-9P 214696-25-0P 214696-26-1P
214696-27-2P 214696-28-3P 214696-29-4P
214696-30-7P 214696-32-9P 214696-33-0P
214696-34-1P 214696-35-2P 214696-36-3P
214696-37-4P 214696-38-5P 214696-39-6P
214696-41-0P 214696-42-1P 214696-45-4P
214696-46-5P 214696-47-6P 214696-48-7P
214696-49-8P 214696-50-1P 214696-52-3P
214696-55-6P 214696-56-7P 214696-57-8P
214696-58-9P 214696-59-0P 214696-60-3P
214696-61-4P 214696-62-5P 214696-63-6P
214696-64-7P 214696-65-8P 214696-66-9P
214696-67-0P 214696-69-2P 214696-71-6P
214696-72-7P 214696-73-8P 214696-74-9P
214696-75-0P 214696-76-1P 214696-77-2P
214696-78-3P 214696-79-4P 214696-80-7P
214696-81-8P 214696-82-9P 214696-83-0P
214696-84-1P 214696-85-2P 214696-86-3P
214696-88-5P 214696-90-9P 214696-91-0P
214696-93-2P 214696-94-3P 214696-95-4P
214696-96-5P 214696-97-6P 214696-98-7P
214696-99-8P 214697-00-4P 214697-01-5P
214697-02-6P 214697-03-7P 214697-04-8P
214697-05-9P 214697-06-0P 214697-07-1P
214697-08-2P 214697-09-3P 214697-10-6P
214697-11-7P 214697-12-8P 214697-13-9P
214697-14-0P 214697-15-1P 214697-16-2P
214697-18-4P 214697-21-9P 214697-22-0P
214697-26-4P 214697-27-5P 214697-28-6P
214697-30-0P 214697-31-1P 214697-32-2P
214697-33-3P 214697-34-4P 214697-35-5P
214697-36-6P 214697-37-7P 214697-38-8P
214697-40-2P 214697-42-4P 214697-43-5P
214697-44-6P 214697-45-7P 214697-46-8P
214697-47-9P 214697-48-0P 214697-49-1P
214697-52-6P 214697-54-8P 214697-55-9P
214697-56-0P 214697-57-1P 214697-60-6P
214697-62-8P 214697-63-9P 214697-67-3P
214697-69-5P 214697-70-8P 214697-71-9P
214697-72-0P 214697-73-1P 214697-74-2P

214697-75-3P 214697-76-4P 214697-77-5P
214697-78-6P 214697-79-7P 214697-80-0P
214697-81-1P 214697-82-2P 214697-83-3P
214697-84-4P 214697-85-5P 214697-86-6P
214697-87-7P 214697-89-9P 214697-91-3P
214697-93-5P 214697-95-7P 214697-99-1P
214698-01-8P 214698-02-9P 214698-06-3P
214698-08-5P 214698-12-1P 214698-14-3P
214698-16-5P 214698-18-7P 214698-20-1P
214698-22-3P 214698-23-4P 214698-25-6P
214698-27-8P 214698-30-3P 214698-32-5P
214698-34-7P 214698-36-9P 214698-37-0P
214698-39-2P 214698-41-6P 214698-43-8P
214698-45-0P 214698-47-2P 214698-50-7P
214698-52-9P 214698-54-1P 214698-56-3P
214698-58-5P 214698-59-6P 214698-62-1P
214698-64-3P 214698-66-5P 214698-68-7P
214698-70-1P 214698-72-3P 214698-74-5P
214698-76-7P 214698-78-9P 214698-81-4P
214698-87-0P 214698-89-2P 214698-91-6P
214698-93-8P 214698-95-0P 214698-97-2P
214698-99-4P 214699-01-1P 214699-05-5P
214699-06-6P 214699-08-8P 214699-10-2P
214699-11-3P 214699-12-4P 214699-14-6P
214699-16-8P 214699-17-9P 214699-19-1P
214699-21-5P 214699-23-7P 214699-25-9P
214699-29-3P 214699-32-8P 214699-35-1P
214699-37-3P 214699-40-8P 214699-43-1P
214699-46-4P 214699-48-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. as adenosine kinase inhibitor)


RN 149065-12-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)




RN 214695-90-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214695-91-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5,7-bis[4-(dimethylamino)phenyl]- (9CI)
(CA INDEX NAME)



RN 214695-92-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214695-93-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[4-(dimethylamino)phenyl]-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214695-94-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214695-96-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-butoxyphenyl)-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214695-97-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-[4-(1-methylethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214695-98-4 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[4-[4-amino-5-(4-butoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214695-99-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-00-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-methoxyphenyl)-5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-01-2 CAPLUS

CN Propanedioic acid, [3-[4-[4-amino-5-[4-(1-methylethyl)phenyl]pyrido[2,3-d]pyrimidin-7-yl]phenyl]-1-propenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 214696-02-3 CAPLUS

CN 2-Penten-1-one, 1-[4-[4-amino-5-[4-(1-methylethyl)phenyl]pyrido[2,3-d]pyrimidin-7-yl]phenyl]-4,4-dimethyl-, (9CI) (CA INDEX NAME)




RN 214696-04-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-05-6 CAPLUS

CN 2-Penten-1-one, 1-[4-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]phenyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 214696-06-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-07-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-08-9 CAPLUS

CN Propanedioic acid, [3-[4-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]phenyl]-1-propenyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 214696-09-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[4-(3-ethenyl-2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-10-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-11-4 CAPLUS

CN Benzamide, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-12-5 CAPLUS

CN Benzonitrile, 3-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214696-13-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-14-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-butoxyphenyl)-
(9CI) (CA INDEX NAME)


RN 214696-15-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-16-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 214696-17-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-18-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 214696-19-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-20-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-bromophenyl)-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-21-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-phenyl- (9CI) (CA INDEX NAME)




RN 214696-22-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 214696-23-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214696-24-9 CAPLUS


CN Benzonitrile, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 214696-25-0 CAPLUS
CN Phenol, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI)
(CA INDEX NAME)



RN 214696-26-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-iodophenyl)- (9CI) (CA INDEX NAME)




RN 214696-27-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-28-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-

(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-29-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dichlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-30-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-32-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-33-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-34-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-35-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 214696-36-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-37-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-38-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-39-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-41-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethoxyethoxy)phenyl]-5-[3-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-42-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(1,3-benzodioxol-5-yl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-45-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 214696-46-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3-(dimethylamino)phenyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-47-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214696-48-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-49-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 214696-50-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(4-iodophenyl)- (9CI)
(CA INDEX NAME)



RN 214696-52-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(4-morpholinyl)phenyl]-5-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 214696-55-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-(2-thienyl)-
(9CI) (CA INDEX NAME)




RN 214696-56-7 CAPLUS
CN Benzamide, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI)

(CA INDEX NAME)




RN 214696-57-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(2-methoxyethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-58-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-59-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(2-thienyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-60-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(4-aminophenyl)-5-(3-bromophenyl)- (9CI)
(CA INDEX NAME)


RN 214696-61-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-(2-thienyl)-
(9CI) (CA INDEX NAME)

RN 214696-62-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-(2-furanyl)-
(9CI) (CA INDEX NAME)

RN 214696-63-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-(4-iodophenyl)-
(9CI) (CA INDEX NAME)


RN 214696-64-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(1H-imidazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-65-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-66-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-67-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-methyl-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-69-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-71-6 CAPLUS

CN Benzenamine, 4-[5-(3-bromophenyl)-4-(4-morpholinyl)pyrido[2,3-d]pyrimidin-7-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 214696-72-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(5-bromo-2-thienyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-73-8 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214696-74-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-75-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dimethoxyphenyl)-7-[4-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-76-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 214696-77-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-78-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214696-79-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 214696-80-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-iodophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214696-81-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3,5-bis(trifluoromethyl)phenyl]-7-[4-(4-(dimethylamino)phenyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214696-82-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[3,5-bis(trifluoromethyl)phenyl]-7-[4-(4-(4-(dimethylamino)phenyl)phenyl)phenyl]- (9CI) (CA INDEX NAME)

morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-83-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dibromophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-84-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,5-dibromophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-85-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[4-(4-methyl-1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-86-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-88-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214696-90-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-91-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3,4-dichlorophenyl)-
(9CI) (CA INDEX NAME)




RN 214696-93-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-94-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214696-95-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(3-amino-4-methoxyphenyl)-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214696-96-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[3-bromo-4-(dimethylamino)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214696-97-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)-3-methylphenyl]- (9CI) (CA INDEX NAME)




RN 214696-98-7 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 214696-99-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)-3-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 214697-00-4 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 214697-01-5 CAPLUS

CN Acetamide, N-acetyl-N-[7-[4-(acetylmethylamino)phenyl]-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-02-6 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-03-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(ethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-04-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 214697-05-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(1-methylethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 214697-06-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[ethyl(2-methoxyethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 214697-07-1 CAPLUS

CN Propanamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-3-methoxy-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 214697-08-2 CAPLUS

CN Formamide, N-[4-{4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl}phenyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214697-09-3 CAPLUS

CN 1,2-Ethanediamine, N'-[4-{4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl}phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 214697-10-6 CAPLUS

CN Propanenitrile, 3-[[4-{4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl}phenyl]methylamino]- (9CI) (CA INDEX NAME)




RN 214697-11-7 CAPLUS

CN Propanamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-3-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-12-8 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-13-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-methyl-4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-14-0 CAPLUS

Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(3-methoxy-1-methylpropyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-15-1 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-1,3-dihydro-N-methyl-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 214697-16-2 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-18-4 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-methylphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-21-9 CAPLUS

CN Benzonitrile, 3-[4-[4-amino-7-[4-(methylsulfonyl)phenyl]pyrido[2,3-d]pyrimidin-5-yl]- (9CI) (CA INDEX NAME)




RN 214697-22-0 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-cyanophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-26-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-27-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-28-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-pyrrolidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-30-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-[(2-methoxyethyl)methylamino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-31-1 CAPLUS

CN Formamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyrimidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214697-32-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(methylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-33-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(1-pyrrolidinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-34-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[2-(4-morpholinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214697-35-5 CAPLUS

CN 2-Oxazolidinone, 3-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214697-36-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214697-37-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214697-38-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-40-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3'-methoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 214697-42-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 214697-43-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-(4-iodophenyl)- (9CI)
(CA INDEX NAME)

RN 214697-44-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(2-thienyl)phenyl]-
(9CI) (CA INDEX NAME)

RN 214697-45-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[4-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-46-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-(4-iodophenyl)- (9CI) (CA INDEX NAME)



RN 214697-47-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214697-48-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(3-bromophenyl)methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-49-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 214697-52-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[2-(4-bromophenyl)ethyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-54-8 CAPLUS

CN Benzonitrile, 3-[[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 214697-55-9 CAPLUS

CN Carbamic acid, [2-[4-amino-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-5-yl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 214697-56-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cycloheptyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-57-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[[5-chloro-2-(3-thienyl)phenyl]methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-60-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[2-(3-bromophenyl)ethyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-62-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclopropyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-63-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-67-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-fluoro-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-69-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 214697-70-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3,4-dichlorophenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-71-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-72-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-73-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-74-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-75-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-76-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-77-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-5-methoxyphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214697-78-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2,3-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-79-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-[3-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214697-80-0 CAPLUS

CN Acetamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-81-1 CAPLUS


CN Formamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-82-2 CAPLUS
CN Acetamide, N-[5-(3-bromophenyl)-7-[4-(diethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 214697-83-3 CAPLUS
CN Acetamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)



RN 214697-84-4 CAPLUS
CN Pentanamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-85-5 CAPLUS
CN Benzamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)




RN 214697-86-6 CAPLUS

CN Carbamic acid, [2-[[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 214697-87-7 CAPLUS

CN 2H-Isoindole-2-acetamide, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-1,3-dihydro-1,3-dioxo- (9CI) (CA INDEX NAME)




RN 214697-89-9 CAPLUS

CN Carbamic acid, [5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 214697-91-3 CAPLUS

CN Urea, N-[5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 214697-93-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



RN 214697-95-7 CAPLUS


CN 1,2-Ethanediamine, N'-[5-(4-bromophenyl)-7-[4-(dimethylamino)phenyl]pyrido[2,3-d]pyrimidin-4-yl]-N,N-dimethyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 214697-99-1 CAPLUS

CN Formamide, N-(7-(4-bromophenyl)-5-(4-(dimethylamino)phenyl)pyrido[2,3-d]pyrimidin-4-yl)-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 214698-01-8 CAPLUS

CN Acetamide, N-acetyl-N-(7-(4-bromophenyl)-5-(4-(dimethylamino)phenyl)pyrido[2,3-d]pyrimidin-4-yl)- (9CI) (CA INDEX NAME)




RN 214698-02-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(5-amino-2-pyridinyl)-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214698-06-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)pyrazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214698-08-5 CAPLUS
CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 214698-12-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(4-chloro-3'-methoxy[1,1'-biphenyl]-2-yl)methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-14-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[(2-bromophenyl)methyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-16-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-[[2-(2-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 214698-18-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-[[2-(3-thienyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 214698-20-1 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 214698-22-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(2-methoxyethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 214698-23-4 CAPLUS

CN 1,2-Ethanediamine, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 214698-25-6 CAPLUS

CN Acetamide, N-[2-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]amino]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 214698-27-8 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 214698-30-3 CAPLUS

CN Acetamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 214698-32-5 CAPLUS

CN 2-Oxazolidinone, 3-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 214698-34-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-methylethyl)-3-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 214698-36-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-methyl-4-(1-pyrrolidinyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 214698-37-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-imidazol-1-yl)-3-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



●3 HCl


RN 214698-39-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 214698-41-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[[2-(3-amino-1-propynyl)phenyl]methyl]-7-[4-(diethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-43-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-45-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(2-bromo-5-pyrimidinyl)-5-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-47-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(2-furanyl)-7-[2-(4-morpholinyl)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 214698-50-7 CAPLUS

CN Urea, [4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 214698-52-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(diethylamino)phenyl]-5-[1-
(phenylmethyl)-3-piperidinyl]- (9CI) (CA INDEX NAME)




RN 214698-54-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(3-methyl-5-
isoxazolyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214698-56-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-chloro-3-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 214698-58-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214698-59-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4H-1,2,4-triazol-4-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214698-62-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(1-pyrrolidinyl)phenyl]-5-(2-thiazolyl)- (9CI) (CA INDEX NAME)




RN 214698-64-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-pyrazol-1-yl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214698-66-5 CAPLUS

CN Urea, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214698-68-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(methyl-2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214698-70-1 CAPLUS

CN Formamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214698-72-3 CAPLUS

CN Formamide, N-[4-[5-(3-bromophenyl)-4-(formylamino)pyrido[2,3-d]pyrimidin-7-yl]-2-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214698-74-5 CAPLUS

CN Methanesulfonamide, N-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214698-76-7 CAPLUS

CN Methanesulfonamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 214698-78-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(2,3-dihydro-1-methyl-1H-indol-5-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-81-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-(1-methyl-1H-benzimidazol-5-yl)-, tetrahydrochloride (9CI) (CA INDEX NAME)



● 4 HCl

RN 214698-87-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1-pyrrolidinyl)-3-pyridazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214698-89-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)pyrazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 214698-91-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-[(2-methoxyethyl)methylamino]pyrazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 214698-93-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(4-morpholinylmethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214698-95-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]-5-(3-bromophenyl)-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 214698-97-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1H-imidazol-1-ylmethyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 214698-99-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(4-morpholinyl)-2-pyridinyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 214699-01-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[(dimethylamino)methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

RN 214699-05-5 CAPLUS


CN Formamide, N-[6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-pyridinyl]-N-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 214699-06-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(2-propenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214699-08-8 CAPLUS


CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214699-10-2 CAPLUS

CN Formamide, N-[1-[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 214699-11-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 214699-12-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214699-14-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-N-(2-methoxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214699-16-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(1-methyl-1H-imidazol-2-yl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 214699-17-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(aminomethyl)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214699-19-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[2-bromo-4-(dimethylamino)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214699-21-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[2-(dimethylamino)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-23-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[3-(dimethylamino)-1-propynyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-25-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(3-amino-3-methyl-1-butynyl)phenyl]-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 214699-29-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(3-methoxy-1-propynyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214699-32-8 CAPLUS

CN 2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 214699-35-1 CAPLUS

CN 2(3H)-Benzoxazolone, 6-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214699-37-3 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 214699-40-8 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 7-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2,2,4-trimethyl- (9CI) (CA INDEX NAME)




RN 214699-43-1 CAPLUS

CN 2H-1,4-Benzoxazin-3(4H)-one, 7-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-4-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 214699-46-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(1-methylethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214699-48-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(1-piperidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




IT 214699-50-0P 214699-52-2P 214699-56-6P
 214699-58-8P 214699-60-2P 214699-62-4P
 214699-66-8P 214699-74-8P 214699-78-2P
 214699-80-6P 214699-82-8P 214699-84-0P
 214699-86-2P 214699-88-4P 214699-90-8P
 214699-91-9P 214699-97-5P 214700-00-2P
 214700-06-8P 214700-08-0P 214700-10-4P
 214700-12-6P 214700-14-8P 214700-18-2P
 214700-21-7P 214700-24-0P 214700-30-8P
 214700-32-0P 214700-35-3P 214700-38-6P
 214700-41-1P 214700-44-4P 214700-47-7P
 214700-53-5P 214700-56-8P 214700-65-9P
 214700-71-7P 214700-74-0P 214700-89-7P
 214700-92-2P 214700-95-5P 214700-98-8P
 214701-00-5P 214701-02-7P 214701-05-0P
 214701-07-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. as adenosine **kinase inhibitor**)


RN 214699-50-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(4-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-52-2 CAPLUS

CN Formamide, N-[[4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 214699-56-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-[1-(dimethylamino)-1-methylethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 214699-58-8 CAPLUS

CN 1H-Indole, 1-acetyl-5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2,3-dihydro- (9CI) (CA INDEX NAME)




RN 214699-60-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(6-chloro-3-pyridinyl)-5-cyclohexyl- (9CI) (CA INDEX NAME)




RN 214699-62-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-66-8 CAPLUS

CN Formamide, N-[5-[4-amino-5-[1-(2-bromophenyl)ethyl]pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214699-74-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-78-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclopentyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214699-80-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(2-chloro-3-pyridinyl)-5-cyclohexyl- (9CI) (CA INDEX NAME)




RN 214699-82-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(dimethylamino)-3-pyridinyl]-5-(3,5-dimethylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 214699-84-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[4-amino-7-[6-(4-morpholinyl)-3-pyridinyl]pyrido[2,3-d]pyrimidin-5-yl]methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

RN 214699-86-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(6-bromo-3-pyridinyl)-5-cyclohexyl- (9CI) (CA INDEX NAME)




RN 214699-88-4 CAPLUS

CN Benzonitrile, 3-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)- (9CI)
(CA INDEX NAME)


RN 214699-90-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(dimethylamino)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-91-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1H-imidazol-1-yl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214699-97-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-[6-(4-morpholinyl)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 214700-00-2 CAPLUS


CN 1H-1,4-Diazepine, 1-acetyl-4-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]hexahydro- (9CI) (CA INDEX NAME)




RN 214700-06-8 CAPLUS
CN 1,2-Ethanediamine, N-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)




RN 214700-08-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(1-azetidiny)-3-pyridinyl]-5-cyclohexyl- (9CI) (CA INDEX NAME)




RN 214700-10-4 CAPLUS
CN Acetamide, N-[1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 214700-12-6 CAPLUS
CN Formamide, N-[1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 214700-14-8 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-1-phenyl- (9CI) (CA INDEX NAME)




RN 214700-18-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[(2-methoxyethyl)propylamino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-21-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[(2,2-dimethoxyethyl)methylamino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214700-24-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[4-(dimethylamino)-1-piperidinyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-30-8 CAPLUS
CN 1,3-Propanediamine, N-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]-N',N'-diethyl-N-methyl- (9CI) (CA INDEX NAME)




RN 214700-32-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[methyl(2-(4-pyridinyl)ethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-35-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-[methyl(3-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-38-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-[1-(2-bromophenyl)ethyl]-7-(1-methyl-1H-indol-5-yl)- (9CI) (CA INDEX NAME)




RN 214700-41-1 CAPLUS

CN 1H-Indole-2,3-dione, 5-[4-amino-5-[1-(2-bromophenyl)ethyl]pyrido[2,3-d]pyrimidin-7-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 214700-44-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[3-fluoro-4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214700-47-7 CAPLUS

CN Phenol, 4-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-nitro- (9CI) (CA INDEX NAME)




RN 214700-53-5 CAPLUS

CN 4-Piperidinone, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-56-8 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-65-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(1,1-dioxido-4-thiomorpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-71-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-methoxyphenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-74-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-89-7 CAPLUS

CN Formamide, N-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-N-[2-(2-hydroxyethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 214700-92-2 CAPLUS

CN Ethanol, 2-[2-[[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-1-oxido-2-pyridinyl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 214700-95-5 CAPLUS

CN 3-Morpholinol, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214700-98-8 CAPLUS

CN 2-Morpholinol, 4-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214701-00-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-methylene-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214701-02-7 CAPLUS

CN 4-Piperidinemethanol, 1-[5-[4-amino-5-(3-bromophenyl)pyrido[2,3-d]pyrimidin-7-yl]-2-pyridinyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 214701-05-0 CAPLUS

CN 4-Piperidinone, 1-[5-(4-amino-5-cyclohexylpyrido[2,3-d]pyrimidin-7-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214701-07-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-cyclohexyl-7-[6-(4-methylene-1-piperidinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)



L66 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:708823 CAPLUS

DOCUMENT NUMBER: 129:316239

TITLE: 5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidine compounds as adenosine kinase inhibitors

INVENTOR(S): Bhagwat, Shripad S.; Perner, Richard J.; Gu, Yu Gui

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846604	A1	19981022	WO 1998-US7201	19980413
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9871080	A1	19981111	AU 1998-71080	19980413
AU 741033	B2	20011122		
EP 975633	A1	20000202	EP 1998-918091	19980413
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
BR 9809056	A	20000801	BR 1998-9056	19980413
JP 2001520654	T2	20011030	JP 1998-544083	19980413
ZA 9803175	A	19981021	ZA 1998-3175	19980415
NO 9905035	A	19991215	NO 1999-5035	19991015
PRIORITY APPLN. INFO.:			US 1997-843484	A 19970416
			WO 1998-US7201	W 19980413

OTHER SOURCE(S):
GI

MARPAT 129:316239




AB Title compds. I [R1, R2 = H, alkyl, aralkyl, acyl; NR1R2 = heterocyclic; R3-R5 = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclic] and their mono- or dihydro derivs. were prepd. as adenosine kinase inhibitors in treatment of cerebral ischemia, epilepsy, pain, nociperception, inflammation and sepsis. Thus, MeONHMe.HCl was treated with Me(CH2)5COCl to give the amide which was treated with 4-BrC6H4NMe2 to give 4-Me2NC6H4CO(CH2)5Me. The ketone was treated with 3,4-Br(F)C6H3CHO to give the pyridinamine which was cyclized with formamidine to give I [R1 = R2 = H, R3 = 3,4-Br(F)C6H3, R4 = pentyl, R5 = 4-Me2NC6H4]. This compd. had an IC50 for adenosine kinase inhibition of 80 nM.

IT 214831-14-8P 214831-18-2P 214831-23-9P
214831-26-2P 214831-28-4P 214831-30-8P
214831-35-3P 214831-42-2P 214831-49-9P
214831-51-3P 214831-52-4P 214831-65-9P
214831-68-2P 214831-69-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 214831-14-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-7-[4-(dimethylamino)phenyl]-6-pentyl- (9CI) (CA INDEX NAME)




RN 214831-18-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-ethyl-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-23-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 214831-26-2 CAPLUS


CN Pyrido[2,3-d]pyrimidine-6-acetic acid, 4-amino-5-(3-bromophenyl)-7-(2-thienyl)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-28-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-[(3-methoxyphenyl)methyl]-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


RN 214831-30-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl


RN 214831-35-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-42-2 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-49-9 CAPLUS
 CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-51-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-[(2-methoxyethyl)methylamino]phenyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-52-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-diphenyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 214831-65-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-68-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-69-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

IT 214831-16-0P 214831-17-1P 214831-20-6P
214831-24-0P 214831-29-5P 214831-36-4P


214831-37-5P 214831-38-6P 214831-39-7P
214831-40-0P 214831-41-1P 214831-43-3P
214831-44-4P 214831-45-5P 214831-46-6P
214831-47-7P 214831-53-5P 214831-54-6P
214831-55-7P 214831-56-8P 214831-57-9P
214831-58-0P 214831-59-1P 214831-60-4P
214831-61-5P 214831-62-6P 214831-63-7P
214831-70-6P 214831-71-7P 214831-72-8P
214831-73-9P 214831-74-0P 214831-75-1P
214831-76-2P 214831-78-4P 214831-79-5P
214831-80-8P 214831-81-9P 214831-82-0P
214831-83-1P 214831-84-2P 214831-85-3P
214831-86-4P 214831-87-5P 214831-88-6P
214831-89-7P 214831-90-0P 214831-91-1P
214831-92-2P 214831-93-3P 214831-94-4P
214831-95-5P 214831-96-6P 214831-97-7P
214831-98-8P 214831-99-9P 214832-00-5P
214832-01-6P 214832-02-7P 214832-03-8P
214832-04-9P 214832-05-0P 214832-06-1P
214832-07-2P 214832-08-3P 214832-09-4P
214832-10-7P 214832-11-8P 214832-12-9P
214832-13-0P 214832-14-1P 214832-15-2P
214832-16-3P 214832-17-4P 214832-18-5P
214832-19-6P 214832-20-9P 214832-21-0P
214832-22-1P 214832-23-2P 214832-24-3P
214832-25-4P 214832-26-5P 214832-27-6P
214832-28-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(5,6,7-trisubstituted-4-aminopyrido[2,3-d]pyrimidines as adenosine kinase inhibitors)


RN 214831-16-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromo-4-fluorophenyl)-6-pentyl-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-17-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6,7-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 214831-20-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-pentyl-7-(2-thienyl)-
(9CI) (CA INDEX NAME)



RN 214831-24-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[4-(dimethylamino)phenyl]-6-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-29-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(3,4-dimethoxyphenyl)-
7-[4-(dimethylamino)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-36-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-37-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-38-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-39-7 CAPLUS



CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-40-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




HCl

RN 214831-41-1 CAPLUS

Searched by Barb O'Bryen, STIC 308-4291


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-43-3 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-44-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-45-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-46-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-47-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-53-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 214831-54-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl

RN 214831-55-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis(3-fluoro-4-methylphenyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-56-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3-fluoro-4-methylphenyl)-7-(2-thienyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-57-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-diphenyl-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 214831-58-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-(dimethylamino)-2-pyridinyl]-5,6-

diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-59-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 214831-60-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-((2-methoxyethyl)methylamino)-2-pyridinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 214831-61-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 214831-62-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-63-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 214831-70-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-71-7 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-72-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-cyclopropyl-7-[6-(dimethylamino)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-73-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-74-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-
[(cyclopropylmethyl)amino]-3-pyridinyl]-6-phenyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 214831-75-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(cyclopropylmethyl)amino]-3-
pyridinyl]-5,6-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 214831-76-2 CAPLUS


RN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-78-4 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-79-5 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-phenyl-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-80-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-81-9 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(1-methylethyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-82-0 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-83-1 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214831-84-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]-6-pentyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214831-85-3 CAPLUS

CN Pyrido[2,3-d]pyrimidine-6-acetic acid, 4-amino-5-(3-bromophenyl)-7-(2-thienyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 214831-86-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-[(3-methoxyphenyl)methyl]-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 214831-87-5 CAPLUS



CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214831-88-6 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




Searched by Barb O'Bryen, STIC 308-4291


PAGE 2-A




RN 214831-89-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-
7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-90-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-5-[4-fluoro-3-(trifluoromethyl)phenyl]-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-91-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-
7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 214831-92-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]-5-[4-fluoro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)





RN 214831-93-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)




RN 214831-94-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 214831-95-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214831-96-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 214831-97-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 214831-98-8 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[4-[(2-methoxyethyl)methylamino]phenyl]- (9CI) (CA INDEX NAME)




RN 214831-99-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)-5-phenyl- (9CI) (CA INDEX NAME)



RN 214832-00-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-(5-methoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 214832-01-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-02-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-[(2-methoxyethyl)methylamino]phenyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-03-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-04-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3,4-dimethoxyphenyl)-7-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 214832-05-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[4-(dimethylamino)phenyl]-5,6-bis(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 214832-06-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5,6-bis(3-fluoro-4-methylphenyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 214832-07-2 CAPLUS


CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[5-(dimethylamino)-2-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-08-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 6-(3,4-dimethoxyphenyl)-7-[5-(dimethylamino)-2-pyridinyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 214832-09-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-(3,4-dimethoxyphenyl)-7-[5-[(2-methoxyethyl)methylamino]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-10-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-11-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[5-(dimethylamino)-2-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-12-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-13-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-14-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-15-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-16-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-17-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-[(2-methoxyethyl)methylamino]-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-18-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-cyclopropyl-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-19-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(4-fluorophenyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-20-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-((cyclopropylmethyl)amino)-3-pyridinyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 214832-21-0 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-[(cyclopropylmethyl)amino]-3-pyridinyl]-5,6-diphenyl- (9CI) (CA INDEX NAME)




RN 214832-22-1 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-chlorophenyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-23-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 7-[6-(4-morpholinyl)-3-pyridinyl]-5-phenyl-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 214832-24-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-heptyl-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-25-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-6-(1-methylethyl)-7-[6-(4-morpholinyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 214832-26-5 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(4-bromo-2-thienyl)-7-[6-(4-morpholinyl)-3-pyridinyl]-6-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 214832-27-6 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-6-cyclohexyl-7-[6-(dimethylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 214832-28-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-4-amine, 5-(3-bromophenyl)-7-[6-(dimethylamino)-3-pyridinyl]-6-pentyl- (9CI) (CA INDEX NAME)



L66 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:542992 CAPLUS

DOCUMENT NUMBER: 129:160642

TITLE: Tolerization and elimination of B-cells producing natural antibodies to galactosyl epitope expressed on xenograft tissue

INVENTOR(S): Thall, Aron

PATENT ASSIGNEE(S): Biotransplant, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9833528	A2	19980806	WO 1998-US2103	19980205
WO 9833528	A3	19990211		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			

Searched by Barb O'Bryen, STIC 308-4291

AU 9863191 A1 19980825 AU 1998-63191 19980205
EP 969872 A2 20000112 EP 1998-907366 19980205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2001518074 T2 20011009 JP 1998-533214 19980205
PRIORITY APPLN. INFO.: US 1997-795925 A 19970205
WO 1998-US2103 W 19980205
AB The invention provides methods and compns. for promoting in a first
species a state of tolerance against Gal.alpha.1,3Gal epitopes present on
a xenograft from a second species, thereby preventing hyperacute rejection
(HAR) of the xenograft. In a first aspect, the invention provides methods
and tolerogenic compns. for inducing anergy in B-cells specific for the
Gal.alpha.1,3Gal epitope. In a second aspect, the invention provides
methods and tolerogenic compns. for inducing apoptosis in B-cells. In a
third aspect, the invention provides methods and compns. for the cytotoxic
elimination of memory B-cells and T-cells.
IT 96187-53-OD, Brequinar, analogs
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(for tolerization and elimination of B-cells producing natural
antibodies to galactosyl epitope expressed on xenograft tissue)
RN 96187-53-0 CAPLUS
CN 4-Quinolincarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-
methyl- (9CI) (CA INDEX NAME)



L66 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:191764 CAPLUS

DOCUMENT NUMBER: 118:191764

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds
(e.g., quinolines) which **inhibit** EGF and/or
PDGF receptor tyrosine **kinase**

INVENTOR(S): Spada, Alfred P.; Maguire, Martin P.; Persons, Paul
E.; Myers, Michael R.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer International (Holdings) Inc., USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 7

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9220642	A1	19921126	WO 1992-US3736	19920506
W:	AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG			
AU 9219934	A1	19921230	AU 1992-19934	19920506
AU 658646	B2	19950427		
EP 584222	A1	19940302	EP 1992-912051	19920506
EP 584222	B1	19971008		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE			
JP 06507643	T2	19940901	JP 1992-500068	19920506

AT 159009	E	19971015	AT 1992-912051	19920506
ES 2108120	T3	19971216	ES 1992-912051	19920506
US 5409930	A	19950425	US 1993-146072	19931108
US 5656643	A	19970812	US 1995-385258	19950208
CN 1187129	A	19980708	CN 1996-194512	19960606
US 36256	E	19990720	US 1997-988005	19971210
US 37650	E	20020409	US 2000-496399	20000202
PRIORITY APPLN. INFO.:			US 1991-698420	A2 19910510
			WO 1992-US3736	A 19920506
			US 1992-988515	B2 19921210
			US 1993-146072	A3 19931108
			US 1993-166199	A5 19931210
			US 1994-229886	A2 19940419
			WO 1994-US14180	W 19941208
			US 1996-652444	A5 19960604

OTHER SOURCE(S): MARPAT 118:191764
GI




AB A method of using the title compds. in which a 1st ring system is (hetero)aryl, a 2nd ring system is (hetero)aryl or (hetero)carboxylic, and both ring systems are either (un)substituted monocyclic with 0-2 heteroatoms, or bicyclic with 0-4 heteroatoms, is claimed, along with pharmaceutical compns. and selected compds. Most of the prepd. and claimed compds. are quinolines and quinoxalines. The compds. are designed to inhibit abnormal cell proliferation, and their use for treating psoriasis, atherosclerosis, and vascular reocclusion is claimed. For example, coupling of 2-methoxy-5-(trimethylstannyl)pyridine with 6,7-dimethoxyquinolin-3-yl trifluoromethanesulfonate (prepn. given) in refluxing dioxane contg. Pd(PPh₃)₄ and LiCl gave pyridylquinoline deriv. I. The IC₅₀ of I for inhibiting PDGF-R cell-free autophosphorylation was 0.030-0.070 .mu.M.

IT **146535-82-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)


RN 146535-82-2 CAPLUS

CN 4-Quinolinecarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:99301 CAPLUS
DOCUMENT NUMBER: 116:99301
TITLE: Maleic anhydride copolymers as antidotes for the
cytotoxicity of neoplasm inhibitors
INVENTOR(S): Bach, Ardalan; Shanahan, William R., Jr.
PATENT ASSIGNEE(S): Searle, G. D., and Co., USA
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 393575	A1	19901024	EP 1990-107246	19900417
EP 393575	B1	19940316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2014732	AA	19901017	CA 1990-2014732	19900417
JP 02292227	A2	19901203	JP 1990-101530	19900417
AT 102838	E	19940415	AT 1990-107246	19900417
ES 2062155	T3	19941216	ES 1990-107246	19900417
PRIORITY APPLN. INFO.:			US 1989-339503	19890417
			EP 1990-107246	19900417
OTHER SOURCE(S):		MARPAT 116:99301		
GI				




AB Half-amide:half-imide copolymers comprising ethylene and maleic anhydride moieties (structure given), specifically carbetimer (I; a/b = 1:2-5), decrease the cytotoxic side effects of neoplasm inhibitors. Mice treated i.v. with 21 mg adriamycin/kg died within 5 days. When 1700 mg I/kg was administered concomitantly, no lethality was shown for >30 days.

IT 96201-88-6, Brequinar sodium
RL: PRP (Properties)
(cytotoxicity of, maleic anhydride copolymer antidote for)

RN 96201-88-6 CAPLUS

CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

L66 ANSWER 32 OF 63 USPATFULL

ACCESSION NUMBER: 2002:72882 USPATFULL
 TITLE: Heterocycles that are inhibitors of IMPDH enzyme
 INVENTOR(S): Iwanowicz, Edwin J., West Windsor, NJ, UNITED STATES
 Watterson, Scott H., Pennington, NJ, UNITED STATES
 Dhar, T.G. Murali, Newtown, PA, UNITED STATES
 Pitts, William J., Newtown, PA, UNITED STATES
 Gu, Henry H., Bordentown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040022	A1	20020404
APPLICATION INFO.:	US 2001-840503	A1	20010423 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-199420P	20000424 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4467	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds of the formula ##STR1##

wherein X^{sup.1} is C(O), --S(O)--, or --S(O).sub.2--;

X^{sup.2} is CR^{sup.3} or N; X^{sup.3} is --NH--, --O--, or --S--;


X^{sup.4} is CR^{sup.4} or N; X^{sup.5} is CR^{sup.5} or N; and X^{sup.6} is CR^{sup.6} or N are useful as inhibitors of IMPDH enzyme. Thus, these compounds can be used as therapeutic agents for IMPDH-associated disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 371249-73-9P 371249-74-0P 371251-26-2P,
 7-Methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)-4-(phenylmethoxy)quinoline 371251-27-3P, 3-[7-Methoxy-6-(5-oxazolyl)-4-(phenylmethoxy)-2-quinolinyl]phenol 371251-28-4P,
 2-[3-[7-Methoxy-6-(5-oxazolyl)-4-(phenylmethoxy)-2-quinolinyl]phenoxy]-N,N-dimethylethanamine 371251-69-3P, 7-Methoxy-4-(methoxymethoxy)-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)quinoline 371251-71-7P, 5-[7-Methoxy-4-(methoxymethoxy)-6-(5-oxazolyl)-2-quinolinyl]-2-methylphenol (intermediate; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)


Searched by Barb O'Bryen, STIC 308-4291

RN 371249-73-9 USPATFULL


CN Quinoline, 2-(3-bromophenyl)-7-methoxy-4-(methoxymethoxy)-6-(5-oxazolyl)-
(9CI) (CA INDEX NAME)

RN 371249-74-0 USPATFULL


CN Quinoline, 7-methoxy-4-(methoxymethoxy)-6-(5-oxazolyl)-2-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 371251-26-2 USPATFULL


CN Quinoline, 7-methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)-
4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

RN 371251-27-3 USPATFULL

CN Phenol, 3-[7-methoxy-6-(5-oxazolyl)-4-(phenylmethoxy)-2-quinolinyl]- (9CI)
(CA INDEX NAME)


RN 371251-28-4 USPATFULL

CN Ethanamine, 2-[3-[7-methoxy-6-(5-oxazolyl)-4-(phenylmethoxy)-2-quinolinyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 371251-69-3 USPATFULL

CN Quinoline, 7-methoxy-4-(methoxymethoxy)-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-71-7 USPATFULL

CN Phenol, 5-[7-methoxy-4-(methoxymethoxy)-6-(5-oxazolyl)-2-quinolinyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 371249-87-5, 2-[3-(4-Methyl-1-piperazinyl)phenyl]-7-methoxy-4-methoxymethoxy-6-(5-oxazolyl)quinoline

(reactant; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

RN 371249-87-5 USPATFULL

CN Quinoline, 7-methoxy-4-(methoxymethoxy)-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



L66 ANSWER 33 OF 63 USPATFULL

ACCESSION NUMBER: 2002:73690 USPATFULL

TITLE: Aryl and heteroaryl quinazoline compounds which
inhibit CSF-1R receptor tyrosine kinaseINVENTOR(S): Myers, Michael R., Reading, PA, United States
Spada, Alfred P., Lansdale, PA, United States
Maguire, Martin P., Mont Clare, PA, United States
Persons, Paul E., King of Prussia, PA, United States
Zilberstein, Asher, Broomall, PA, United States
Hsu, Chin-Yi Jenny, West Chester, PA, United States
Johnson, Susan E., Upper Darby, PA, United StatesPATENT ASSIGNEE(S): Aventis Pharmaceutical Products, Inc., Bridgewater, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 37650	E1	20020409
	US 5714493		19980203 (Original)
	WO 9515758		19950615
APPLICATION INFO.:	US 2000-496399		20000202 (9)
	US 1996-652444		19960604 (Original)
	WO 1994-US14180		19941208
RELATED APPLN. INFO.:			19960604 PCT 371 date
	Continuation-in-part of Ser. No. US 1994-229886, filed on 19 Apr 1994, now patented, Pat. No. US 5710158		
	Continuation-in-part of Ser. No. US 1993-166199, filed on 10 Dec 1993, now patented, Pat. No. US 5480883		
DOCUMENT TYPE:	Continuation-in-part of Ser. No. US 1992-988515, filed on 10 Dec 1992, now abandoned Continuation-in-part of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned Continuation-in-part of Ser. No. WO 1992-US3736, filed on 6 May 1992		
	Reissue		
	FILE SEGMENT: GRANTED		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner LLP		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1,2		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	941		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.		


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146535-82-2P

(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolinecarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 34 OF 63 USPATFULL

ACCESSION NUMBER: 2001:224132 USPATFULL

TITLE: Antioxidant enhancement of therapy for hyperproliferative conditions

INVENTOR(S): Chinery, Rebecca, Nashville, TN, United States
Beauchamp, R. Daniel, Nashville, TN, United States
Coffey, Robert J., Woodside, CA, United States
Medford, Russell M., Atlanta, GA, United States
Wadzinski, Brian E., Nashville, TN, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001049349	A1	20011206
APPLICATION INFO.:	US 2001-779086	A1	20010207 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-108609, filed on 1 Jul 1998, ABANDONED Continuation of Ser. No. US 1997-967492, filed on 11 Nov 1997, ABANDONED Continuation-in-part of Ser. No. US 1997-886653, filed on 1 Jul 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Sherry M. Knowles, Esq., KING & SPALDING, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	28 Drawing Page(s)		
LINE COUNT:	2353		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 96201-88-6, Brequinar sodium

(antioxidant enhancement of therapy for hyperproliferative conditions)

RN 96201-88-6 USPATFULL

CN 4-Quinolinecarboxylic acid, 6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-, sodium salt (9CI) (CA INDEX NAME)



● Na

L66 ANSWER 35 OF 63 USPATFULL

ACCESSION NUMBER:

2001:134230 USPATFULL

TITLE:

Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds

INVENTOR(S):

Tang, Peng C., Moraga, CA, United States
McMahon, Gerald, San Francisco, CA, United States
Weinberger, Heinz, Sulzbach/Ts., Germany, Federal Republic of
Kutscher, Bernhard, Maintal, Germany, Federal Republic of
App, Harald, San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014679	A1	20010816
APPLICATION INFO.:	US 2001-769360	A1	20010126 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-71682, filed on 1 May 1998, GRANTED, Pat. No. US 6204267		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60152P	19970926 (60)
	US 1997-45351P	19970502 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Beth A. Burrous, FOLEY & LARDNER, Washington Harbour, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2709	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 215925-73-8P

(modulating serine/threonine protein kinase function with quinazoline-based compds. and their use as antitumor and anti-fibrotic agents)

RN 215925-73-8 USPATFULL

CN 4-Quinazolinamine, 5-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



L66 ANSWER 36 OF 63 USPATFULL
ACCESSION NUMBER: 2001:208897 USPATFULL
TITLE: Use of a compound with affinity for the mitochondrial
benzodiazepine receptor in cancer therapy
INVENTOR(S): Kroemer, Guido, Paris, France
Hirsch, Tamara, Paris, France
Decaudin, Didier, Verrieres-le-Buisson, France
PATENT ASSIGNEE(S): Centre National de al Recherche Scientifique (CNRS),
Paris Cedex, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6319931	B1	20011120
APPLICATION INFO.:	US 1999-332152		19990614 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-7864	19980622
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Davis, Zinna Northington	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	1059	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates in particular to a combination product comprising at least one compound with affinity for the mitochondrial benzodiazepine receptor, and to at least one apoptosis-inducing agent for simultaneous or separate use or for use spread out over time, which is intended for the treatment of cancer. Another aspect of the present invention relates to the use of the said compound and/or of the said combination product for the manufacture of a medicinal product intended to facilitate the induction of apoptosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 253264-85-6P

(compd. having affinity for benzodiazepine mitochondrial receptor and apoptosis-inducing agent in cancer therapy)

RN 253264-85-6 USPATFULL

CN 4-Quinazolinepropanamide, N-methyl-N,2-diphenyl- (9CI) (CA INDEX NAME)



L66 ANSWER 37 OF 63 USPATFULL

ACCESSION NUMBER: 2001:44225 USPATFULL

TITLE: 1,3 diazines with platelet-derived growth factor
receptor inhibitory activityINVENTOR(S): Matsuno, Kenji, Shizuoka, Japan
Ichimura, Michio, Mishima, Japan
Nomoto, Yuji, Shizuoka, Japan
Fujiwara, Shigeki, Mishima, Japan
Ide, Shinichi, Numadzu, Japan
Tsukuda, Eiji, Odawara, Japan
Irie, Junko, Shizuoka, Japan
Oda, Shoji, Shizuoka, JapanPATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207667	B1	20010327
APPLICATION INFO.:	US 2000-481544		20000112 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-88199, filed on 1 Jun 1998 Continuation-in-part of Ser. No. WO 1997-JP3510, filed on 1 Oct 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-260743	19961001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Sripada, Pavanaram K	
LEGAL REPRESENTATIVE:	Fitzpatrick, Cella, Harper & Scinto	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8631	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1,3 Diazines according to formula (I): ##STR1##

and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205255-49-8P 205255-50-1P

(prepn. of nitrogenous heterocyclic compds. inhibiting phosphorylation
of platelet-derived growth factors (PDGF) receptors)


RN 205255-49-8 USPATFULL

CN 1-Piperazinecarboxamide, N-(4-nitrophenyl)-4-(2-phenyl-4-quinazolinyl)-
(9CI) (CA INDEX NAME)



RN 205255-50-1 USPATFULL

CN 1-Piperazinecarboxamide, 4-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




IT 181115-48-0 205259-64-9 205259-65-0


(prepn. of nitrogenous heterocyclic compds. inhibiting phosphorylation of platelet-derived growth factors (PDGF) receptors)

RN 181115-48-0 USPATFULL


CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 205259-64-9 USPATFULL
CN Quinazoline, 6,7-dimethoxy-2-phenyl-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 205259-65-0 USPATFULL
CN Quinazoline, 4-(hexahydro-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L66 ANSWER 38 OF 63 USPATFULL
ACCESSION NUMBER: 2001:40481 USPATFULL
TITLE: Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
INVENTOR(S): Tang, Peng C., Moraga, CA, United States
McMahon, Gerald, San Francisco, CA, United States
Weinberger, Heinz, Sulzbach/Ts., Germany, Federal Republic of
Kutscher, Bernhard, Maintal, Germany, Federal Republic of
App, Harald, San Francisco, CA, United States
PATENT ASSIGNEE(S): Sugen, Inc., South San Francisco, CA, United States (U.S. corporation)

NUMBER KIND DATE

Searched by Barb O'Bryen, STIC 308-4291

PATENT INFORMATION: US 6204267 B1 20010320
APPLICATION INFO.: US 1998-71682 19980501 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-60152P	19970926 (60)
	US 1997-45351P	19970502 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Coleman, Brenda
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 2365

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to quinazoline compounds and pharmaceutical compositions comprising these compounds.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 215925-73-8P

(modulating serine/threonine protein kinase function with quinazoline-based compds. and their use as antitumor and anti-fibrotic agents)

RN 215925-73-8 USPATFULL

CN 4-Quinazolinamine, 5-phenoxy-2-phenyl- (9CI) (CA INDEX NAME)



L66 ANSWER 39 OF 63 USPATFULL

ACCESSION NUMBER: 2001:1775 USPATFULL

TITLE: 1,3 diazines with platelet-derived growth factor receptor inhibitory activity

INVENTOR(S): Matsuno, Kenji, Shizouka, Japan
Ichimura, Michio, Mishima, Japan
Nomoto, Yuji, Shizouka, Japan
Fujiwara, Shigeki, Mishima, Japan
Ide, Shinichi, Numadzu, Japan
Tsukuda, Eiji, Odawara, Japan
Irie, Junko, Shizouka, Japan
Oda, Shoji, Shizouka, Japan

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

NUMBER	KIND	DATE

Searched by Barb O'Bryen, STIC 308-4291

PATENT INFORMATION: US 6169088 B1 20010102
APPLICATION INFO.: US 1998-88199 19980601 (9)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 1997-JP3510, filed
on 1 Oct 1997

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-260743	19960110
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Sripada, Pavanaram K	
LEGAL REPRESENTATIVE:	Fitzpatrick, Cella, Harper & Scinto	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8987	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 1,3 Diazines and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 205255-49-8P 205255-50-1P

(prepn. of 1,3-diazines with platelet-derived growth factor receptor inhibitory activity)


RN 205255-49-8 USPATFULL

CN 1-Piperazinecarboxamide, N-(4-nitrophenyl)-4-(2-phenyl-4-quinazolinyl)-(9CI) (CA INDEX NAME)




RN 205255-50-1 USPATFULL


CN 1-Piperazinecarboxamide, 4-(6,7-dimethoxy-2-phenyl-4-quinazolinyl)-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




IT 181115-48-0 205259-64-9 205259-65-0
 (prepn. of 1,3-diazines with platelet-derived growth factor receptor
 inhibitory activity)
 RN 181115-48-0 USPATFULL
 CN Quinazoline, 2-phenyl-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 205259-64-9 USPATFULL
 CN Quinazoline, 6,7-dimethoxy-2-phenyl-4-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 205259-65-0 USPATFULL
 CN Quinazoline, 4-(hexahydro-1H-1,4-diazepin-1-yl)-6,7-dimethoxy-2-phenyl- (9CI) (CA INDEX NAME)



L66 ANSWER 40 OF 63 USPATFULL

ACCESSION NUMBER: 2000:157421 USPATFULL

TITLE: Pyridopyrimidine analogs and related compounds and methods for treating inflammatory conditions

INVENTOR(S): Palanki, Moorthy S. S., Encinitas, CA, United States
Suto, Mark J., La Jolla, CA, United States

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150372		20001121
APPLICATION INFO.:	US 1999-340557		19990628 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-886198, filed on 1 Jul 1997, now patented, Pat. No. US 5939421		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Rao, Deepak R.		
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1052		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219773-50-9P 219773-51-0P 219773-55-4P

219773-56-5P 219773-60-1P 219773-64-5P

219773-68-9P 219773-72-5P 219773-75-8P


219773-78-1P 219773-81-6P 219773-85-0P

219773-89-4P 219773-93-0P 219773-94-1P

(prepn. of quinazoline analogs and related compds. for treating inflammatory conditions)


RN 219773-50-9 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[2-(2-thienyl)-4-quinazolinyl]amino]-(9CI) (CA INDEX NAME)




RN 219773-51-0 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[methyl[2-(2-thienyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 219773-55-4 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-56-5 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]methylamino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-60-1 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[6-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-64-5 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[7-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-68-9 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[8-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-72-5 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-75-8 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[6,7,8-trimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 219773-78-1 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-fluoro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-81-6 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-chloro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-85-0 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[5-methyl-2-(2-thienyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 219773-89-4 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[7-(dimethylamino)-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-93-0 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[(2-(2-thienyl)pyrido[3,4-d]pyrimidin-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 219773-94-1 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[(2-phenyl-4-quinazolinyl)amino]- (9CI) (CA INDEX NAME)



L66 ANSWER 41 OF 63 USPATFULL

ACCESSION NUMBER: 2000:54103 USPATFULL

TITLE: Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

INVENTOR(S): Spada, Alfred P., Lansdale, PA, United States
Myers, Michael R., Reading, PA, United States
Maguire, Martin P., Louisville, KY, United States
Persons, Paul E., Westborough, MA, United States

Searched by Barb O'Bryen, STIC 308-4291

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Collegeville,
PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057320		20000502
APPLICATION INFO.:	US 1997-881991		19970625 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-439027, filed on 11 May 1995, now patented, Pat. No. US 5646153 which is a division of Ser. No. US 1993-166199, filed on 10 Dec 1993, now patented, Pat. No. US 5480883 which is a continuation-in-part of Ser. No. US 1992-988515, filed on 10 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lambkin, Deborah C.		
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner LLP		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1861		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine **kinase inhibition** activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **146535-82-2P**

(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolinecarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 42 OF 63 USPATFULL

ACCESSION NUMBER: 1999:96372 USPATFULL

TITLE: Quinazoline analogs and related compounds and methods for treating inflammatory conditions

INVENTOR(S): Palanki, Moorthy S. S., Encinitas, CA, United States
Suto, Mark J., La Jolla, CA, United States

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939421		19990817
APPLICATION INFO.:	US 1997-886198		19970701 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Truong, Tamthom N.		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1076		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are quinazoline-containing compounds. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 219773-50-9P 219773-51-0P 219773-55-4P
219773-56-5P 219773-60-1P 219773-64-5P
219773-68-9P 219773-72-5P 219773-75-8P
219773-78-1P 219773-81-6P 219773-85-0P
219773-89-4P 219773-93-0P 219773-94-1P
(prepn. of quinazoline analogs and related compds. for treating inflammatory conditions)


RN 219773-50-9 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[2-(2-thienyl)-4-quinazolinyl]amino]-
(9CI) (CA INDEX NAME)




RN 219773-51-0 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[methyl[2-(2-thienyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 219773-55-4 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-56-5 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-methoxy-2-(2-thienyl)-4-quinazolinyl]methylamino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-60-1 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[6-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-64-5 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[7-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-68-9 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[8-methoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-72-5 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[6,7-dimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-75-8 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[6,7,8-trimethoxy-2-(2-thienyl)-4-quinazolinyl]amino]- (9CI) (CA INDEX NAME)




RN 219773-78-1 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-fluoro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-81-6 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[5-chloro-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-85-0 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-([5-methyl-2-(2-thienyl)-4-quinazolinyl]amino)- (9CI) (CA INDEX NAME)




RN 219773-89-4 USPATFULL

CN 1H-Pyrrole-2,5-dione, 1-[[7-(dimethylamino)-2-(2-thienyl)-4-quinazolinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)




RN 219773-93-0 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[[2-(2-thienyl)pyrido[3,4-d]pyrimidin-4-yl]amino]- (9CI) (CA INDEX NAME)



RN 219773-94-1 USPATFULL

CN 1H-Pyrrole-2,5-dione, 3-methyl-1-[(2-phenyl-4-quinazolinyl)amino]- (9CI)
(CA INDEX NAME)

L66 ANSWER 43 OF 63 USPATFULL

ACCESSION NUMBER: 1999:80322 USPATFULL

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

INVENTOR(S): Spada, Alfred P., Lansdale, PA, United States
Myers, Michael R., Reading, PA, United States
Maguire, Martin P., Mont Clare, PA, United States
Persons, Paul E., King of Prussia, PA, United States

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals, Inc.,
Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 36256		19990720
	US 5480883		19960102 (Original)
APPLICATION INFO.:	US 1997-988005		19971210 (8)
	US 1993-166199		19931210 (Original)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-988515, filed on 10 Dec 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-146072, filed on 8 Nov 1993, now patented, Pat. No. US 5409930 which is a continuation-in-part of Ser. No. WO 1992-US3736, filed on 6 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned , said Ser. No. US 988515		
DOCUMENT TYPE:	Reissue		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Bell, Boyd & Lloyd
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1,9,10
LINE COUNT: 2149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine **kinase inhibition** activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146535-82-2P

(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolinedicarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 44 OF 63 USPATFULL

ACCESSION NUMBER: 1998:98913 USPATFULL

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
INVENTOR(S): Spada, Alfred P., Lansdale, PA, United States
Myers, Michael R., Reading, PA, United States
Maguire, Martin P., Mont Clare, PA, United States
Persons, Paul E., King of Prussia, PA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795889		19980818
APPLICATION INFO.:	US 1995-386271		19950209 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-166199, filed on 10 Dec 1993, now patented, Pat. No. US 5480883 which is a continuation-in-part of Ser. No. US 1992-988515, filed on 10 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Cebulak, Mary C.		
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Nicholson, James A., Savitzky,		

Searched by Barb O'Bryen, STIC 308-4291

Martin F.

NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 2280

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine **kinase inhibition** activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146535-82-2P

(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolinecarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 45 OF 63 USPATFULL

ACCESSION NUMBER: 97:71077 USPATFULL

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
INVENTOR(S): Spada, Alfred P., Lansdale, PA, United States
Maguire, Martin P., King of Prussia, PA, United States
Persons, Paul E., King of Prussia, PA, United States
Myers, Michael R., Reading, PA, United States

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656643		19970812
APPLICATION INFO.:	US 1995-385258		19950208 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-146072, filed on 8 Nov 1993, now patented, Pat. No. US 5409930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Nicholson, James A., Savitzky, Martin F.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1225		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to bis mono- and/or bicyclic aryl and/or

heteroaryl compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146535-82-2P

--- (prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolinecarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 46 OF 63 USPATFULL

ACCESSION NUMBER: 97:59211 USPATFULL

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

INVENTOR(S): Spada, Alfred P., Lansdale, PA, United States
Myers, Michael R., Reading, PA, United States
Maguire, Martin P., Mont Clare, PA, United States
Persons, Paul E., King of Prussia, PA, United States

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646153		19970708
APPLICATION INFO.:	US 1995-439027		19950511 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-166199, filed on 10 Dec 1993, now patented, Pat. No. US 5480883 which is a continuation-in-part of Ser. No. US 1992-988515, filed on 10 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Cebulak, Mary C.		
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Nicholson, James A., Savitzky, Martin F.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2254		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine kinase

inhibition activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **146535-82-2P**

(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolinecarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 47 OF 63 USPATFULL

ACCESSION NUMBER: 95:36404 USPATFULL

TITLE: Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase

INVENTOR(S): Spada, Alfred P., Lansdale, PA, United States
Maquire, Martin P., King of Prussia, PA, United States
Persons, Paul E., King of Prussia, PA, United States
Myers, Michael R., Reading, PA, United States

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5409930		19950425
	WO 9220642		19921126
APPLICATION INFO.:	US 1993-146072		19931108 (8)
	WO 1992-US3736		19920506
			19931108 PCT 371 date
			19931108 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-698420, filed on 10 May 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lone, Werren B.		
LEGAL REPRESENTATIVE:	Nicholsen, James A., Savitzky, Martin F., Parker, III, Raymond S.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1264		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to bis mono- and/or bicyclic aryl and/or heteroaryl compounds exhibiting protein tyrosine **kinase inhibition** activity. More specifically, it relates to the method of inhibiting abnormal cell proliferation in a patient suffering from a

disorder characterized by such proliferation comprising the administration thereto of an EGF and/or PDGF receptor inhibiting effective amount of said bis mono- and/or bicyclic aryl and/or heteroaryl compound and to the preparation of said compounds and their use in pharmaceutical compositions used in this method.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146535-82-2P

(prepn. of, as intermediate for heterocyclic tyrosine kinase inhibitors)

RN 146535-82-2 USPATFULL

CN 4-Quinolincarboxylic acid, 6,7-dimethoxy-2-[1-(phenylsulfonyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L66 ANSWER 48 OF 63

MEDLINE

ACCESSION NUMBER: 2001301593 MEDLINE

DOCUMENT NUMBER: 21129706 PubMed ID: 11235018

TITLE: Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis.

AUTHOR: Kobayashi K; Nakashima A; Nagata H; Nakajima H; Yamaguchi K; Sato S; Miki I

CORPORATE SOURCE: Department of Immunology, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Sunto-gun, Shizuoka-ken, Japan.

SOURCE: INFLAMMATION RESEARCH, (2001 Jan) 50 (1) 24-31. Journal code: 9508160. ISSN: 1023-3830.

PUB. COUNTRY: Switzerland

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200105

ENTRY DATE: Entered STN: 20010604

Last Updated on STN: 20010604

Entered Medline: 20010531

ABSTRACT:

OBJECTIVE AND DESIGN: A newly synthesized inhibitor of pyrimidine de novo biosynthesis, KF20444 (6,7-dihydro-10-fluoro-3-(2-fluorophenyl)-5H-benzo [6,7] cyclohepta [1,2-b] quinoline-8-carboxylic acid), was evaluated as an inhibitor of dihydroorotate dehydrogenase (DHO-DHase) and tested in the rat collagen-induced arthritis (CIA) model. MATERIAL AND METHODS: Female Sprague Dawley rats, 5 weeks-old, were used for evaluation of KF20444 in the CIA model. Arthritis was evaluated by arthritis score, serum anti-type II collagen antibody titer, body weight loss, radiographical and histological changes. TREATMENT: KF20444 was orally administered 5 times per week (0.3, 1, 3 mg/kg/day). RESULTS: KF20444 inhibited rat liver dihydroorotate dehydrogenase in vitro with $K_i = 8.5 \pm 3.2$ nM, which was a comparable effect to that of

brequinar sodium ($K_i = 25.3 \pm 5.3$ nM). The anti-proliferative effect of KF20444 was caused by cell cycle arrest at the S-phase. Treatment with 3 mg/kg/day of KF20444 completely prevented the development of CIA based on reduction of the arthritis score. The 50% effective dose (ED50) of KF20444 on arthritis score was 0.64 mg/kg. KF20444 ameliorated body weight loss associated with disease onset. The compound also inhibited the increase in serum anti-type II collagen antibody level, and reduced both pannus formation and bone erosion. Importantly, KF20444 suppressed the development of arthritis, even when it was administered after booster immunization of collagen. CONCLUSIONS: KF20444 is a novel immunosuppressant which inhibits DHO-DHase and its effects in CIA suggest that it could be useful in the treatment of rheumatoid arthritis.

CONTROLLED TERM: Check Tags: Animal; Female; Human
*Arthritis: CI, chemically induced
*Arthritis: DT, drug therapy
Arthritis: PA, pathology
Autoantibodies: BL, blood
Biphenyl Compounds: AD, administration & dosage
Biphenyl Compounds: PD, pharmacology
*Biphenyl Compounds: TU, therapeutic use
Cell Cycle: DE, drug effects
Cell Division: DE, drug effects
*Collagen
Collagen: IM, immunology
Dose-Response Relationship, Drug
*Enzyme Inhibitors
*Immunosuppressive Agents: TU, therapeutic use
Jurkat Cells
Liver: EN, enzymology
Lymphocyte Specific Protein Tyrosine Kinase p56(lck):
AI, antagonists & inhibitors
*Oxidoreductases: AI, antagonists & inhibitors
Rats
Weight Loss
9007-34-5 (Collagen); 96187-53-0 (brequinar)
CAS REGISTRY NO.: 0 (Autoantibodies); 0 (Biphenyl Compounds); 0 (Enzyme
CHEMICAL NAME: Inhibitors); 0 (Immunosuppressive Agents); 0 (KF 20444); EC
1. (Oxidoreductases); EC 1.3.99.11 (dihydroorotate
dehydrogenase); EC 2.7.11.- (Lymphocyte Specific Protein
Tyrosine Kinase p56(lck))

*structures for
highlighted
Seq #'s
are printed
at end.*

L66 ANSWER 49 OF 63 MEDLINE
ACCESSION NUMBER: 96295589 MEDLINE
DOCUMENT NUMBER: 96295589 PubMed ID: 8700108
TITLE: 2',3'-Didehydro-3'-deoxythymidine: regulation of its
metabolic activation by modulators of thymidine-5'-
triphosphate biosynthesis.
AUTHOR: Ahluwalia G S; Gao W Y; Mitsuya H; Johns D G
CORPORATE SOURCE: Laboratory of Medicinal Chemistry, National Cancer
Institute, National Institutes of Health, Bethesda,
Maryland 20892-4255, USA.
SOURCE: MOLECULAR PHARMACOLOGY, (1996 Jul) 50 (1) 160-5.
Journal code: 0035623. ISSN: 0026-895X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199609
ENTRY DATE: Entered STN: 19960912
Last Updated on STN: 19960912
Entered Medline: 19960903

ABSTRACT:
The anti-human immunodeficiency virus (anti-HIV) agent 2',3'-didehydro-3'-

deoxythymidine (d4T), like other 2',3'-dideoxynucleosides, requires conversion to its 5'-triphosphate to exert its pharmacological effect. Although d4T-triphosphate is unusually potent as an inhibitor of HIV-1 reverse transcriptase, the phosphorylation of the drug at low dose levels is inefficient because of its low affinity as an alternate substrate for the initial phosphorylation enzyme thymidine kinase. Because thymidine kinase is under feedback regulatory control by the physiological deoxynucleoside-5'-triphosphate dTTP, we examined the effect on d4T phosphorylation and thus, potentially, on its antiviral activity, of a variety of agents that lower intracellular dTTP pools. We found that agents that inhibit the de novo pyrimidine biosynthetic pathway have the ability to increase d4T phosphorylation, the most effective being two inhibitors of thymidylate formation, methotrexate and 5-fluoro-2'-deoxyuridine, compounds that block the enzymes dihydrofolate reductase and thymidylate synthetase, respectively. Because HIV itself lacks the capacity to synthesize dTTP and the other deoxynucleoside triphosphates essential for viral replication, combinations of d4T with modulatory agents that deplete host-cell dTTP, unlike conventional anti-HIV drug monotherapy directed solely at viral enzymes, have the ability to inhibit replication of mutant HIV strains as well as of wild-type virus.

CONTROLLED TERM: Check Tags: Human
Biotransformation
*Biphenyl Compounds: PD, pharmacology
Cell Line
*Deoxyguanosine: PD, pharmacology
*Floxuridine: PD, pharmacology
HIV: DE, drug effects
HIV-1: EN, enzymology
HIV-1 Reverse Transcriptase
Hydroxyurea: PD, pharmacology
Kinetics
*Methotrexate: PD, pharmacology
Models, Biological
Phosphorylation
RNA-Directed DNA Polymerase: ME, metabolism
Reverse Transcriptase Inhibitors: CH, chemistry
*Reverse Transcriptase Inhibitors: ME, metabolism
*Ribonucleosides: PD, pharmacology
Stavudine: CH, chemistry
*Stavudine: ME, metabolism
Thymidine Kinase: ME, metabolism
*Thymine Nucleotides: BI, biosynthesis
Tumor Cells, Cultured
CAS REGISTRY NO.: 127-07-1 (Hydroxyurea); 3056-17-5 (Stavudine); 30868-30-5 (pyrazofurin); 365-08-2 (thymidine 5'-triphosphate); 50-91-9 (Floxuridine); 59-05-2 (Methotrexate); 961-07-9 (Deoxyguanosine); 96187-53-0 (brequinar)
CHEMICAL NAME: 0 (Biphenyl Compounds); 0 (Reverse Transcriptase Inhibitors); 0 (Ribonucleosides); 0 (Thymine Nucleotides); EC 2.7.1.21 (Thymidine Kinase); EC 2.7.7.- (HIV-1 Reverse Transcriptase); EC 2.7.7.49 (RNA-Directed DNA Polymerase)
L66 ANSWER 50 OF 63 DRUGU COPYRIGHT 2002 THOMSON DERWENT
ACCESSION NUMBER: 1998-36166 DRUGU T P S
TITLE: Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.
AUTHOR: Burris H A; Raymond E; Awada A; Kuhn J G; O'Rourke T J; Brentzel J; Lynch W; King S Y P; Brown T D; Von Hoff D D
CORPORATE SOURCE: Univ.Texas-Syst.; Inst.Gustave-Roussy; Inst.Jules.Bordet; Dupont-Merck; Univ.Duke
LOCATION: San Antonio, Tex.; Wilmington; Newark, Del.; Durham, N.C., USA, Villenglisch

SOURCE: Invest.New Drugs (16, No. 1, 19-27, 1998) 1 Fig. 7 Tab. 26
Ref.
CODEN: INNDDK ISSN: 0167-6997
AVAIL. OF DOC.: Institute for Drug Development- Cancer Therapy and Research
Center, 14960 Omicron Drive, San Antonio, Texas 78245-3215,
U.S.A. (D.D.V.H.).
LANGUAGE: English
DOCUMENT TYPE: Journal

ABSTRACT:

The pharmacokinetics and toxicity of brequinar sodium (DuPont) in combination with cisplatin were investigated in 24 patients with tumors types such as non-small cell lung, colon, breast, head and neck, melanoma and gastric tumors. Dose-limiting toxicities reported included neutropenia, thrombocytopenia and mucositis. The results show that co-administration of brequinar and cisplatin does not change the pharmacokinetic properties or the toxicity profile of either drug. In conclusion, the full dose of 75 mg/sq.m cisplatin (day 1) can be given with 650 mg/sq.m brequinar (days 1, 8 and 15) without significant changes in individual pharmacokinetic parameters.

SECTION HEADING: T Therapeutics
P Pharmacology
S Adverse Effects

CLASSIF. CODE: 8 Pharmacokinetics
35 Adverse Reactions
51 Chemotherapy - clinical
66 Drug Interactions

CONTROLLED TERM:

COLON *TR; INTESTINE *TR; GASTROENTEROPATHY *TR; MAMMA *TR;
MAMMA-DISEASE *TR; HEAD *TR; NECK *TR; MELANOMA *TR; STOMACH
*TR; LUNG *TR; PNEUMOPATHY *TR; NEOPLASM *TR; NEUTROPENIA
*AE; THROMBOCYTOPENIA *AE; MUCOSITIS *AE; MARROW-DISEASE *AE;
CASES *FT; IN-VIVO *FT; CYTOSTATIC *FT; COMB. *FT; CONC. *FT;
BLOOD-SERUM *FT; PHARMACOKINETICS *FT; CYTOSTATIC *FT
[01] BREQUINAR SODIUM *TR; BREQUINAR SODIUM *AE; BREQUINAR SODIUM
*DM; BREQUINAR SODIUM *DI; DU-PONT *FT; CISPLATIN *DI;
DUP-785 *RN; CYTOSTATICS *FT; TR *FT; AE *FT; DM *FT; DI *FT
CAS REGISTRY NO.: 96201-88-6
[02] CISPLATIN *TR; CISPLATIN *AE; CISPLATIN *DM; CISPLATIN *DI;
BREQUINAR *DI; CISPLATIN *RN; CYTOSTATICS *FT; PROTEIN-
KINASE-C-INHIBITORS *FT;
TELOMERASE-INHIBITORS *FT; TR *FT; AE *FT; DM *FT; DI *FT

CAS REGISTRY NO.: 15663-27-1
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

L66 ANSWER 51 OF 63 DRUGU COPYRIGHT 2002 THOMSON DERWENT
ACCESSION NUMBER: 1994-36646 DRUGU P S
TITLE: Application of pharmacokinetically guided dose escalation
with respect to cell cycle phase specificity.
AUTHOR: Fuse E; Kobayashi S; Inaba M; Suzuki H; Sgiyama Y
CORPORATE SOURCE: Kyowa-Hakko; Univ.Tokyo
LOCATION: Shizuoka, Tokyo, Japan
SOURCE: J.Natl.Cancer Inst. (86, No. 13, 989-96, 1994) 4 Fig. 4 Tab.
75 Ref.

CODEN: JNCIEQ ISSN: 0027-8874
AVAIL. OF DOC.: Kyowa Hakko Kogyo Co., Ltd., Pharmaceutical Research
Laboratories, 1188, Shimotogari, Nagaizumi-Cho, Sunto-Gun,
Shizuoka-Ken 411, Japan.
LANGUAGE: English

DOCUMENT TYPE: Journal

ABSTRACT:

The validity of the assumption that the AUC at the mouse LD10 is equal to the AUC at the human maximum tolerated dose (MTD) was tested for cell cycle phase-non-specific (type 1) (carboplatin, cisplatin, thiotepa, teroxirone, aclarubicin, JM-40, cyclophosphamide, diacetyldianhydrogalactitol, ACNU (nimustine), CI-941, CI-921, piroxantrone HCl, doxorubicin, etoposide, mitomycin, bleomycin, 4'-iodo-4'-deoxydoxorubicin and amsacrine) and cell cycle phase-specific (type 2) (amphethinile, vincristine, vinorelbine ditartrate, rhizoxin, fludarabine, 5-aza-2'-deoxycytidine, cytarabine, fluorouracil, mercaptoporine, aphidicoline glycinate, brequinar Na, acivicin, methotrexate and flavone acetate) antitumor drugs. The assumption was valid for type 1, but not for type 2, drugs.

SECTION HEADING: P Pharmacology
S Adverse Effects

CLASSIF. CODE: 8 Pharmacokinetics
34 Toxicology
52 Chemotherapy - non-clinical
73 Trial Preparations

CONTROLLED TERM:

IN-VIVO *FT; HUMAN *FT; BIOAVAILABILITY *FT; TOX. *FT; MOUSE *FT; I.V. *FT; I.P. *FT; CELL-CYCLE *FT; PHARMACOKINETICS *FT; DOSAGE *FT; LAB.ANIMAL *FT; INJECTION *FT; CYTOLOGY *FT
[01] CARBOPLATIN *DM; CARBOPLATIN *AE; CARBOPLAT *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 41575-94-4
[02] CISPLATIN *DM; CISPLATIN *AE; CISPLATIN *RN; CYTOSTATICS *FT; PROTEIN-KINASE-C-INHIBITORS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 15663-27-1
[03] THIOTEPA *DM; THIOTEPA *AE; THIOTEPA *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 52-24-4
[04] TEROXIRONE *DM; TEROXIRONE *AE; TEROXIRON *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 59653-73-5
[05] ACLARUBICIN *DM; ACLARUBICIN *AE; ACLARUBIC *RN; ANTIBIOTICS *FT; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 57576-44-0
[06] JM-40 *DM; JM-40 *AE; JM-40 *RN; TRIAL-PREP. *FT; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 41666-77-7
[07] CYCLOPHOSPHAMIDE *DM; CYCLOPHOSPHAMIDE *AE; CYCLOPHOS *RN; CYTOSTATICS *FT; IMMUNOSUPPRESSIVES *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 50-18-0
[08] DIACETYLDIANHYDROGALACTITOL *DM; DIACETYLDIANHYDROGALACTITOL *AE; DIACDIANG *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 57230-48-5
[09] NIMUSTINE *DM; NIMUSTINE *AE; NIMUSTINE *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 42471-28-3
[10] AMSALOG *DM; AMSALOG *AE; AMSALOG *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 80841-47-0
[11] BIANTRAZOLE *DM; BIANTRAZOLE *AE; CI-941 *RN; CYTOSTATICS *FT; DM *FT; AE *FT
CAS REGISTRY NO.: 88303-60-0
[12] PIROXANTRONE *DM; PIROXANTRONE *AE; HYDROCHLORIDE *DM;

HYDROCHLORIDE *AE; CI-942 *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 91441-23-5
[13] DOXORUBICIN *DM; DOXORUBICIN *AE; DOXORUBIC *RN; ANTIBIOTICS *FT; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 23214-92-8
[14] ETOPOSIDE *DM; ETOPOSIDE *AE; ETOPOSIDE *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 33419-42-0
[15] MITOMYCIN *DM; MITOMYCIN *AE; MITOMYCIN *RN; ANTIBIOTICS *FT; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 50-07-7
[16] BLEOMYCIN *DM; BLEOMYCIN *AE; BLEOMYCIN *RN; ANTIBIOTICS *FT; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 11056-06-7
[17] IODODEOXYDOXORUBICIN-4+ *DM; IODODEOXYDOXORUBICIN-4+ *AE; IDEOXDOX4 *RN; DM *FT; AE *FT

[18] AMSACRINE *DM; AMSACRINE *AE; AMSACRINE *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 51264-14-3
[19] AMPHETHINILE *DM; AMPHETHINILE *AE; ICI134154 *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 91531-98-5
[20] VINCRISTINE *DM; VINCRISTINE *AE; VINCRISTI *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 57-22-7
[21] VINORELBINE *DM; VINORELBINE *AE; NAVELBINE *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 71486-22-1
[22] RHIZOXIN *DM; RHIZOXIN *AE; RHIZOXIN *RN; CYTOSTATICS *FT; ANTIBIOTICS *FT; FUNGICIDES *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 90996-54-6
[23] FLUDARABINE *DM; FLUDARABINE *AE; FLUDARABI *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 21679-14-1
[24] AZADEOXYCYTIDINE *DM; AZADEOXYCYTIDINE *AE; AZADEOXYCY *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 2353-33-5
[25] CYTARABINE *DM; CYTARABINE *AE; CYTARABIN *RN; CYTOSTATICS *FT; VIRUCIDES *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 147-94-4
[26] FLUOROURACIL *DM; FLUOROURACIL *AE; FLUOROURA *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 51-21-8
[27] MERCAPTOPURINE *DM; MERCAPTOPURINE *AE; MERCAPURI *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 50-44-2
[28] APHIDICOLINE-GLYCINATE *DM; APHIDICOLINE-GLYCINATE *AE; APHIDIGLY *RN; CYTOSTATICS *FT; DM *FT; AE *FT

[29] BREQUINAR SODIUM *DM; BREQUINAR SODIUM *AE; DUP-785 *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 96201-88-6
[30] ACIVICIN *DM; ACIVICIN *AE; ACIVICIN *RN; ANTIBIOTICS *FT; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 42228-92-2
[31] METHOTREXATE *DM; METHOTREXATE *AE; METHOTREX *RN; CYTOSTATICS *FT; DM *FT; AE *FT

CAS REGISTRY NO.: 59-05-2
[32] LM-975 *DM; LM-975 *AE; LM-975 *RN; CYTOSTATICS *FT; TRIAL-PREP. *FT; DM *FT; AE *FT

FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

L66 ANSWER 52 OF 63 DRUGU COPYRIGHT 2002 THOMSON DERWENT
ACCESSION NUMBER: 1993-16230 DRUGU T S
TITLE: Choice of Starting Dose and Escalation for Phase I Studies of
Antitumor Agents.
AUTHOR: Penta J S; Rosner G L; Trump D L
CORPORATE SOURCE: Wellcome
LOCATION: Research Triangle Park, Durham, North Carolina, United States
SOURCE: Cancer Chemother.Pharmacol. (31, No. 3, 247-50, 1992) 2 Tab.
13 Ref.
CODEN: CCPHDZ ISSN: 0344-5704
AVAIL. OF DOC.: Cancer Therapy Department, Burroughs Wellcome Co., Research
Triangle Park, NC 27709, U.S.A.
LANGUAGE: English
DOCUMENT TYPE: Journal

ABSTRACT:

The maximum tolerable dose (MTD) was compared to starting dose in phase I studies and numbers of dose-escalation steps for SM-5887, deoxyspergualin, amonafide, LM-975, MZPES, dexrazoxane, piroxantrone, menadiol, brequinar Na, biantrazole, carbetimer, AZP, CB-10-277, 3-deazaguanine, acodazole, didemnin B, liblomycin, taxol, datelliptium, didox, ara-AC (fazarabine), KRN-8602, gemcitabine, CIBA-21381-BA, trimetrexate, 3-deazauridine, echinomycin, tiazaforin, fludarabine, bisantrene, aminothiadiaazole, L-alanosine, mitoxantrone, pentamethylmelamine, PCNU, bruceantin, chlorozotocin, indicine-N-oxide, sparfosate, amsacrine, anguidine, gallium-nitrate, piperazinedione (593-A), maitansine and pyrazomycin. Response rates were studied for 1110 patients treated with 21 phase I study drugs. Dose-limiting toxicities included vomiting, leukopenia, thrombocytopenia and hypotension.

SECTION HEADING: T Therapeutics
S Adverse Effects

CLASSIF. CODE: 35 Adverse Reactions
51 Chemotherapy - clinical
73 Trial Preparations

CONTROLLED TERM:

EMESIS *AE; GASTROENTEROPATHY *AE; LEUKOPENIA *AE;
Marrow-disease *AE; THROMBOCYTOPENIA *AE; HYPOTENSION *AE;
VASCULAR-DISEASE *AE; NEOPLASM *TR; DOSAGE *FT; CASES *FT;
IN-VIVO *FT; PHASE-I *FT; CYTOSTATIC *FT; CLIN.TRIAL *FT
[01] SM-5887 *TR; SM-5887 *AE; TRIAL-PREP. *FT; CYTOSTATICS *FT;
ANTIBIOTICS *FT; SM-5887 *RN; TR *FT; AE *FT
[02] DEOXYSPERGUALIN *TR; DEOXYSPERGUALIN *AE; CYTOSTATICS *FT;
ANTIBIOTICS *FT; DEOXYSPER *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 104317-84-2
[03] AMONAFIDE *TR; AMONAFIDE *AE; CYTOSTATICS *FT; AMONAFIDE *RN;
TR *FT; AE *FT
CAS REGISTRY NO.: 69408-81-7
[04] LM-975 *TR; LM-975 *AE; CYTOSTATICS *FT; TRIAL-PREP. *FT;
LM-975 *RN; TR *FT; AE *FT
[05] DEXRAZOXANE *TR; DEXRAZOXANE *AE; ICRF-187 *RN; TR *FT; AE
*FT
[06] PIROXANTRONE *TR; PIROXANTRONE *AE; CYTOSTATICS *FT; CI-942
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 91441-23-5
[07] MENADIOL *TR; MENADIOL *AE; VITAMINS-K4 *FT; MENADIOL *RN; TR
*FT; AE *FT
CAS REGISTRY NO.: 481-85-6
[08] BREQUINAR SODIUM *TR; BREQUINAR SODIUM *AE; CYTOSTATICS *FT;
DUP-785 *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 96201-88-6

[09] BIANTRAZOLE *TR; BIANTRAZOLE *AE; CYTOSTATICS *FT; CI-941
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 88303-60-0
[10] CARBETIMER *TR; CARBETIMER *AE; CYTOSTATICS *FT; CARBETIME
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 82230-03-3
[11] CB-10-277 *TR; CB-10-277 *AE; CYTOSTATICS *FT; TRIAL-PREP.
*FT; CB-10-277 *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 95536-27-9
[12] DEZAGUANINE *TR; DEZAGUANINE *AE; CYTOSTATICS *FT; DEZAGUANI
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 41729-52-6
[13] ACODAZOLE *TR; ACODAZOLE *AE; CYTOSTATICS *FT; ACODAZOLE *RN;
TR *FT; AE *FT
CAS REGISTRY NO.: 79152-85-5
[14] DIDEMNIN-B *TR; DIDEMNIN-B *AE; VIRUCIDES *FT; CYTOSTATICS
*FT; DIDEMNIN-B *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 77327-05-0
[15] LIBLOMYCIN *TR; LIBLOMYCIN *AE; ANTIBIOTICS *FT; CYTOSTATICS
*FT; LIBLOMYCIN *RN; TR *FT; AE *FT
[16] TAXOL *TR; TAXOL *AE; CYTOSTATICS *FT; TAXOL *RN; TR *FT; AE
*FT
CAS REGISTRY NO.: 33069-62-4
[17] DATELLIPTIUM-CHLORIDE *TR; DATELLIPTIUM-CHLORIDE *AE;
CYTOSTATICS *FT; DATELLIPTIUM *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 105118-14-7
[18] DIDOX *TR; DIDOX *AE; CYTOSTATICS *FT; DIDOX *RN; TR *FT; AE
*FT
[19] KR-8602 *TR; KR-8602 *AE; TRIAL-PREP. *FT; ANTIBIOTICS *FT;
CYTOSTATICS *FT; KR-8602 *RN; TR *FT; AE *FT
[20] GEMCITABINE *TR; GEMCITABINE *AE; CYTOSTATICS *FT; LY-188011
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 95058-81-4
[21] CIBA-21381-BA *TR; CIBA-21381-BA *AE; CYTOSTATICS *FT;
TRIAL-PREP. *FT; CIBA-21381-BA *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 6714-29-0
[22] TRIMETREXATE *TR; TRIMETREXATE *AE; CYTOSTATICS *FT;
FOLATE-ANTAGONISTS *FT; TRIMETREXATE *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 52128-35-5
[23] DEAZAURIDINE-3 *TR; DEAZAURIDINE-3 *AE; CYTOSTATICS *FT;
DEAZAURIDINE-3 *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 23205-42-7
[24] ECHINOMYCIN *TR; ECHINOMYCIN *AE; ANTIBIOTICS *FT; ECHINOMYCIN
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 512-64-1
[25] TIAZOFURINE *TR; TIAZOFURINE *AE; CYTOSTATICS *FT; TIAZOFURINE
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 60084-10-8
[26] FLUDARABINE *TR; FLUDARABINE *AE; CYTOSTATICS *FT; FLUDARABINE
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 21679-14-1
[27] BISANTRENE *TR; BISANTRENE *AE; CYTOSTATICS *FT; BISANTRENE
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 78186-34-2
[28] AMINOTHIADIAZOLE *TR; AMINOTHIADIAZOLE *AE; ANTIVITAMINS *FT;
AMINOTHIADIAZOLE *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 6504-55-8
[29] ALANOSINE *TR; ALANOSINE *AE; LEVO-ISOMER *FT; STEREOISOMER
*FT; STEREOCHEM. *FT; ANTIBIOTICS *FT; CYTOSTATICS *FT;
ALANOSINE *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 16931-22-9
[30] MITOXANTRONE *TR; MITOXANTRONE *AE; CYTOSTATICS *FT; PROTEIN-
KINASE-C-INHIBITORS *FT; MITOXANTRONE *RN; TR

*FT; AE *FT
CAS REGISTRY NO.: 65271-80-9
[31] PENTAMETHYLMELAMINE *TR; PENTAMETHYLMELAMINE *AE; CYTOSTATICS
*FT; PENTAMEME *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 16268-62-5
[32] PCNU *TR; PCNU *AE; CYTOSTATICS *FT; PCNU *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 13909-02-9
[33] BRUCEANTIN *TR; BRUCEANTIN *AE; CYTOSTATICS *FT; BRUCEANTI
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 41451-75-6
[34] CHLOROZOTOCIN *TR; CHLOROZOTOCIN *AE; CYTOSTATICS *FT;
ANTIBIOTICS *FT; CHLOROZOT *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 54749-90-5
[35] INDICINE-N-OXIDE *TR; INDICINE-N-OXIDE *AE; CYTOSTATICS *FT;
INDICINNO *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 41708-76-3
[36] SPARFOSATE *TR; SPARFOSATE *AE; CYTOSTATICS *FT; SPARFOSAT
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 51321-79-0
[37] AMSACRINE *TR; AMSACRINE *AE; CYTOSTATICS *FT; AMSACRINE *RN;
TR *FT; AE *FT
CAS REGISTRY NO.: 51264-14-3
[38] ANGUIDIN *TR; ANGUIDIN *AE; ANTIBIOTICS *FT; VIRUCIDES *FT;
IMMUNOSUPPRESSIVES *FT; CYTOSTATICS *FT; ANGUIDIN *RN; TR
*FT; AE *FT
CAS REGISTRY NO.: 2270-40-8
[39] GALLIUM-NITRATE *TR; GALLIUM-NITRATE *AE; GANITRATE *RN; TR
*FT; AE *FT
CAS REGISTRY NO.: 13494-90-1
[40] 593-A *TR; 593-A *AE; CYTOSTATICS *FT; TRIAL-PREP. *FT; 593-A
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 41871-93-6
[41] MAITANSINE *TR; MAITANSINE *AE; CYTOSTATICS *FT; MAITANSIN
*RN; TR *FT; AE *FT
CAS REGISTRY NO.: 35846-53-8
[42] PYRAZOMYCIN *TR; PYRAZOMYCIN *AE; ANTIBIOTICS *FT; VIRUCIDES
*FT; CYTOSTATICS *FT; PYRAZOMYC *RN; TR *FT; AE *FT
CAS REGISTRY NO.: 30868-30-5
[43] FAZARABINE *TR; FAZARABINE *AE; CYTOSTATICS *FT; NSC281272
*RN; TR *FT; AE *FT
FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

L66 ANSWER 53 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:285421 BIOSIS
DOCUMENT NUMBER: PREV200100285421
TITLE: Anti-inflammatory effects of ABT-702, a novel
non-nucleoside adenosine **kinase inhibitor**
, in rat adjuvant arthritis.
AUTHOR(S): Boyle, David L.; Kowaluk, Elizabeth A.; Jarvis, Michael F.;
Lee, Chih-Hung; Bhagwat, Shripad S.; Williams, Michael;
Firestein, Gary S. (1)
CORPORATE SOURCE: (1) Division of Rheumatology, Allergy and Immunology,
University of California San Diego School of Medicine, 9500
Gilman Dr.; Mail Code 0656, La Jolla, CA, 92093-0656:
gfirestein@ucsd.edu USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics,
(February, 2001) Vol. 286, No. 2, pp. 495-500. print.
ISSN: 0022-3565.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:

Adenosine (ADO) is a homeostatic inhibitory autocoid that is released at sites of inflammation and tissue injury, and exerts anti-inflammatory effects via multiple interactions at ADO receptor subtypes. **Inhibition** of ADO

*****kinase***** (AK) increases extracellular ADO concentrations and AK inhibitors have demonstrated ADO-mediated anti-inflammatory effects in acute models of inflammation. To evaluate the potential utility of this approach in chronic inflammation, a novel, potent, and selective non-nucleoside AK inhibitor, ABT-702, was tested in the rat adjuvant arthritis model. Animals were immunized with complete Freund's adjuvant on day 0 and were treated with vehicle or ABT-702 (20 mg/kg/b.i.d. p.o.) beginning on day 8. ABT-702 significantly inhibited arthritis as determined by paw volume. In addition, histologic and radiographic evidence of bone and cartilage destruction was significantly decreased in the treated group. Coadministration of the ADO receptor antagonist theophylline attenuated the anti-inflammatory effects of ABT-702, suggesting that this action was mediated through endogenous ADO release. To evaluate the mechanism of chondroprotection, Northern blot and electrophoretic mobility shift assays were performed on joints samples. These studies demonstrated that ABT-702 suppressed collagenase and stromelysin gene expression in treated animals. In addition, the activator protein-1 and nuclear factor-kappaB binding activity was also decreased. Therefore, ABT-702 inhibited arthritis. The mechanism of joint protection is likely related to suppressed transcription factor activation and matrix metalloproteinase gene expression.

CONCEPT CODE: Biochemical Studies - Proteins, Peptides and Amino Acids *10064
Biochemical Studies - General *10060
Biochemical Studies - Nucleic Acids, Purines and Pyrimidines *10062
Enzymes - General and Comparative Studies; Coenzymes *10802
Pathology, General and Miscellaneous - Therapy *12512
Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry *18004
Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology *18006
Pharmacology - General *22002
Pharmacology - Connective Tissue, Bone and Collagen - Acting Drugs *22012

BIOSYSTEMATIC CODE: Muridae 86375

INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Skeletal System (Movement and Support); Pharmacology

INDEX TERMS: Diseases
arthritis: adjuvant, joint disease, model

INDEX TERMS: Chemicals & Biochemicals
ABT-702: antiinflammatory - drug, non-nucleoside adenosine **kinase inhibitor**; activator protein-1; adenosine; adenosine kinase; nuclear factor-kappa B: binding activity; theophylline

INDEX TERMS: Alternate Indexing
Arthritis (MeSH)

ORGANISM: Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISM: Organism Name
rat (Muridae): male, strain-Lewis

ORGANISM: Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman Vertebrates; Rodents; Vertebrates

REGISTRY NUMBER: 214697-26-4 (ABT-702)
58-61-7 (ADENOSINE)
9027-72-9 (ADENOSINE KINASE)
58-55-9 (THEOPHYLLINE)

L66 ANSWER 54 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:247479 BIOSIS

DOCUMENT NUMBER: PREV200100247479

TITLE: Disparate effects of acute and subchronic adenosine
kinase inhibition on renal excretory
function in conscious rats.

AUTHOR(S): Reinhart, Glenn A. (1); Jarvis, Michael F. (1); Kowaluk,
Elizabeth A. (1); Cox, Bryan F. (1)

CORPORATE SOURCE: (1) Abbott Laboratories, 100 Abbott Park Road, Abbott Park,
IL, 60064-6119 USA

SOURCE: FASEB Journal, (March 7, 2001) Vol. 15, No. 4, pp. A232.
print.

Meeting Info.: Annual Meeting of the Federation of American
Societies for Experimental Biology on Experimental Biology
2001 Orlando, Florida, USA March 31-April 04, 2001
ISSN: 0892-6638.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT:

ABT-702, a novel, potent, and selective, orally active non-nucleoside
inhibitor of adenosine **kinase** (AK) exerts analgesic and
antiinflammatory effects in rodents by increasing extracellular adenosine (ADO)
levels. Since intrarenal ADO is known to influence renal function, the present
studies assessed the effects of acute (5 hr) and subchronic AK inhibition on
the renal excretion of fluid, sodium (Na+) and potassium (K+) in conscious rats
housed in metabolism cages. Single doses of ABT-702 (13.9, 139 mg/kg, po; bid)
were acutely antinatriuretic as urinary Na+ excretion fell to 10+-2 and 6+-4%
of control, respectively; K+ excretion fell to 34+-8 and 76+-5% of control. In
contrast, repeated dosing of ABT-702 (5 days; bid) produced a marked
natriuresis and kaliuresis. ABT-702 (13.9 mg/kg) reduced 24hr Na+ balance on
Day 1 (from 20+-38 to -150+-48 muEq/100gm). Responses to ABT-702 at 139 mg/kg
were more pronounced; 24hr Na+ balance fell from 2+-36 to -220+-69, -252+-30
and -204+-30 muEq/100gm on Days 1, 2 and 3, respectively; 24hr Na+ balance was
not different from control thereafter. K+ balance fell from -73+-33 to -308+-86
muEq/100gm/day on Day 1. On Day 5, hematocrit, plasma Na+ and K+ values were
not different between groups. The disparate acute and subchronic renal
excretory responses to AK inhibition are consistent with a differential,
temporal activation of intrarenal ADO-A1 (acute antinatriuresis) vs. ADO-A2
(subchronic natriuresis) receptors. Thus, these data suggest that intrarenal
ADO-A1 and ADO-A2 receptor mediated responses may be differentially regulated
during conditions of sustained ADO-activation in the rat.

CONCEPT CODE: Biochemical Studies - Nucleic Acids, Purines and
Pyrimidines *10062
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Biochemical Studies - General *10060
Enzymes - General and Comparative Studies; Coenzymes
*10802
Urinary System and External Secretions - Physiology and
Biochemistry *15504

BIOSYSTEMATIC CODE: Muridae 86375

INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Urinary System
(Chemical Coordination and Homeostasis)

INDEX TERMS: Chemicals & Biochemicals
ABT-702: non-nucleoside **inhibitor** of adenosine
kinase; adenosine: activation, extracellular
levels; adenosine **kinase**: **inhibition**

INDEX TERMS: Miscellaneous Descriptors
renal excretory function; Meeting Abstract

ORGANISM: Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISM: Organism Name
rat (Muridae)
ORGANISM: Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman
Vertebrates; Rodents; Vertebrates
REGISTRY NUMBER: 214697-26-4 (ABT-702)
58-61-7 (ADENOSINE)
9027-72-9 (ADENOSINE KINASE)

L66 ANSWER 55 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:297188 BIOSIS
DOCUMENT NUMBER: PREV200100297188
TITLE: ABT-702, an orally active, non-nucleoside adenosine
kinase inhibitor.
AUTHOR(S): Lee, Chih-Hung (1); Jiang, Meiqun (1); Cowart, Marlon (1);
Perner, Richard (1); Kim, Ki (1); Muchmore, Steven (1);
Jacob, Clarissa (1); Gu, Yu Gui (1); Williams, Mike;
Jarvis, Michael (1); Kowaluk, Elizabeth (1); Stewart,
Andrew O.; Bhagwat, Shripad
CORPORATE SOURCE: (1) 4PM, Abbott Laboratory, 100 Abbott Park Road, Abbott
Park, IL, 60064: lance.lee@abbott.com USA
SOURCE: Abstracts of Papers American Chemical Society, (2001) Vol.
221, No. 1-2, pp. MEDI 208. print.
Meeting Info.: 221st National Meeting of the American
Chemical Society San Diego, California, USA April 01-05,
2001
ISSN: 0065-7727.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English
CONCEPT CODE: Enzymes - General and Comparative Studies; Coenzymes
*10802
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Pathology, General and Miscellaneous - Therapy *12512
Pharmacology - General *22002
Pharmacology - Connective Tissue, Bone and Collagen -
Acting Drugs *22012
Pharmacology - Neuropharmacology *22024
INDEX TERMS: Major Concepts
Enzymology (Biochemistry and Molecular Biophysics);
Pharmacology
INDEX TERMS: Chemicals & Biochemicals
ABT-702: analgesic - drug, antiinflammatory - drug, enzyme
inhibitor - drug; adenosine kinase
INDEX TERMS: Miscellaneous Descriptors
inflammatory model; pain model; Meeting Abstract
REGISTRY NUMBER: 214697-26-4 (ABT-702)
9027-72-9 (ADENOSINE KINASE)

L66 ANSWER 56 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:88976 BIOSIS
DOCUMENT NUMBER: PREV200100088976
TITLE: ABT-702, a novel orally effective adenosine **kinase**
(AK) **inhibitor**: in vitro characterization and
acute analgesic effects in mice.
AUTHOR(S): Yu, H. (1); Kohlhaas, K.; Alexander, K. A.; Lee, C. H.;
Jiang, M.; Bhagwat, S. S.; Williams, M.; Jarvis, M. F.;
Kowaluk, E. A.
CORPORATE SOURCE: (1) Abbott Laboratories, Abbott Park, IL USA
SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No.
1-2, pp. Abstract No.-453.5. print.
Meeting Info.: 30th Annual Meeting of the Society of

Neuroscience New Orleans, LA, USA November 04-09, 2000
Society for Neuroscience
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:

AK inhibition provides a means of potentiating local concentrations of the endogenous neuromodulator, antinociceptive and anti-inflammatory autocoid, adenosine (ADO). AK inhibitors increase ADO concentrations at sites of tissue trauma and may have therapeutic potential as analgesic and anti-inflammatory agents. ABT-702 is a novel and potent ($IC_{50} = 1$ nM) non-nucleoside AK inhibitor with several orders of magnitude selectivity over other sites of adenosine interaction (A1, A2A, A3 receptors, ADO transporter and ADO deaminase). ABT-702 was found to be between 1300-fold to greater than 7700-fold selective for AK as compared to a wide array of neurotransmitter and peptide receptors, ion channel proteins, reuptake sites and enzymes. ABT-702 was equally potent ($IC_{50} = 1.5 \pm 0.3$ nM) to inhibit native human AK (placenta) and two human recombinant isoforms (AKlong and AKshort and AK from monkey, dog, and mouse brain. Kinetic studies revealed that AK inhibition by ABT-702 was competitive with respect to ADO and noncompetitive with respect to $MgATP_{2-}$. AK inhibition by ABT-702 was demonstrated to be reversible following exhaustive (4 hr) dialysis. ABT-702 is orally active and fully efficacious to relieve acute somatic nociception ($ED_{50} = 8$ μ mol/kg, i.p., 65 μ mol/kg p.o.) in the mouse hotplate assay. The antinociceptive effects of ABT-702 were blocked by the non-selective ADO receptor antagonist, theophylline, and by the A1-selective antagonist, cyclopentyltheophylline (10 mg/kg, i.p.), but not by the A2A selective antagonist DMPX (1 mg/kg, i.p.) or the opioid antagonist, naloxone (5 mg/kg, i.p.). Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that shows acute non-opioid antinociceptive effects in vivo.

CONCEPT CODE: Pharmacology - General *22002
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Biochemical Studies - General *10060
Biochemical Studies - Nucleic Acids, Purines and
Pyrimidines *10062
Pathology, General and Miscellaneous - Therapy *12512
Nervous System - Physiology and Biochemistry *20504
BIOSYSTEMATIC CODE: Muridae 86375
INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Nervous System
(Neural Coordination); Pharmacology
INDEX TERMS: Parts, Structures, & Systems of Organisms
brain: nervous system
INDEX TERMS: Diseases
tissue trauma: disease-miscellaneous
INDEX TERMS: Chemicals & Biochemicals
ABT-702: acute analgesic effects, enzyme inhibitor, orally
effective; adenosine: anti-inflammatory effects,
antinociceptive effects, endogenous neuromodulator;
naloxone: opioid antagonist
INDEX TERMS: Methods & Equipment
kinetic studies: analytical method
INDEX TERMS: Miscellaneous Descriptors
Meeting Abstract
ORGANISM: Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
ORGANISM: Organism Name
mouse (Muridae)
ORGANISM: Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman
Vertebrates; Rodents; Vertebrates
REGISTRY NUMBER: 214697-26-4 (ABT-702)

58-61-7 (ADENOSINE)
465-65-6 (NALOXONE)

L66 ANSWER 57 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:88973 BIOSIS

DOCUMENT NUMBER: PREV200100088973

TITLE: Antinociceptive effects of a novel adenosine kinase
(AK) **inhibitor**, ABT-702, in rat models of
persistent and neuropathic pain.

AUTHOR(S): Zhu, C. Z. (1); Lynch, J.; Mikusa, J.; Schwietzer, E.; Lee,
C. H.; Jiang, M.; Bhagwat, S. S.; Williams, M.; Jarvis, M.
F.; Kowaluk, E. A.

CORPORATE SOURCE: (1) Abbott Laboratories, Abbott Park, IL USA

SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No.
1-2, pp. Abstract No.-453.2. print.
Meeting Info.: 30th Annual Meeting of the Society of
Neuroscience New Orleans, LA, USA November 04-09, 2000
Society for Neuroscience
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT:

Tactile allodynia, the sensation of pain produced by normally non-painful mechanical stimuli, is a common feature of neuropathic pain. Adenosine (ADO) and ADO Alreceptor agonists have been shown to reduce tactile allodynia in humans. Inhibition of intracellular AK can enhance extracellular ADO concentrations and AK inhibitors have potential therapeutic utility as analgesic agents. ABT-702, a novel, potent ($IC_{50} = 1 \text{ nM}$), and selective non-nucleoside AK inhibitor, was orally effective ($ED_{50} = 60 \text{ mumol/kg}$, p.o.) in reducing nociception in the persistent (30-50 min) phase of the formalin test. The ability of ABT-702 to attenuate tactile allodynia as assessed using von Frey hair thresholds was evaluated in two rat models of neuropathic pain: the L5 L6 spinal nerve ligation (Chung) model and the streptozotocin (STZ)-induced diabetes rat model of neuropathic pain. ABT-702 was fully efficacious to relieve tactile allodynia in the Chung model after oral ($ED_{50} = 50 \text{ mumol/kg}$, p.o.) and intraperitoneal ($ED_{50} = 5 \text{ mumol/kg}$, i.p.) administration. The antiallodynic effects of ABT-702 were blocked by the non-selective ADO receptor antagonist theophylline and by the A1-selective antagonist, cyclopentyltheophylline (10 mg/kg , i.p.), but not by the A2A selective antagonist DMPX (1 mg/kg , i.p.) or the opioid antagonist, naloxone. Unlike morphine (21 mumol/kg , i.p.), the anti-allodynic effects of ABT-702 (30 mumol/kg , i.p.) were sustained following twice daily administration for four days. ABT-702 was also effectively reduced tactile allodynia in STZ-treated diabetic rats ($ED_{50} = 5 \text{ mumol/kg}$, i.p.) and these antinociceptive effects were attenuated by theophylline. Thus, ABT-702 is a novel and potent non-nucleoside AK inhibitor that effectively attenuates chemically-induced persistent pain (formalin test) and blocks tactile allodynia in two rat models of neuropathic pain.

CONCEPT CODE: Nervous System - Pathology *20506
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Biochemical Studies - General *10060
Biochemical Studies - Nucleic Acids, Purines and
Pyrimidines *10062
Enzymes - General and Comparative Studies; Coenzymes
*10802
Anatomy and Histology, General and Comparative - Surgery
*11105
Pathology, General and Miscellaneous - Therapy *12512
Nervous System - Physiology and Biochemistry *20504
Pharmacology - General *22002

BIOSYSTEMATIC CODE: Muridae 86375

INDEX TERMS: Major Concepts

Biochemistry and Molecular Biophysics; Nervous System
(Neural Coordination); Pharmacology

INDEX TERMS: Diseases
neuropathic pain: nervous system disease

INDEX TERMS: Chemicals & Biochemicals
ABT-702: analgesic effects, antinociceptive effects, enzyme
inhibitor; adenosine kinase; theophylline: antinociceptive
effects

INDEX TERMS: Alternate Indexing
Pain (MeSH)

INDEX TERMS: Methods & Equipment
spinal nerve ligation: surgical method, therapeutic method

INDEX TERMS: Miscellaneous Descriptors
Chung Model; tactile allodynia: pain sensation; von Frey
hair thresholds; Meeting Abstract

ORGANISM: Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISM: Organism Name
rat (Muridae)

ORGANISM: Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman
Vertebrates; Rodents; Vertebrates

REGISTRY NUMBER: 214697-26-4 (ABT-702)
9027-72-9 (ADENOSINE KINASE)
58-55-9 (THEOPHYLLINE)

L66 ANSWER 58 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:88974 BIOSIS

DOCUMENT NUMBER: PREV200100088974

TITLE: Antiinflammatory effects of the novel adenosine
kinase (AK) inhibitor, ABT-702, in the
rat carrageenan-induced paw edema model.

AUTHOR(S): Wismer, C. T. (1); Lee, C. H.; Jiang, M.; Bhagwat, S. S.;
Williams, M.; Jarvis, M. F.; Kowaluk, E. A.

CORPORATE SOURCE: (1) Abbott Labs, Abbott Park, IL USA

SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No.
1-2, pp. Abstract No.-453.3. print.
Meeting Info.: 30th Annual Meeting of the Society of
Neuroscience New Orleans, LA, USA November 04-09, 2000
Society for Neuroscience
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT:

The endogenous inhibitory modulator, adenosine (ADO) produces a variety of antiinflammatory effects including inhibition of neutrophil function and release of pro-inflammatory mediators like TNFdelta. Inhibition of AK, the primary intracellular metabolic enzyme for ADO enhances extracellular ADO concentrations and exerts antiinflammatory actions at sites of tissue trauma. The potent AK inhibitor, ABT-702 (IC50=1 nM) was evaluated for its ability to reduce paw edema 2 hr following the injection of 1% carrageenan (CARR) into the rat hind paw. ABT-702 dose-dependently reduced paw edema (ED50= 70 mumol/kg, p.o.) and was equally effective when administered 1 hr before or after CARR. ABT-702 also dose-dependently reduced neutrophil influx into the inflamed paw as assessed by using myeloperoxidase activity (ED50=60 mumol/kg, p.o.). The antiinflammatory actions of ABT-702 were block by the non-selective ADO receptor antagonist theophylline and partially attenuated by the A1 receptor selective antagonist, cyclopentyltheophylline (10 mg/kg, i.p.) and the A2A receptor selective antagonist DMPX (1 mg/kg, i.p.). Intraplantar administration of ABT-702 (30-300 nmol) with CARR was also effective in reducing CARR-induced paw edema. These data demonstrate that ABT-702 produces antiinflammatory effects on both paw edema and neutrophil functions as was equally effective

whether administered before or after tissue injury.

CONCEPT CODE: Immunology and Immunochemistry - General; Methods *34502
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Cytology and Cytochemistry - Animal *02506
Biochemical Studies - General *10060
Biochemical Studies - Nucleic Acids, Purines and
Pyrimidines *10062
Enzymes - General and Comparative Studies; Coenzymes
*10802
Pathology, General and Miscellaneous - Therapy *12512
Blood, Blood-Forming Organs and Body Fluids - Blood and
Lymph Studies *15002
Blood, Blood-Forming Organs and Body Fluids - Blood Cell
Studies *15004
Nervous System - Physiology and Biochemistry *20504
Pharmacology - General *22002
Pharmacology - Connective Tissue, Bone and Collagen -
Acting Drugs *22012
INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Nervous System
(Neural Coordination); Pharmacology
INDEX TERMS: Parts, Structures, & Systems of Organisms
neutrophil: blood and lymphatics, function, immune system;
paw: inflamed
INDEX TERMS: Chemicals & Biochemicals
ABT-702: adenosine **kinase inhibitor**,
antiinflammatory - drug; TNF-delta [tumor necrosis
factor-delta]; adenosine: endogenous inhibitory modulator;
myeloperoxidase; theophylline: ADO receptor antagonist,
non-selective
INDEX TERMS: Miscellaneous Descriptors
carrageenan-induced paw edema model; Meeting Abstract
REGISTRY NUMBER: **214697-26-4** (ABT-702)
58-61-7 (ADENOSINE)
9003-99-0 (MYELOPEROXIDASE)
58-55-9 (THEOPHYLLINE)

L66 ANSWER 59 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:88975 BIOSIS

DOCUMENT NUMBER: PREV200100088975

TITLE: ABT-702, a novel orally effective adenosine **kinase**
(AK) **inhibitor**: comparison of antihyperalgesic
actions and effects on motor and cardiovascular function in
rats.

AUTHOR(S): Mikusa, J. (1); Schwietzer, E.; Wismer, C. T.; Zhu, C.;
Lee, C. H.; Jiang, M.; Bhagwat, S. S.; Cox, B.; Polakowski,
J.; Reinhart, G.; Williams, M.; Jarvis, M. F.; Kowaluk, E.
A.

CORPORATE SOURCE: (1) Abbott Laboratories, Abbott Park, IL USA
SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No.
1-2, pp. Abstract No.-453.4. print.
Meeting Info.: 30th Annual Meeting of the Society of
Neuroscience New Orleans, LA, USA November 04-09, 2000
Society for Neuroscience
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT:

Inhibition of AK, the primary intracellular metabolic enzyme for adenosine
(ADO), increases ADO concentrations at sites of tissue trauma and AK inhibitors
have been shown to produce both antinociceptive and antiinflammatory effects.

The potent and selective AK inhibitor, ABT-702 (IC₅₀ = 1 nM) was evaluated for its ability to increase paw withdrawal latencies from a thermal stimulus following the injection of 1% carrageenan (CARR) into the rat hind paw. ABT-702 was orally active and fully efficacious to block CARR-induced hyperalgesia (ED₅₀ = 5 µmol/kg, p.o.). At the same doses, ABT-702 had no effect on paw withdrawal latencies of the uninjured paw. The antihyperalgesic effects of ABT-702 were long-lasting (up to 8 hr) and were present when ABT-702 was administered 1 hr before or after CARR. The antinociceptive effects of ABT-702 were attenuated by the A1-selective antagonist, cyclopentyltheophylline (10 mg/kg, i.p.) and by the A2A selective antagonist DMPX (1 mg/kg, i.p.). Intraplantar administration of ABT-702 (30 nmol/paw) was also fully effective in blocking CARR-induced hyperalgesia. ABT-702 had no effect on exploratory motor activity at antihyperalgesic doses (1-10 µmol/kg, p.o.). Higher doses (> 30 µmol/kg, p.o.) of ABT-702 reduced motor activity, but mean arterial pressure was not reduced at doses up to 100 µmol/kg, p.o. ABT-702 did not significantly reduce rotorod performance, or heart rate at doses up to 300 µmol/kg, p.o. These data demonstrate that ABT-702 is fully efficacious to relieve inflammatory hyperalgesia via activation of ADO A1 and A2A receptors and at antihyperalgesic doses, ABT-702 does not impair cardiovascular or motor function.

CONCEPT CODE: Biochemical Studies - General *10060
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Biochemical Studies - Nucleic Acids, Purines and
Pyrimidines *10062
Enzymes - General and Comparative Studies; Coenzymes
*10802
Nervous System - Physiology and Biochemistry *20504

BIOSYSTEMATIC CODE: Muridae 86375

INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Nervous System
(Neural Coordination)

INDEX TERMS: Chemicals & Biochemicals
ABT-702: adenosine **kinase inhibitor**,
antihyperalgesic effects, antiinflammatory effects,
antinociceptive effects, orally effective; DMPX: selective
antagonist; adenosine; adenosine kinase;
cyclopentyltheophylline: A1 selective antagonist

INDEX TERMS: Miscellaneous Descriptors
cardiovascular function; motor function; paw withdrawal
latency; Meeting Abstract

ORGANISM: Super Taxa
Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISM: Organism Name
rat (Muridae)

ORGANISM: Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman
Vertebrates; Rodents; Vertebrates

REGISTRY NUMBER: **214697-26-4** (ABT-702)
58-61-7 (ADENOSINE)
9027-72-9 (ADENOSINE KINASE)

L66 ANSWER 60 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2001:88977 BIOSIS

DOCUMENT NUMBER: PREV200100088977

TITLE: Effects of the adenosine **kinase** (AK)
inhibitor ABT-702 on cortical EEG in the rat.

AUTHOR(S): Radek, R. J. (1); Decker, M. W.; Kowaluk, E. A.; Jarvis, M.
F.

CORPORATE SOURCE: (1) Abbott Laboratories, Abbott Park, IL USA

SOURCE: Society for Neuroscience Abstracts, (2000) Vol. 26, No.
1-2, pp. Abstract No.-453.6. print.
Meeting Info.: 30th Annual Meeting of the Society of

Neuroscience New Orleans, LA, USA November 04-09, 2000
Society for Neuroscience
. ISSN: 0190-5295.

DOCUMENT TYPE: Conference

LANGUAGE: English

SUMMARY LANGUAGE: English

ABSTRACT:

ABT-702 is a novel, non-nucleoside AK inhibitor with anti-nociceptive effects in animal models of pain. AK inhibition potentiates concentrations of endogenous adenosine that can elicit behavioral and EEG signs of sedation and somnolence. ABT-702 was characterized for effects on EEG to establish a dose-relationship between the ability of AK inhibitors to produce analgesia and to lower arousal. The EEG was recorded from rats implanted with cortical electrodes for 2 hr following ip injection of test compounds. ABT-702 (10.0-30.0 $\mu\text{mol/kg}$) rapidly increased the amplitude of the 1-4 Hz band (FFT analysis, $p < 0.05$) which is indicative of lowered arousal. The effective doses of ABT-702 on EEG were similar to those that reduced motor activity (10.0 $\mu\text{mol/kg}$), but higher than those effective (0.6 $\mu\text{mol/kg}$) on the carrageenan hyperalgesia model (Mikusa et al., Soc. Neurosci. Abstr., this meeting). Theophylline (5.0 $\mu\text{mol/kg}$), a centrally active non-selective adenosine receptor antagonist, attenuated the effects of ABT-702 (20.0 $\mu\text{mol/kg}$) on EEG, whereas 8-(p-sulfophenyl)-theophylline (150.0 $\mu\text{mol/kg}$), a peripherally active antagonist, did not, indicating that the EEG effects of ABT-702 are mediated by central adenosine receptors. The selective A1 adenosine agonist N6-cyclopentyladenosine (CPA, 1.0-10.0 $\mu\text{mol/kg}$) was not as efficacious as ABT-702 in augmenting 1-4 Hz amplitude. The A2 agonist CGS-21680 (3.0-10.0 $\mu\text{mol/kg}$) lowered 1-4 Hz amplitude for 2 hr after injection, an effect that is dissimilar to either ABT-702 or CPA. These studies suggest that there is a greater sensitivity for AK inhibitor anti-nociception than for sedation. Furthermore, AK inhibition may elicit, possibly through multiple receptor subtypes, effects on arousal that can be differentiated from selective receptor activation.

CONCEPT CODE: Nervous System - Pathology *20506
General Biology - Symposia, Transactions and Proceedings of
Conferences, Congresses, Review Annuals *00520
Biochemical Studies - General *10060
Biochemical Studies - Nucleic Acids, Purines and
Pyrimidines *10062
Pathology, General and Miscellaneous - Therapy *12512
Nervous System - Physiology and Biochemistry *20504
Pharmacology - General *22002
Pharmacology - Neuropharmacology *22024

BIOSYSTEMATIC CODE: Muridae 86375

INDEX TERMS: Major Concepts
Biochemistry and Molecular Biophysics; Methods and
Techniques; Nervous System (Neural Coordination);
Pharmacology

INDEX TERMS: Diseases
pain: nervous system disease

INDEX TERMS: Chemicals & Biochemicals
ABT-702: adenosine **kinase inhibitor**,
analgesic - drug; adenosine: endogenous; theophylline:
non-selective adenosine receptor antagonist

INDEX TERMS: Alternate Indexing
Pain (MeSH)

INDEX TERMS: Methods & Equipment
cortical EEG [cortical electroencephalography]: recording
method

INDEX TERMS: Miscellaneous Descriptors
carrageenan hyperalgesia model; Meeting Abstract

ORGANISM: Super Taxa

ORGANISM: Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia
Organism Name

ORGANISM: rat (Muridae)
Organism Superterms
Animals; Chordates; Mammals; Nonhuman Mammals; Nonhuman
Vertebrates; Rodents; Vertebrates

REGISTRY NUMBER: 214697-26-4 (ABT-702)
58-61-7 (ADENOSINE)
58-55-9 (THEOPHYLLINE)

L66 ANSWER 61 OF 63 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1996:113129 BIOSIS

DOCUMENT NUMBER: PREV199698685264

TITLE: Effects of leflunomide and other immunosuppressive agents
on T cell proliferation in vitro.

AUTHOR(S): Chong, Anita S.-F. (1); Rezai, Katayhoun; Gebel, Howard M.;
Finnegan, Alison; Foster, Preston; Xu, Xiulong; Williams,
James W.

CORPORATE SOURCE: (1) Dep. General Surg., Rush Presbyterian St., Luke's Med.
Center, 1653 W. Congress Parkway, Chicago, IL 60612 USA

SOURCE: Transplantation (Baltimore), (1996) Vol. 61, No. 1, pp.
140-145.
ISSN: 0041-1337.

DOCUMENT TYPE: Article

LANGUAGE: English

ABSTRACT:

Leflunomide and its active metabolite, A771726, are structurally unrelated to immunosuppressive agents currently under investigation. Previous in vitro studies have revealed that leflunomide primarily inhibits interleukin-2-stimulated T cell proliferation. In the current study, we have extended our previous work and demonstrate that leflunomide prevents T cell progression induced by phytohemagglutinin into the S phase of the cell cycle. To discriminate further the action on T cells of leflunomide from other immunosuppressive agents, we performed kinetic studies where leflunomide was added either after the initiation of mixed lymphocyte cultures (MLC) or after interleukin-2 stimulation of CTLL-4 cell proliferation. These studies revealed that leflunomide acted comparably to rapamycin, but was distinct from brequinar sodium in the MLC, and from cyclosporine and mycophenolic acid in both MLC and CTLL-4. Although previous biochemical studies indicated that leflunomide can ***inhibit*** src-family tyrosine kinase activity, more recent studies have suggested that leflunomide can also inhibit pyrimidine synthesis. Our data demonstrate that the ability of leflunomide (25-100 μ M) to inhibit MLC and CTLL-4 cell proliferation is partially antagonized by uridine (25-100 μ M), and support the hypothesis that leflunomide inhibits pyrimidine synthesis in T cells. Unique molecular mechanisms of immunosuppression suggest that drug combinations may result in synergistic immunosuppression. Our in vitro studies revealed synergistic inhibition of T cell proliferation with the combinations of leflunomide with cyclosporine or with rapamycin. We have extended those studies to quantitate inhibition of MLC by the combinations of leflunomide and brequinar sodium or mycophenolic acid.

CONCEPT CODE: Biochemical Studies - General 10060
Biochemical Studies - Proteins, Peptides and Amino Acids
10064
Enzymes - Physiological Studies *10808
Blood, Blood-Forming Organs and Body Fluids - Blood Cell
Studies *15004
Blood, Blood-Forming Organs and Body Fluids - Lymphatic
Tissue and Reticuloendothelial System *15008
Endocrine System - General *17002
Pharmacology - Clinical Pharmacology *22005
Pharmacology - Immunological Processes and Allergy *22018
In Vitro Studies, Cellular and Subcellular *32600
Immunology and Immunochemistry - Immunopathology, Tissue
Immunology *34508

BIOSYSTEMATIC CODE: Hominidae *86215

INDEX TERMS: Major Concepts
Blood and Lymphatics (Transport and Circulation); Cell
Biology; Clinical Immunology (Human Medicine, Medical
Sciences); Endocrine System (Chemical Coordination and
Homeostasis); Enzymology (Biochemistry and Molecular
Biophysics); Pharmacology

INDEX TERMS: Chemicals & Biochemicals
LEFLUNOMIDE; CYCLOPHOSPHAMIDE; RAPAMYCIN; BREQUINAR SODIUM;
MYCOPHENOLIC ACID; A771726; TYROSINE KINASE

INDEX TERMS: Miscellaneous Descriptors
A771726; BREQUINAR SODIUM; CYCLOPHOSPHAMIDE;
IMMUNOSUPPRESSANT-DRUG; INTERLEUKIN-2; LEFLUNOMIDE;
MYCOPHENOLIC ACID; RAPAMYCIN; TYROSINE KINASE

ORGANISM: Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata,
Animalia

ORGANISM: Organism Name
human (Hominidae)

ORGANISM: Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

REGISTRY NUMBER: 75706-12-6 (LEFLUNOMIDE)
50-18-0 (CYCLOPHOSPHAMIDE)
53123-88-9 (RAPAMYCIN)
96201-88-6 (BREQUINAR SODIUM)
24280-93-1 (MYCOPHENOLIC ACID)
108605-62-5 (A771726)
80449-02-1 (TYROSINE KINASE)

L66 ANSWER 62 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 2000212972 EMBASE
TITLE: Immunosuppressive drugs: The first 50 years and a glance
forward.
AUTHOR: Allison A.C.
CORPORATE SOURCE: A.C. Allison, SurroMed Corporation, 1060 E. Meadow Circle,
Palo Alto, CA 94303, United States
SOURCE: Immunopharmacology, (2000) 47/2-3 (63-83).
Refs: 146
ISSN: 0162-3109 CODEN: IMMUDF
PUBLISHER IDENT.: S 0162-3109(00)00186-7
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 026 Immunology, Serology and Transplantation
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ABSTRACT:
During the past 50 years, many immunosuppressive drugs have been described.
Often their mechanisms of action were established long after their discovery.
Eventually these mechanisms were found to fall into five groups: (i) regulators
of gene expression; (ii) alkylating agents; (iii) inhibitors of de novo purine
synthesis; (iv) inhibitors of de novo pyrimidine synthesis; and (v) inhibitors
of kinases and phosphatases. Glucocorticoids exert immunosuppressive and
anti-inflammatory activity mainly by inhibiting the expression of genes for
interleukin-2 and other mediators. Cyclophosphamide metabolites alkylate DNA
bases and preferentially suppress immune responses mediated by B-lymphocytes.
Methotrexate and its polyglutamate derivatives suppress inflammatory responses
through release of adenosine; they suppress immune responses by inducing the
apoptosis of activated T-lymphocytes and inhibiting the synthesis of both
purines and pyrimidines. Azathioprine metabolites inhibit several enzymes of
purine synthesis. Mycophenolic acid and mizoribine inhibit inosine
monophosphate dehydrogenase, thereby depleting guanosine nucleotides.
Mycophenolic acid induces apoptosis of activated T-lymphocytes. A leflunomide

metabolite and Brequinar inhibit dihydroorotate dehydrogenase, thereby suppressing pyrimidine nucleotide synthesis. Cyclosporine and FK-506 (Tacrolimus) inhibit the phosphatase activity of calcineurin, thereby suppressing the production of IL-2 and other cytokines. In addition, these compounds have recently been found to block the JNK and p38 signaling pathways triggered by antigen recognition in T-cells. In contrast, rapamycin inhibits kinases required for cell cycling and responses to IL-2. Rapamycin also induces apoptosis of activated T-lymphocytes. Immunosuppressive and anti-inflammatory compounds in development include inhibitors of p38 kinase and of the type IV isoform of cyclic AMP phosphodiesterase which is expressed in lymphocytes and monocytes. A promising future application of immunosuppressive drugs is their use in a regime to induce tolerance to allografts. The role of leukocytes in grafts, and the induction of apoptosis of clones of responding T-lymphocytes, is discussed. Copyright (C) 2000 Elsevier Science B.V.

CONTROLLED TERM: Medical Descriptors:
*immunosuppressive treatment
*apoptosis
*drug development
gene expression regulation
lymphocyte proliferation
purine synthesis
T lymphocyte activation
pyrimidine synthesis
graft rejection: PC, prevention
graft rejection: DT, drug therapy
human
review
priority journal
Drug Descriptors:
*immunosuppressive agent: PD, pharmacology
*alkylating agent: PD, pharmacology
rapamycin: PD, pharmacology
rapamycin: DT, drug therapy
tsukubaenolide: PD, pharmacology
glucocorticoid: PD, pharmacology
leflunomide: PD, pharmacology
brequinar: PD, pharmacology
purine: EC, endogenous compound
pyrimidine: EC, endogenous compound
mycophenolic acid 2 morpholinoethyl ester: PD, pharmacology
azathioprine: PD, pharmacology
cyclosporin: PD, pharmacology
phosphotransferase: EC, endogenous compound
phosphatase: EC, endogenous compound
CAS REGISTRY NO.: (rapamycin) 53123-88-9; (tsukubaenolide) 104987-11-3;
(leflunomide) 75706-12-6; (brequinar) 96187-53-0,
96201-88-6; (purine) 120-73-0; (pyrimidine)
289-95-2; (mycophenolic acid 2 morpholinoethyl ester)
116680-01-4, 128794-94-5; (azathioprine) 446-86-6;
(cyclosporin) 79217-60-0; (phosphotransferase) 9031-09-8,
9031-44-1; (phosphatase) 9013-05-2

L66 ANSWER 63 OF 63 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95235938 EMBASE
DOCUMENT NUMBER: 1995235938
TITLE: Leflunomide: A potential new disease-modifying
anti-rheumatic drug.
AUTHOR: Parnham M.J.
CORPORATE SOURCE: Parnham Advisory Services, Von Guericke Allee 4, D-53125
Bonn, Germany
SOURCE: Expert Opinion on Investigational Drugs, (1995) 4/8

(777-779).
ISSN: 1354-3784 CODEN: EOIDER
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 031 Arthritis and Rheumatism
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
CONTROLLED TERM: Medical Descriptors:
*autoimmunity
*immunomodulation
*rheumatic disease: DT, drug therapy
article
enzyme activity
human
mouse
nonhuman
oral drug administration
rat
Drug Descriptors:
interleukin 2 receptor
*antirheumatic agent: PD, pharmacology
*leflunomide: PD, pharmacology
*leflunomide: DT, drug therapy
*leflunomide: DO, drug dose
*leflunomide: CM, drug comparison
brequinar: TO, drug toxicity
brequinar: DT, drug therapy
brequinar: CM, drug comparison
dihydroorotate dehydrogenase: EC, endogenous compound
protein tyrosine kinase: EC, endogenous compound
CAS REGISTRY NO.: (leflunomide) 75706-12-6; (brequinar) **96187-53-0**,
96201-88-6; (dihydroorotate dehydrogenase)
9029-03-2; (protein tyrosine kinase) 80449-02-1
COMPANY NAME: Hoechst; Marion; Roussel

THIS PAGE BLANK (USPTO)